# EDGAR Filing Document

**Accession Number:** 0000939930
**File Stem:** 0000939930-26-000017
**Filing Date:** 2026-6
**Character Count:** 437479
**Document Hash:** 80942c41efad396ca6f87dcb0db694ef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000939930-26-000017.hdr.sgml**: 20260604

**ACCESSION NUMBER**: 0000939930-26-000017

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 154

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260604

**DATE AS OF CHANGE**: 20260604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PYXUS INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0000939930
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-FARM PRODUCT RAW MATERIALS [5150]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 852386250
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-25734
- **FILM NUMBER:** 261063187

**BUSINESS ADDRESS:**
- **STREET 1:** 6001 HOSPITALITY COURT
- **STREET 2:** SUITE 100
- **CITY:** MORRISVILLE
- **STATE:** NC
- **ZIP:** 27560-2009
- **BUSINESS PHONE:** 9193794300

**MAIL ADDRESS:**
- **STREET 1:** 6001 HOSPITALITY COURT
- **STREET 2:** SUITE 100
- **CITY:** MORRISVILLE
- **STATE:** NC
- **ZIP:** 27560-2009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLIANCE ONE INTERNATIONAL, INC.
- **DATE OF NAME CHANGE:** 20050516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DIMON INC
- **DATE OF NAME CHANGE:** 19950301

?xml version='1.0' encoding='ASCII'? pyx-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES**

&nbsp;&nbsp;&nbsp;&nbsp;**EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED March 31, 2026** 

**&nbsp;&nbsp;&nbsp;&nbsp;☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO _______.**

---

| |
|:---|
| **000-25734** |
| (Commission File Number) |

---

![Image1.jpg](pyx-20260331_g1.jpg)

**Pyxus International, Inc.** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Virginia** | **Virginia** | **85-2386250** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
| **6001 Hospitality Court, Suite 100** | **6001 Hospitality Court, Suite 100** | |
| **Morrisville,** | **North Carolina** | **27560** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

**(919) 379-4300** 

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock (no par value)

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes **☐** No **☒**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes **☐** No **☒** 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes **☒** No **☐**

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes **☒** No **☐**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | **☐** | Accelerated filer | **☐** | Smaller reporting company | **☒** |
| Non-accelerated filer | **☒** | | | Emerging growth company | **☐** |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transaction period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **☐**

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. **☐**

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. **☐**

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). **☐**

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes **☒** No **☐**

As of September 30, 2025, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $34.6 million based on the closing price of the common stock as reported on the OTCID Basic Market.

As of May 31, 2026, there were 24,607,791 shares of common stock outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

Certain information contained in the Proxy Statement for the 2026 Annual Meeting of Shareholders (to be held August 13, 2026) of the registrant is incorporated by reference into Part III hereof.

------

![Image1.jpg](pyx-20260331_g1.jpg)

---

| | | |
|:---|:---|:---|
| **Table of Contents** | **Table of Contents** | **Table of Contents** |
| **<u>Part I</u>** | | **<u>Page No.</u>** |
| Item 1. | <u>[Business](#i6f44eae8422d46cd9f377051509c10a4_19)</u> | <u>[4](#i6f44eae8422d46cd9f377051509c10a4_19)</u> |
| Item 1A. | <u>[Risk Factors](#i6f44eae8422d46cd9f377051509c10a4_22)</u> | <u>[7](#i6f44eae8422d46cd9f377051509c10a4_22)</u> |
| Item 1B. | <u>[Unresolved Staff Comments](#i6f44eae8422d46cd9f377051509c10a4_25)</u> | <u>[18](#i6f44eae8422d46cd9f377051509c10a4_25)</u> |
| Item 1C. | <u>[Cybersecurity](#i6f44eae8422d46cd9f377051509c10a4_28)</u> | <u>[18](#i6f44eae8422d46cd9f377051509c10a4_28)</u> |
| Item 2. | <u>[Properties](#i6f44eae8422d46cd9f377051509c10a4_31)</u> | <u>[20](#i6f44eae8422d46cd9f377051509c10a4_31)</u> |
| Item 3. | <u>[Legal Proceedings](#i6f44eae8422d46cd9f377051509c10a4_34)</u> | <u>[20](#i6f44eae8422d46cd9f377051509c10a4_34)</u> |
| Item 4. | <u>[Mine Safety Disclosures](#i6f44eae8422d46cd9f377051509c10a4_37)</u> | <u>[20](#i6f44eae8422d46cd9f377051509c10a4_37)</u> |
| **<u>Part II</u>** | | |
| Item 5. | <u>[Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i6f44eae8422d46cd9f377051509c10a4_43)</u> | <u>[20](#i6f44eae8422d46cd9f377051509c10a4_43)</u> |
| Item 6. | <u>[\[Reserved\]](#i6f44eae8422d46cd9f377051509c10a4_46)</u> | <u>[21](#i6f44eae8422d46cd9f377051509c10a4_46)</u> |
| Item 7. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i6f44eae8422d46cd9f377051509c10a4_49)</u> | <u>[21](#i6f44eae8422d46cd9f377051509c10a4_49)</u> |
| Item 7A. | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i6f44eae8422d46cd9f377051509c10a4_109)</u> | <u>[36](#i6f44eae8422d46cd9f377051509c10a4_109)</u> |
| Item 8. | <u>[Financial Statements and Supplementary Data](#i6f44eae8422d46cd9f377051509c10a4_112)</u> | <u>[38](#i6f44eae8422d46cd9f377051509c10a4_112)</u> |
| Item 9. | <u>[Changes In and Disagreements With Accountants on Accounting and Financial Disclosure](#i6f44eae8422d46cd9f377051509c10a4_229)</u> | <u>[86](#i6f44eae8422d46cd9f377051509c10a4_229)</u> |
| Item 9A. | <u>[Controls and Procedures](#i6f44eae8422d46cd9f377051509c10a4_232)</u> | <u>[86](#i6f44eae8422d46cd9f377051509c10a4_232)</u> |
| Item 9B. | <u>[Other Information](#i6f44eae8422d46cd9f377051509c10a4_238)</u> | <u>[87](#i6f44eae8422d46cd9f377051509c10a4_238)</u> |
| Item 9C. | <u>[Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i6f44eae8422d46cd9f377051509c10a4_241)</u> | <u>[87](#i6f44eae8422d46cd9f377051509c10a4_241)</u> |
| **<u>Part III</u>** | | |
| Item 10. | <u>[Directors, Executive Officers and Corporate Governance](#i6f44eae8422d46cd9f377051509c10a4_247)</u> | <u>[87](#i6f44eae8422d46cd9f377051509c10a4_247)</u> |
| Item 11. | <u>[Executive Compensation](#i6f44eae8422d46cd9f377051509c10a4_250)</u> | <u>[88](#i6f44eae8422d46cd9f377051509c10a4_250)</u> |
| Item 12. | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i6f44eae8422d46cd9f377051509c10a4_253)</u> | <u>[89](#i6f44eae8422d46cd9f377051509c10a4_253)</u> |
| Item 13. | <u>[Certain Relationships and Related Transactions, and Director Independence](#i6f44eae8422d46cd9f377051509c10a4_256)</u> | <u>[89](#i6f44eae8422d46cd9f377051509c10a4_256)</u> |
| Item 14. | <u>[Principal Accountant Fees and Services](#i6f44eae8422d46cd9f377051509c10a4_259)</u> | <u>[89](#i6f44eae8422d46cd9f377051509c10a4_259)</u> |
| **<u>Part IV</u>** | | |
| Item 15. | <u>[Exhibits and Financial Statement Schedules](#i6f44eae8422d46cd9f377051509c10a4_265)</u> | <u>[89](#i6f44eae8422d46cd9f377051509c10a4_265)</u> |
| Item 16. | <u>[Form 10-K Summary](#i6f44eae8422d46cd9f377051509c10a4_274)</u> | <u>[92](#i6f44eae8422d46cd9f377051509c10a4_274)</u> |
| | <u>[Signatures](#i6f44eae8422d46cd9f377051509c10a4_277)</u> | <u>[93](#i6f44eae8422d46cd9f377051509c10a4_277)</u> |

---

------

**PART I**

**<u>Item 1. Business</u>**

**Company Overview**

This Annual Report on Form 10-K (this "Annual Report") is filed by Pyxus International, Inc. (the "Company," "Pyxus," "we," "us," or "our"). Pyxus is a global agricultural company with businesses having more than 150 years of experience delivering value-added products and services to customers. The Company is a trusted provider of responsibly sourced, independently verified, sustainable, and traceable products and ingredients, principally leaf tobacco. The Company has one reportable segment for financial reporting purposes: Leaf. An All Other category is included for purposes of reconciliation of the respective balances of the Leaf segment to the consolidated financial statements. All Other revenue is primarily composed of revenue from the sale of non-tobacco agricultural products. See "<u>[Note 1. Basis of Presentation and Summary of Significant Accounting Policies](#i6f44eae8422d46cd9f377051509c10a4_136)</u>" to the "Notes to the Consolidated Financial Statements" for additional information.

**Leaf Tobacco Operations**

Our leaf tobacco revenues are principally comprised of sales of processed leaf tobacco and fees charged for processing and related services to manufacturers of tobacco products. Our leaf tobacco operations deal primarily in flue-cured, burley, and oriental tobaccos that are used in international cigarette brands. We purchase tobacco on five continents and ship to customers globally. We primarily purchase tobacco from suppliers and assume the risk of matching the quantities and grades required by our customers to the crop we are contractually obligated to purchase.

Our arrangements with suppliers vary depending on our predictions of future supply and demand, local historical practice, and availability of capital. In some locales, we purchase crop inputs, such as seeds, fertilizer, pesticides, and other products related to tobacco crop production, and issue them to suppliers with whom we have purchase contracts. The suppliers, who generally operate small farms, then utilize these inputs to grow tobacco, which we are contractually obligated to purchase if the supplier meets our specifications. The advances of inputs for the current crop generally include the original cost of the inputs plus a mark-up and interest as it is earned. Where contractually permitted, we charge interest to the suppliers during the period the current crop advance is outstanding. We account for our advances to suppliers using a cost accumulation model, which results in us reporting our advances at the lower of cost or recoverable amounts excluding the mark-up and interest. The mark-up and interest on our advances are recognized when the tobacco is delivered as a decrease in our cost of the current crop. Upon delivery of tobacco, part of the purchase price paid to the supplier is paid in cash and part through a reduction of the advance balance. The advances applied to the delivery are reclassified out of advances and into unprocessed inventory. Under longer-term arrangements with suppliers, we may advance or guarantee financing on suppliers' capital assets, which are also recovered through the delivery of tobacco to us by our suppliers.

Our agronomy team maintains frequent contact with suppliers prior to and throughout the growing and curing seasons to provide technical assistance to improve the quality and yield of the crop. As a result of various factors, including weather, not all suppliers are able to fully settle advances through delivery of tobacco in a given crop year. Throughout the crop cycle, we monitor events that may impact the suppliers' ability to deliver tobacco. If we determine we will not be able to recover the original cost of the advances with deliveries of the current crop or future crop deliveries, the unit cost of tobacco received is increased when unrecoverable costs are within a normal range or expensed immediately when they are above a normal range. The normal range is based on our historical results.

We process tobacco to meet each customer's specifications as to quality, yield, chemistry, particle size, moisture content, and other characteristics. Unprocessed tobacco is a semi-perishable commodity. The processing of leaf tobacco facilitates shipping by preventing spoilage and is an essential service to our customers as the quality of processed leaf tobacco substantially affects the quality of the manufacturer's products. Accordingly, our production facilities are in proximity to our principal tobacco sourcing locations. We process tobacco in Company-owned and third-party facilities around the world, including in Argentina, Brazil, China, India, Indonesia, Jordan, North Macedonia, Malawi, Tanzania, Thailand, Turkey, United States, and Zimbabwe. After processing, whole leaves, bundles, strips or stems, and scrap, where applicable, are separately packed in cases, bales, cartons or hogsheads for storage and shipment. Packed flue-cured, burley and oriental tobacco generally is transported in the country of origin by truck or rail, and exports are moved by ship.

Our production processes and capabilities are optimized to extract maximum utility from the tobacco leaf, which in turn creates additional products to serve the needs of our customers. These products, referred to as Value-Added Tobacco Products ("VATP"), are derived from the tobacco we process in our facilities. A large portion of the VATP business is comprised of our cut rag tobacco operations where processed tobacco strips are blended and flavored to create a cut filler for use by manufacturers of nicotine products. A smaller portion of the VATP business leverages other byproducts from our tobacco processing operations, such as stems, small lamina, and scrap that would otherwise be discarded, and are used to create cut rolled expanded stems, rolled stems, and reconstituted tobacco products, which are used as inputs for various nicotine products.

------

We utilize contracts, joint ventures, and other arrangements for the purchase of tobacco grown in other countries that produce export-quality flue-cured and burley tobacco. Much of the tobacco we purchase is sourced from the African, Asian, and South American regions in which we operate. The approximate percentage of tobacco purchases from these regions were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Africa | 33.1% | 34.4% | 32.7% |
| Asia | 21.6% | 19.6% | 18.7% |
| South America | 22.7% | 23.7% | 28.1% |

---

*Seasonality*

The purchasing and processing activities of our leaf tobacco business are seasonal and vary by market and tobacco variety. Tobacco grown in North America is purchased, processed, and marketed generally during a five-month period beginning in August and ending in December. Tobacco grown in South America is usually purchased, processed, and marketed from January through July and, for tobacco grown in Africa, from March through September. Other tobacco markets around the world have similar purchasing and processing activities, although these activities occur at various times of the year.

During the purchasing, processing, and marketing seasons, inventories of unprocessed tobacco, inventories of redried tobacco, and trade accounts receivable normally reach peak levels in succession. Current liabilities, particularly advances from customers and short-term notes payable, normally reach their peak in this period as a means of financing the seasonal expansion of current assets. At March 31, the end of our fiscal year, the seasonal components of our working capital primarily reflect the foreign-grown tobacco operations.

*Track and Trace Technology*

In connection with our leaf tobacco operations, the Company leverages its proprietary "track-and-trace" platform, branded as SENTRI<sup>®</sup>, to provide transparency into the lifecycle of agricultural products. SENTRI<sup>®</sup> houses our farm monitoring information and supports our analysis of data related to the production, harvest, processing, formulation, testing, and release of individual batches of products. By tracking data on products at each stage of our supply chain, SENTRI<sup>®</sup> permits proactive decision making for both the Company and our leaf tobacco customers. The key features of SENTRI<sup>®</sup> include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Product Tracking*: Data collection and tracking at various stages in the product lifecycle can provide customers with visibility into where products originate, how they were produced, and the product testing completed along the product journey.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Control and Visibility*: With access to increased supply chain data, we can monitor quality control at various points in the product route to market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Sustainability Commitments*: SENTRI<sup>®</sup> incorporates visibility into the crop production practices and procedures, helping promote compliance with applicable regulations throughout a product's supply chain journey.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Lot Number Tracking*: We can track specific products through the manufacturing process by lot number with full visibility to our customers. This provides more information about the product, its origin, and other information relevant to quality control and product transparency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Agronomic Services*: SENTRI<sup>®</sup> utilizes an experienced team to track and analyze data and insights regarding growing practices.

------

*Key Customers*

In our leaf tobacco business, our primary customers are major consumer tobacco product manufacturers. See "<u>[Note 26. Segment Information](#i6f44eae8422d46cd9f377051509c10a4_211)</u>" to the "Notes to Consolidated Financial Statements" for additional information regarding customers, and their respective affiliates, that account for more than 10% of our annual revenues. Our sales to customers were delivered to the following geographic regions:

---

| | |
|:---|:---|
| | Year Ended March 31,<br>2026 |
| *(dollars in millions)* | $% |
| Africa | 17.0 |
| Asia | 31.3 |
| Europe | 36.7 |
| Other | 15.0 |
| &nbsp;&nbsp;Total | 100.0 |

---

*Competition*

Leaf tobacco industry competition is based on the Company's ability to meet individual customer specifications, including, but not limited to, crop production and curing, sustainable best practices, buying, processing, residue compliance and crop financing, as well as the price charged for products and services. Pyxus is one of only two global, publicly held leaf tobacco merchants. We hold a leading position in most major tobacco growing regions in the world, including the principal export markets for flue-cured, burley, and oriental tobacco. In addition to the primary global independent leaf tobacco merchants, there are other global, regional, or national competitors. These include local independent leaf merchants that have low fixed costs and overhead and some of our customers that have vertically integrated operations in certain markets.

We have long-standing relationships with growers across the globe with whom we contract directly to procure tobacco, and our grower base is critical to our ability to provide sustainable, compliant crops that meet the specific requirements of our customers. We strive to maintain strong, productive relationships with our growers by providing them with agronomic expertise, which includes training on good agricultural practices to support quality and high-yielding crops, and training on our agricultural labor practices that set human rights standards by which they are expected to comply. We remain committed to conducting our global business in an ethical and responsible manner, in accordance with international standards and practices relating to human rights and the environment, to give our customers confidence that we can satisfy their demand requirements through a sustainable and compliant value chain.

*Regulation*

See "<u>[Item 1A. Risk Factors](#i6f44eae8422d46cd9f377051509c10a4_22)</u>" for a discussion of applicable government regulation of leaf tobacco.

**All Other**

We are also engaged in the sale of non-tobacco agricultural products, which represented less than 1% of our consolidated revenues for each of the fiscal years ended March 31, 2026, 2025, and 2024. These operations have been combined and reported in an "All Other" category included for purposes of reconciliation of the respective balances of the Leaf segment to the consolidated financial statements. See "<u>[Note 26. Segment Information](#i6f44eae8422d46cd9f377051509c10a4_211)</u>" for additional information.

**Human Capital Management**

Our workforce plays a fundamental role in fulfilling our corporate mission—to transform people's lives so that, together, we can grow a better world. Attracting, developing, and retaining top talent is essential to advancing our business strategy and impact. We remain committed to fostering a workplace culture rooted in ethics and responsibility, and we invest in employee engagement, prioritize workplace safety, and celebrate the contributions of our team in furtherance of organizational success.

As of March 31, 2026, we employed approximately 3,300 people, excluding seasonal employees, in our worldwide operations, of which approximately 83.3% were employed outside of the United States. We maintain positive relationships with the Company's employees and their respective organizations. We have collective bargaining agreements in place in many of the countries in which we operate, and we have long-term agreements in-place in certain jurisdictions to resolve disputes through binding arbitration.

*Oversight and Management*

Our Human Resources department is responsible for managing employment-related matters, including recruiting, hiring, onboarding, compensation, performance management, advancement, succession planning, and professional and learning development. Our Board of Directors provides oversight of various matters pertaining to our workforce. The Compensation

------

Committee of the Board of Directors is responsible for executive compensation matters and oversight of the risks and programs related to talent management. Our Human Rights Policy and Code of Business Conduct highlight our commitment to diversity, inclusion, fairness, safety, and equal opportunity in all aspects of employment.

*Supply Chain Human Rights Matters*

We support efforts to address human rights concerns throughout the tobacco supply chain. For example, in our tobacco supply chain, we use on-farm good agricultural practices assessments to assess suppliers' compliance with labor practices. Our subsidiaries establish contract terms and conditions with suppliers related to forced and child labor and other agricultural labor practices, and they conduct due diligence throughout our tobacco growing regions to monitor compliance.

**Environmental Compliance**

As an agricultural company, we recognize the effects our business activities have on the environment, and we understand that climate change could have long-term consequences on our business, our employees, suppliers, and the communities where we operate. We are committed to reducing our environmental impact by working with our suppliers to integrate sustainable agricultural methods and practices. Additional information regarding our activities related to our sustainability strategy can be found in our Sustainability Report, which is published on our website.

Currently, there are no material estimated capital expenditures related to environmental control facilities. In addition, there is no material effect on capital expenditures, results of operations or competitive position anticipated from compliance with current or pending federal or state laws and regulations relating to protection of the environment.

**Available Information**

Our website is <u>www.pyxus.com</u>. Our Annual Report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge at <u>http://investors.pyxus.com</u> as soon as reasonably practicable after we file such material with, or furnish it to, the United States ("U.S.") Securities and Exchange Commission (the "SEC"). The information contained on our website shall not be deemed part of this annual report on Form 10-K. The SEC maintains a website <u>(www.sec.gov</u>) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

**Development of the Business**

A description of the general development of the Company's business is included in Item 1 of Part I of the Company's <u>[Annual Report on Form 10-K for the fiscal year ended](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000939930/000093993022000030/pyx-20220331.htm)[March 31, 2022](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000939930/000093993022000030/pyx-20220331.htm)</u> under the heading "Company Overview" and the paragraph immediately preceding such heading, which description is incorporated herein by reference.

**<u>Item 1A. Risk Factors</u>**

The following risk factors should be read carefully in connection with evaluating our business and the forward-looking statements contained in this Annual Report. Any of the following risks could materially adversely affect our business, our operating results, our financial condition, and the actual outcome of matters as to which forward-looking statements are made in this Annual Report. These disclosures reflect our beliefs and opinions as to factors that could materially and adversely affect the Company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future.

**<u>Risks Related to Our Indebtedness</u>**

**We may not be able to refinance or renew our indebtedness or be able to borrow under our ABL credit facility or other future credit facilities, which may have a material adverse effect on our financial condition.**

We may not be able to renew or refinance our senior secured indebtedness, including our ABL credit facility, or other indebtedness on substantially similar terms, or at all, whether due to volatility and disruption of global credit markets or otherwise. We may have to pay additional fees and expenses that we might not have to pay under normal circumstances, and we may have to agree to terms that could increase the cost of our debt structure. If we are unable to renew or refinance our ABL credit facility and other senior secured indebtedness on terms that are substantially similar to the terms currently available to us or obtain alternative or additional financing arrangements, we may not be able to repay the ABL credit facility, our senior secured indebtedness, or certain of our other indebtedness, which may result in a default.

**We may not continue to have access to the capital markets to obtain long-term and short-term financing on acceptable terms and conditions.**

We access the short-term capital markets and, from time to time, the long-term markets to obtain financing. Our access to, and the availability of acceptable terms and conditions of, such financing are impacted by many factors, including: (i) our credit ratings; (ii) the liquidity and volatility of the overall capital markets; and (iii) the current state of the economy, including the

------

tobacco industry. There can be no assurances that we will continue to have access to the capital markets on terms acceptable to us.

**We require a significant amount of cash to service our indebtedness, and our ability to generate cash depends on many factors beyond our control.**

We require a significant amount of cash to service our indebtedness, and a substantial portion of our cash flow is required to fund the interest payments on our indebtedness. Our ability to service our indebtedness and to fund planned capital expenditures depends on our ability to generate cash. This is subject to general economic, financial, competitive, legislative, regulatory, and other factors that are beyond our control. Also, a substantial portion of our debt, including borrowings under our ABL credit facility, bears interest at variable rates. If market interest rates increase, variable-rate debt will create higher debt-service requirements, which would adversely affect our cash flow. We cannot assure you that our businesses will generate sufficient cash flow from operations or that future borrowings will be available to us in an amount sufficient to enable us to service our indebtedness or to fund our other liquidity needs.

**We have substantial debt which may adversely affect us by limiting future sources of financing, interfering with our ability to pay interest and principal on our indebtedness, and subjecting us to additional risks.**

We have a significant amount of indebtedness and debt service obligations. As of March 31, 2026, we had approximately $932.9 million in aggregate principal amount of indebtedness. Our substantial debt could have important consequences, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• making it more difficult for us to satisfy our obligations with respect to our senior credit obligations and our other obligations,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• requiring us to dedicate a substantial portion of our cash flows from operations to payments on our indebtedness, thereby reducing the funds available for operations, working capital, capital expenditures, acquisitions, product development, and other purposes,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limiting our ability to obtain additional financing on satisfactory terms and to otherwise fund working capital, capital expenditures, debt refinancing, acquisitions, and other general corporate requirements,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• hampering our ability to adjust to changing market conditions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increasing our vulnerability to general adverse economic and industry conditions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• placing us at a competitive disadvantage compared to our competitors that have less debt or are less leveraged,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• limiting our flexibility in planning for, or reacting to, changes in our business, and the industries in which we operate,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restricting us from making strategic acquisitions or exploiting business opportunities, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exposing us to the risk of increased interest rates, as a substantial portion of our debt is subject to variable interest rates.

**Despite current indebtedness levels, we may incur additional debt, which could increase the risks associated with our significant leverage.**

We may incur substantial additional indebtedness in the future to the extent permitted under our existing credit arrangements. As of March 31, 2026, $747.3 million was available for borrowing under our short and long-term credit facilities, including letters of credit. If new debt is added to our current debt levels, the risks discussed above could intensify.

**<u>Risks Related to Our Leaf Tobacco Operations</u>**

**Our reliance on a small number of significant customers may adversely affect our financial results.**

The customers of our leaf tobacco business are manufacturers of cigarette and other tobacco products. Several of these customers individually may account for a significant portion of our sales in a normal year. For the year ended March 31, 2026, Philip Morris International Inc., China National Tobacco Corporation, and Japan Tobacco International each accounted for 10% or more of our total sales and other operating revenues. In addition, tobacco product manufacturers have experienced consolidation, and further consolidation among our customers could decrease customer demand for our leaf tobacco or processing services. The loss of one or more of our significant customers could have a material adverse effect on our financial results.

**Vertical integration by our customers could materially adversely affect our financial performance.**

Demand for our leaf tobacco or processing services could be materially reduced if cigarette manufacturers decide to significantly vertically integrate their operations, whether through the acquisition of our competitors, establishing new operations, contracting directly with suppliers, or otherwise. In general, our results of operations have not been adversely affected by vertical integration initiatives, and some customers have reversed certain aspects of their previous efforts to

------

vertically integrate operations. However, significant vertical integration by our customers could have a material adverse effect on our financial performance.

**Shifts in customer requirements for sourcing tobacco could negatively affect our organizational structure, asset base, and results of operations, including shifts resulting from the imposition of tariffs.**

We procure and process leaf tobacco across multiple countries and regions, and customer procurement strategies and decisions may be influenced by prevailing macroeconomic conditions, including currency fluctuations, such as changes in currency exchange rates relative to the United States Dollar ("USD"), the imposition of tariffs and other changes in international trade policies.

For example, tariffs announced by the U.S. government have resulted in the imposition of retaliatory tariffs by impacted governments, and recent tariff actions, and future tariff actions, by the U.S. government may result in additional tariffs being imposed. As a result, we have experienced, and continue to experience, shifts in customer purchasing behavior in affected jurisdictions. In addition to risks that we may not be able to fully supply customer needs from unaffected regions in response to such shifts in purchasing behavior, such shifts have required, and may continue to require, the Company to evaluate and adjust how we conduct our business and operations in affected regions. While we continue to monitor trade developments that could impact our customers and our business, our sales opportunities may be adversely affected by such shifts in customer purchasing behavior and we may not be able to adjust our operations in a timely or efficient manner, which could adversely affect our results of operations.

We have incurred, and may continue to incur, costs as we continue to adjust to shifts in sourcing, including in response to tariff actions. If our customers significantly alter their requirements for tobacco volumes from certain regions, we may have to change our production facilities and alter our fixed asset base in certain origins. Adjusting our capacity and adjusting to shifts in sourcing may have an adverse impact on our ability to manage our costs and could have an adverse effect on our financial performance.

In addition, certain of our most significant customers, including Philip Morris International Inc. and British American Tobacco, have publicly announced intentions to move toward smoke-free, alternative tobacco and nicotine products replacing traditional cigarettes. Generally, these alternative tobacco and nicotine products require less, and in some cases no, tobacco in production as compared to traditional cigarettes and other combustible tobacco products. An increasing shift toward alternative tobacco and nicotine products, whether driven by our customers or by consumer preferences, could materially adversely affect our results of operations.

**Our financial results will vary according to growing season conditions, customer indications, and other factors, which significantly impacts our ability to forecast our quarterly and annual financial performance.**

Our financial results may be significantly affected by fluctuations in tobacco growing season conditions and crop sizes, which affect the supply of tobacco to our customers. Crop sizes may be affected by, among other things, precipitation levels, crop infestation and disease, the volume of annual tobacco plantings and yields realized by suppliers, the availability of crop inputs, and suppliers' elections to grow crops other than tobacco. The cultivation period for tobacco is dependent upon a number of factors, including the weather and other natural events, such as hurricanes, floods, and tornadoes, and our processing schedule and results of operations for any quarterly period can be significantly altered by these factors. The unpredictability may be exacerbated by the effects of climate change, which could increase the likelihood or severity of disruptive weather events.

The cost of acquiring tobacco can fluctuate greatly due to crop sizes and increased competition in certain markets where we purchase tobacco. For example, short crops in periods of high demand translate into higher average green tobacco prices, higher throughput costs, and less volume to sell. Conversely, large crops translate into lower average green tobacco prices, lower throughput costs, and excess volume to sell.

From time to time in the ordinary course of business, we may hold significant quantities of processed tobacco in inventory due to the timing and unpredictability of customer indications, orders, and shipments, which increases our balance sheet risk and may contribute to variability in financial results. The timing of shipments can be materially impacted by shortages of containers and vessels for shipping, increased spot-prices for shipping prompting vessel operators to reduce cargo allocations of our customers' containers covered by lower-priced, long-term shipping arrangements, and infrastructure and accessibility issues in the ports we use for shipment.

Control of processed tobacco is transferred and revenue is recognized for the sale of inventory at a point in time, in accordance with the shipping terms of the contract. As individual shipments may represent significant amounts of revenue, our financial results may vary significantly depending on our customers' needs and shipping instructions. These fluctuations result in varying volumes and sales in given periods, which may limit your ability to compare our financial results in different periods or in the same periods in different years.

------

**Loss of confidence in us by our customers and suppliers may have a material adverse impact on our business, financial condition, results of operations, and cash flows.** 

If our customers and suppliers lose confidence in us, they may seek to establish alternative commercial relationships. In addition, in such circumstances, our suppliers, vendors, counterparties, and service providers may seek to renegotiate the terms of our agreements, attempt to terminate their relationships with us or require financial assurances from us. If our suppliers, vendors, and other providers require stricter terms and conditions, we may not find these terms and conditions acceptable. Failure to timely obtain or sell suitable inventory at competitive prices could materially adversely affect our businesses, financial condition, liquidity, and results of operations.

**Suppliers who have historically grown tobacco may elect to grow other crops instead of tobacco, which could affect the global supply of tobacco and impact our financial performance.**

Increases in the prices for other crops have led, and may in the future lead, suppliers who have historically grown tobacco to elect to grow other, more profitable, crops instead of tobacco. A decrease in the volume of tobacco available for purchase may increase the purchase price of such tobacco. As a result, we could experience an increase in tobacco crop acquisition costs, which may impact our financial performance.

**Our advancement of inputs to tobacco suppliers could expose us to losses.**

Our arrangements with suppliers vary depending on our predictions of future supply and demand dynamics, local historical practice, and availability of capital. In some locales, we purchase seeds, fertilizer, pesticides, and other products related to growing tobacco, which represent prepaid inventory, and issue them to suppliers with whom we have purchase contracts. The suppliers then utilize these inputs to grow tobacco, which we are contractually obligated to purchase if it meets our specifications. These advances to tobacco suppliers are settled as part of the consideration paid upon the suppliers delivering us unprocessed tobacco at market prices. The quantity and quality of tobacco delivered, both of which are outside of our control at the time we make advances to suppliers, ultimately determine the market value of the tobacco sourced. Unsatisfactory quantities or quality of the tobacco delivered could result in losses with respect to the advances made to these suppliers or the deferral of those advances.

**When we purchase tobacco directly from suppliers, we bear the risk that the tobacco will not meet our customers' quality and quantity requirements.**

In countries where we contract directly with suppliers, we bear the risk that the tobacco delivered will not meet the quality and quantity requirements defined by customers. If the tobacco does not meet customer requirements, we may not be able to sell the tobacco we agreed to buy from suppliers and may not be able to satisfy our customers' orders, which would have an adverse effect on our profitability and results of operations.

**Weather and other conditions can affect the marketability of our inventory, and climate change may adversely alter weather patterns in tobacco-growing regions.**

Like other agricultural products, the quality of tobacco is affected by weather and the environment, which can impact the quality or size of the crop. If a weather event is severe, such as a major drought or hurricane, the affected crop could be destroyed or damaged to an extent that it would be less desirable to our customers and result in lower revenues. If such an event is also widespread, it could affect our ability to acquire the quantity of products at the specifications required by customers.

In addition, the potential impact of climate change is uncertain and may vary by geographic region. The possible effects could include changes in rainfall patterns, water shortages, changing storm patterns and intensities, and changing temperature levels, all of which may be of greater permanence than typical weather fluctuations. These impacts could adversely affect the ability of farmers in the regions in which we source leaf tobacco to continue to produce crops of acceptable quality and in sufficient quantities. Their inability to do so could materially adversely affect our operations, results of operations, and financial condition.

In addition, other items can affect the marketability of tobacco, including, among other things, the presence of non-tobacco related material, genetically modified organisms, and excess residues of pesticides, fungicides, and herbicides. A significant event impacting the condition or quality of a large amount of the tobacco crops we buy could make it difficult for us to sell such tobacco or to fill our customers' orders.

**Competition could erode our earnings.**

The leaf tobacco industry is highly competitive. Competition is based primarily on the prices charged for products and services as well as the merchant's ability to meet customer specifications in the buying, processing, and financing of tobacco. The loss or substantial reduction of one or more of our significant customers could reduce our earnings. Although Pyxus is one of only two primary global independent publicly held leaf tobacco merchants, cigarette manufacturers also buy tobacco directly from local and regional suppliers. We face increasing competition from new local and regional independent leaf merchants with low fixed costs and overhead and good local customer connections, where the new entrants have been able to capitalize in the global transition to those markets. Due to their lower cost structures, these merchants may offer prices on products and services that

------

are lower than our prices. Additionally, some of our customers may also directly source leaf tobacco from farmers to meet some of their raw material needs. Any of these sources of new competition may result in less tobacco available for us to purchase and process in the applicable markets.

**Continued high inflation may adversely affect our profitability and the demand for our leaf tobacco products.**

Global economies have recently experienced higher levels of consumer price inflation. Continued inflationary pressures may continue to increase our costs, including the cost of leaf tobacco that we purchase. If these increased costs cannot successfully be passed on to our customers, then our profitability and results of operations may be adversely affected. In addition, since our leaf tobacco products are used in the manufacturing of tobacco consumer goods, consumer behavior that deprioritizes the purchase of tobacco consumer goods in response to inflationary increases in the price of such goods could result in reduced overall demand for consumer tobacco products and, consequently, for the leaf tobacco we provide to manufacturers, which could materially adversely affect our profitability, results of operations, and financial position.

**<u>Risks Related to Our Financial Condition and Capital Structure</u>**

**We may be unable to continue to access short-term operating credit lines to fund local operations on terms that are acceptable or at all.**

We have historically financed our foreign local leaf tobacco operations with short-term operating credit lines at the local level. These operating lines are typically seasonal in nature, corresponding to the tobacco crop cycle in that location. Certain of these facilities are uncommitted in that the lenders have the right to cease making loans or demand payment of outstanding loans at any time. Moreover, as these facilities mature, local lenders may not renew them or otherwise offer replacement financing facilities. If local lenders lose confidence in us as a borrower, they may cease making loans or demand payment of outstanding loans with respect to uncommitted facilities or, with respect to committed facilities, decline to renew or extend existing facilities, or require stricter terms and conditions with respect to future facilities. We may not find these terms and conditions acceptable, or they may overly restrict our ability to conduct our businesses successfully. An inability to maintain adequate financing to fund our foreign local leaf tobacco operations in any significant location could result in a significant decline in our revenues, profitability, and cash flow and may require us to exit operations in that jurisdiction.

**We may not be able to achieve our stated goals, which may adversely affect our liquidity.**

We face several risks, such as changes in economic conditions, changes in the leaf tobacco market, changes in regulations affecting the tobacco industry, other changes in demand for our products, increasing expenses, the occurrence of a public health crisis, including a pandemic or epidemic, and increasingly severe and frequent weather-related events and natural disasters. We may need to raise additional funds through public or private debt, including the local short-term credit lines, equity financing, or other various means to fund our business, both at a holding-company level and at our foreign local leaf tobacco subsidiaries. Our access to necessary financing may be limited, if it is available at all. Therefore, adequate funds may not be available when needed, or on favorable terms, or at all.

**Failure of foreign banks in which our subsidiaries deposit funds or the failure of those foreign banks to transfer funds or honor withdrawals, may affect our results of operations.**

Funds held by our foreign subsidiaries are often deposited in their local banks. In addition, we maintain deposit accounts with numerous financial institutions around the world in amounts that exceed applicable governmental deposit insurance levels. Banks in certain foreign jurisdictions may be subject to a higher rate of failure or may not honor withdrawals of deposited funds. In addition, the countries in which these local banks operate may lack sufficient regulatory oversight or suffer from structural weaknesses in the local banking system. Due to uncertainties and risks relating to the political stability of certain foreign governments, these local banks also may be subject to exchange controls and, therefore, may be unable to perform transfers of certain currencies. If our ability to gain access to these funds was impaired, it could have a material adverse effect on our results of operations.

**Developments with respect to our liquidity needs and sources of liquidity could result in a deficiency in liquidity.**

Our liquidity requirements are affected by various factors from our core tobacco leaf business, including crop seasonality, foreign currency and interest rates, green tobacco prices, customer mix and shipping requirements, crop size, and quality. Our leaf tobacco business is seasonal. Purchasing, processing, and selling activities have several associated peaks where cash on-hand and outstanding indebtedness may vary significantly during the fiscal year. We anticipate periods in the next twelve months during which our liquidity needs will approach the levels of our anticipated available cash and permitted borrowings under our credit facilities. Developments affecting our liquidity needs, including with respect to the foregoing factors, and sources of liquidity, including impacts affecting our cash flows from operations (including as a result of delays with respect to the anticipated timing of shipments of leaf tobacco and the availability of capital resources and an inability to renew or refinance short-term operating lines of credit and other short-term indebtedness), may result in a deficiency in liquidity. To address a potential liquidity deficiency, we may continue to undertake plans to minimize cash outflows, which could include exiting operations that do not generate positive cash flow. It is possible that, depending on the occurrence of events affecting

------

our liquidity needs and sources of liquidity, such plans may not be sufficient to adequately or timely address a liquidity deficiency.

**Derivative transactions may expose us to potential losses and counterparty risk.**

We may, from time to time, enter certain derivative transactions, including interest rate swaps and foreign exchange contracts. Changes in the fair value of these derivative financial instruments that are not accounted for as cash flow hedges are reported as income and could materially affect our reported income in any period. In addition, the counterparties to these derivative transactions may be financial institutions or affiliates of financial institutions, and we would be subject to risks that these counterparties default under these transactions. In some of these transactions, our exposure to counterparty credit risk may not be secured by any collateral. Global economic conditions over the last few years have resulted in the actual or perceived failure or financial difficulties of many financial institutions, including bankruptcy. If one or more of the counterparties to one or more of our derivative transactions not secured by collateral becomes subject to insolvency proceedings, we would become an unsecured creditor in those proceedings with a claim equal to our exposure at the time under those transactions. We cannot assure you of the financial stability or viability of our counterparties.

**<u>Risks Related to the Scope of Our International Operations</u>**

**We face increased risks of doing business due to the extent of our international operations.**

Some of the countries where we conduct business do not have stable economies or governments. As such, our international operations are subject to international business risks, including unsettled political conditions, uncertainty in the enforcement of legal obligations, including the collection of accounts receivable, fraud risks, expropriation, import and export restrictions, exchange controls, inflationary economies, currency risks, and risks related to the restrictions on repatriation of earnings or proceeds from liquidated assets of foreign subsidiaries. These risks are exacerbated in countries where we have advanced substantial sums or guaranteed local loans or lines of credit for the purchase of tobacco from suppliers.

In 2006, as a result of the political environment, economic instability, foreign currency controls, and governmental regulations in Zimbabwe, we deconsolidated our Zimbabwe subsidiary, Mashonaland Tobacco Company (Pvt.) Ltd. ("MTC"). Subsequently, we determined that the significant doubt about our ability to control MTC was eliminated and reconsolidated MTC as of March 31, 2016. MTC utilizes local currencies for local transactions that are exchanged at a government specified rate with USD. To convert these currencies to USD, the Company must obtain foreign currency resources from the Reserve Bank of Zimbabwe, which are subject to the monetary and exchange control policy in Zimbabwe. If the foreign exchange restrictions and government-imposed controls become severe, we may have to reassess our ability to control MTC.

In recent years, economic problems in certain countries where we conduct operations have experienced significant currency volatility and inflation, including countries with highly inflationary economies like Argentina, Malawi, Turkey, and Zimbabwe. Devaluation and appreciation of the local currency and inflation can affect our purchase costs of tobacco and our processing costs. In addition, we conduct business with suppliers and customers in countries that have experienced or may be subject to dramatic political regime change. In the event of such dramatic changes in the government of such countries, we may be unable to continue to operate our business, or adequately enforce legal obligations after a political regime change, in a manner consistent with prior practice.

Further, the imposition of governmental sanctions or other restrictions may preclude us from continuing to sell to certain customers or to source leaf tobacco from certain jurisdictions and could have a material adverse effect on our profitability, results of operations, and financial position.

**We face risks related to global conflicts, which could significantly disrupt our operations and access to capital.**

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing conflicts in the Middle East, including conflicts involving Iran and Israel. Our business, financial condition and results of operations may be materially and adversely affected by any negative impact on the global economy and capital markets resulting from such conflicts or any other geopolitical tensions. U.S. and global markets have experienced and will likely continue to experience volatility and disruption following the escalation of geopolitical tensions and the start of the conflicts in the Middle East. Although the length and impact of the ongoing military conflict is highly unpredictable, the impact of these military conflicts could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. Disruption of global financial markets and a recession or market correction, including the significant tariffs imposed by the United States on imports from other countries and other global macroeconomic factors such as inflation and rising interest rates, could reduce our ability to access capital, which could in the future negatively affect our liquidity and could materially affect our business.

In addition, we maintain a number of operations in the Middle East, including a processing facility in Jordan, and supply a number of customers in that region. The scope of the ongoing military conflicts in the Middle East is highly unpredictable, and nations in the Middle East not directly involved in the conflict have been targeted for attacks. Accordingly, such hostilities may

------

directly impact our operations and customers in that region, which could have a material adverse effect on our business and results of operations. Further, such armed conflicts have adversely affected shipping in that region. The timing of shipments of our tobacco can be materially impacted by shortages of containers and vessels for shipping, increased spot-prices for shipping prompting vessel operators to reduce cargo allocations of our customers' containers covered by lower-priced, long-term shipping arrangements, and infrastructure and accessibility issues in the ports we use for shipment. Our results of operations may be materially adversely affected if such conflicts continue to disrupt shipping to the extent that our shipments cannot be made as anticipated or at all.

**We are subject to the Foreign Corrupt Practices Act (the "FCPA"), and we operate in jurisdictions that pose a high risk of potential FCPA violations.**

We are subject to the FCPA, which generally prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or maintaining business and/or other benefits. Certain of our customers, including China National Tobacco Corporation, are state-owned, and their officers and employees may qualify as foreign officials under the FCPA. In addition, we operate in certain jurisdictions that pose a high risk of potential FCPA violations. Although our corporate policy prohibits foreign bribery and we have adopted procedures to promote compliance, we cannot assure you that our policy, procedures, and controls will operate effectively at all times to protect us against liability under the FCPA for actions taken by our agents, employees, and intermediaries with respect to our business or any businesses that we may acquire. Failure to comply with the FCPA, other anti-corruption laws and other laws governing the conduct of business with government entities (including local laws) could lead to criminal and civil penalties and other remedial measures (including further changes or enhancements to our policies, procedures, and controls, the imposition of a compliance monitor at our expense, potential personnel changes and/or disciplinary actions), any of which could have an adverse impact on our business, financial condition, results of operations, and liquidity. Investigation of any potential violations of the FCPA or other anti-corruption laws by U.S. or foreign authorities also could have an adverse impact on our business, financial condition, and results of operations.

**Changes in tax laws or challenges to our tax positions pursuant to ongoing tax audits could adversely affect our business.**

Our multinational operations are taxed under the laws of the various countries and jurisdictions where we operate. Changes in tax laws or in their application could lead to an increased risk of international tax disputes and an increase in our effective tax rate, which could adversely affect our financial results. The integrated nature of our worldwide operations can produce conflicting claims from revenue authorities in different countries as to the profits to be taxed in the individual countries. Many of the jurisdictions in which we operate have double tax treaties with other foreign jurisdictions, which provide a framework for mitigating the impact of double taxation. However, procedures developed to resolve such conflicting claims are largely untried and may be lengthy. Accruals for tax contingencies are made based on experience, interpretations of tax law, and judgments about potential actions by tax authorities. Due to the complexity of tax contingencies, the ultimate resolution of any tax matter may result in payments materially different from the amounts accrued.

We conduct business in countries where tax regimes may not be clear or consistently applied and are subject to sudden change. Our subsidiaries are and may in the future be subject to audit, investigation, or other tax controversies. While the outcome of such matters cannot be predicted with certainty, we do not currently expect that such matters will have a material adverse effect on our business or financial position. However, should one or more of these matters be resolved in a manner adverse to our current expectation, the effect on our results of operations for a particular fiscal reporting period could be material.

In 2019, the Organization for Economic Co-operation and Development (OECD) launched an initiative on behalf of the G20 to minimize profit shifting by working toward a global tax framework to ensure that corporate income taxes are paid where consumption takes place, in addition to introducing a global standard on minimum taxation combined with new tax dispute resolution processes. The implementation of these new global principles has begun for many member countries. However, some countries have announced postponement of implementation to future years, while others have not taken steps toward implementation. The OECD is issuing guidelines that are different, in some respects, from long-standing international tax principles. While the Company is actively pursuing mitigation strategies, as countries unilaterally amend their tax laws to adopt certain parts of the OECD guidelines, this may increase tax uncertainty and may adversely impact the Company's provision for income taxes and cash tax liability.

**Fluctuations in foreign currency exchange and interest rates could adversely affect our results of operations.**

Though we conduct business in many countries around the world, our sales of tobacco, consistent with the business of the leaf tobacco industry, are generally conducted in USD. Generally, we are required to purchase tobacco in foreign countries using local currency. As a result, local country operating costs, including the purchasing and processing costs for tobaccos, are subject to the effects of exchange fluctuations of the local currency against the USD. When the USD weakens against foreign currencies, our costs for purchasing and processing tobacco in such currencies increases. Although we operate in many foreign countries and are exposed to fluctuations in the currencies of numerous foreign countries, exchange fluctuation in the Brazilian Real against the USD has the greatest potential for impact on our financial results. We attempt to reduce such currency risks by matching the timing of our working capital borrowing needs against the tobacco purchasing and processing funds requirements

------

in the currency of the country where the tobacco is grown. Fluctuations in the value of foreign currencies can significantly affect our operating results.

In addition, the devaluation of foreign currencies has resulted and may in the future result in reduced purchasing power from customers whose capital resources are denominated in those currencies. We may incur a loss of business from the devaluation of these currencies now or in the future.

**<u>Risks Related to Other Aspects of Our Operations</u>**

**We rely on internally and externally hosted information technology systems and disruption, failure, or security breaches of these systems could adversely affect our business.**

We rely on information technology systems, including systems hosted by third-party service providers. For example, our enterprise resource planning system and our domestic employee payroll system are hosted by external service providers. Although we have disaster recovery plans and intrusion preventive mitigating tools and services, our portfolio of hardware and software products, solutions and services and our enterprise IT systems, including those hosted by service providers, may be vulnerable to damage or disruption caused by circumstances beyond our control, such as catastrophic events, power outages, natural disasters, computer system, or network failures, computer viruses or other malicious software programs, and cyber-attacks, including system hacking and other cyber-security breaches. We may face more sophisticated cyber-security attacks as a result of the proliferation of generative artificial intelligence providing bad actors with advanced cyber-attack tools. The failure or disruption of our IT systems to perform as anticipated could disrupt our business and result in decreased performance, significant remediation costs, transaction errors, loss of data, processing inefficiencies, downtime, litigation, and the loss of suppliers or customers. A significant disruption or failure could have a material adverse effect on our business operations, financial performance, and financial condition.

**We cannot assure you that material weaknesses in our internal control over financial reporting ("ICFR") will not be identified in the future.**

Although we monitor our ICFR, and improve them as needed, we cannot assure you that material weaknesses will not occur in the future. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations or result in misstatements in our financial statements in amounts that could be material. Ineffective ICFR could cause investors to lose confidence in our reported financial information, which could have a negative effect on the value of our common stock and/or publicly traded debt and could also require additional restatements of our prior reported financial information. In addition, because we are not an "accelerated filer" under applicable SEC regulations, we are not required to obtain and present a report of our independent accounting firm with respect to the effectiveness of our ICFR and we have not obtained such a report with respect to an evaluation of our internal controls as of March 31, 2026. Accordingly, no such report is included in this Form 10-K.

**Regulations regarding environmental matters may substantially increase our costs and expose us to potential liability.**

We are subject to environmental, health, and safety laws and regulations in the jurisdictions where we operate. Such regulations govern, among other things, emissions of pollutants into the air, wastewater discharges, waste disposal, the investigation and remediation of soil and groundwater contamination, and the health and safety of our employees. For example, our products and the raw materials used in their production processes are subject to numerous environmental laws and regulations. We may be required to obtain environmental permits from governmental authorities for certain of its current or proposed operations. From time to time, we may not be in full compliance with such laws, regulations, and permits. If we violate or fail to comply with these laws, regulations, or permits, we could be fined or otherwise sanctioned by regulators.

As with other companies engaged in similar activities or that own or operate real property, we face inherent risks of environmental liability at our current and historical production sites. Certain environmental laws impose strict and, in certain circumstances, joint and several liability on current or previous owners or operators of real property for the cost of the investigation, removal, or remediation of hazardous substances as well as liability for related damages to natural resources. In addition, we may discover new facts or conditions that may change our expectations or be faced with changes in environmental laws or their enforcement that would impose additional liabilities. Furthermore, our costs of complying with current and future environmental, health, and safety laws, or our liabilities arising from past or future releases of, or exposure to, regulated materials, may have a material adverse effect on our business, financial condition, and results of operations.

**We are subject to changing sustainability regulatory requirements and expectations, which exposes us to increased costs and legal and reputational risks.** 

Governments, the non-governmental community, and industry increasingly understand the importance of implementing comprehensive environmental, labor, and governance practices. We are committed to implementing a robust sustainability management system, and we continue to implement what we believe are responsible sustainability and governance practices. Government regulations, however, could result in new or more stringent forms of regulatory oversight and disclosures. These

------

may lead to increased expenditures for environmental controls, land use restrictions, reporting, and other conditions, which could have an adverse effect on our results of operations.

In addition, several governments have implemented or are considering implementing due diligence procedures to ensure strict compliance with environmental, labor, and government regulations. For example, the European Union enacted broad due diligence reporting requirements applicable to all industries operating within its Member States. Due to general uncertainty regarding the timing, content, and extent of any such regulatory changes, we cannot predict the impact, if any, that these changes could have to our business, financial condition, and results of operations.

**Our joint venture manufactures and supplies e-liquid and consumable nicotine-related products, which inherently carry the risk of exposure to product liability claims, regulatory action, and litigation in the event such products are alleged to have caused injury, harm, or death, and the Company and our related joint venture could be affected by such actions through reputational impact or claims alleging that our supplied materials contributed to the alleged harm.**

As a contract manufacturer of, and supplier of inputs for, products that are ingested or otherwise consumed by humans, our joint venture business faces the risk of exposure to product liability claims, regulatory action, and other litigation (including class proceedings and individual proceedings) if such products are alleged to have caused loss, injury, or death. E-liquids and other consumable nicotine product manufacturers and their suppliers may be subject to these types of claims, including that: (i) the products caused or contributed to injury, illness, or death; (ii) the manufacturer or supplier made false, misleading or impermissible statements regarding the products; (iii) the products lacked adequate labeling and instructions for use; and/or (iv) the products failed to include sufficient warnings concerning potential side effects or interactions with other substances.

Previously unknown adverse reactions resulting from human consumption of these e-liquids and other consumable nicotine products alone or in combination with other medications or substances could also occur. In addition, the manufacture and sale of any ingested or consumable product involves a risk of injury to consumers due to tampering by unauthorized third parties or product contamination, and our joint venture engaged in e-liquids and other consumable nicotine business may in the future have to recall certain of its manufactured products due to potential quality assurance concerns. Product liability claims or regulatory actions involving e-liquids and other consumable nicotine could increase costs and adversely affect our reputation and relationships with our customers and their consumers. We cannot assure you that product liability insurance held by the Company or our joint venture can be maintained on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could result in the Company or our joint venture becoming subject to significant liabilities that are uninsured.

The risk of class-based litigation (and individual litigation) for manufacturers and distributors of e-liquids and other consumable nicotine products, and others involved in the consumable nicotine industry, is significant, particularly in the face of increasing health and marketing concerns, the potential for product recalls, or other product-related issues. The U.S. has a highly active plaintiffs' bar. Recent years have seen several purported class action lawsuits in the U.S. against manufacturers, distributors and suppliers of e-liquid and other consumable nicotine-related products. These circumstances create enhanced risk and exposure for the Company given the nature of its operations, the products it manufactures, distributes, and sells, and its business environment.

In addition, our joint venture's customers operate in a highly regulated industry. Changes in federal, state, and local regulations applicable to e-liquids and other consumable nicotine products (e.g., nicotine content limits, prohibitions on sales of flavored products, imposition of or increases in the rates of excise taxes) could inhibit these customers' ability to market products in certain jurisdictions or generally. Further, even under existing laws, these customers may not obtain required regulatory authorizations for some or all products manufactured by, or containing inputs supplied by, our joint venture. Should changes in regulations or regulatory actions inhibit our joint venture's customers' ability to market such products, the Company's business, financial condition, and results of operations could in turn be adversely affected.

**<u>Risks Related to the Ownership of Our Common Stock</u>**

**Certain shareholders have the ability to exercise controlling influence on various corporate matters.**

Two shareholders and their respective affiliates, Glendon Capital Management LP (together with its affiliates, the "Glendon Investor") and Monarch Alternative Capital LP (together with its affiliates, the "Monarch Investor;" the Glendon Investor and the Monarch Investor are together referred to as the "Significant Shareholders") beneficially own in the aggregate approximately 59% of our issued and outstanding common stock and, therefore, have significant control on the outcome of matters submitted to a vote of shareholders, including, but not limited to, electing directors and approving corporate transactions. Pursuant to the terms of a Shareholders Agreement dated as of August 24, 2020, as amended, among the Company and certain shareholders, including the Significant Shareholders, each of the Glendon Investor and the Monarch Investor has the right (depending on its continued ownership of a specified percentage of the outstanding shares of our common stock) to

------

nominate up to two individuals for election as directors, and each of them and the other shareholders that are parties to the Shareholders Agreement have agreed to take the necessary action to elect such nominees as directors. Under our articles of incorporation, the affirmative vote of each of the Glendon Investor and the Monarch Investor, so long as it continues to maintain an Investor Percentage Interest (as defined in the Shareholders Agreement) of at least five percent, is required for the approval of any amendment to the articles of incorporation. It is our understanding that the Glendon Investor holds a significant amount of our senior secured indebtedness. Circumstances may occur where the interests of the Significant Shareholders could conflict with the interests of other shareholders, and the Significant Shareholders could have substantial influence to cause us to take actions that align with their interests. Should conflicts arise, we can provide no assurance that the Significant Shareholders would act in the best interests of other shareholders or that any conflicts of interest would be resolved in a manner favorable to our other shareholders.

**The price of our common stock may be negatively impacted by factors that are unrelated to our operations.**

Although our common stock is currently listed for quotation on the OTC Markets, we understand that no securities brokerage firm is making a market in the Company's common stock. Trading through the OTC Markets is frequently thin and may be highly volatile. There is no assurance that a sufficient market will continue in our stock, in which case it could be difficult for shareholders to sell their stock. The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of the industry and regions where our businesses operate, the operating results of our customers and competitors, trading volume in our common stock, changes in general conditions in the economy and the financial markets, or other developments affecting us and our customers and competitors. In addition, the stock market is subject to extreme price and volume fluctuations. This volatility has significantly affected the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same influence on our common stock.

**<u>Risks Related to the Tobacco Industry</u>**

**Reductions in demand for cigarettes and other consumer tobacco products could adversely affect our results of operations.**

The tobacco industry continues to face several issues that may reduce the consumption of cigarettes and other consumer tobacco products, which could adversely affect our business, sales volume, results of operations, cash flows, and financial condition.

These issues, some of which are more fully discussed below, include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• governmental actions seeking to ascribe to tobacco product manufacturers liability for adverse health effects associated with smoking and exposure to environmental tobacco smoke,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• smoking and health litigation against tobacco product manufacturers,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased consumer acceptance of alternative tobacco and nicotine products, including tobacco-free nicotine products,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• tax increases on consumer tobacco products,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• current and potential actions by state attorneys general to enforce the terms of the Master Settlement Agreement between state governments in the U.S. and tobacco product manufacturers,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the proliferation of investment policies and practices that restrict investments in tobacco-related companies,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• actual and proposed price controls and restrictions on imports in certain jurisdictions outside the U.S.,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restrictions on tobacco product manufacturing, marketing, advertising, and sales,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the diminishing social acceptance of smoking,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• tariffs and other trade restrictions on agricultural products, including tobacco,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential prohibition on the sale of menthol cigarettes and other tobacco products,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased pressure from anti-smoking groups,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• other tobacco product legislation that may be considered by the U.S. Congress, states, municipalities, and other countries, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of consolidation among multinational cigarette manufacturers.

**Legislation, regulatory, and other governmental initiatives could impose burdensome restrictions on the tobacco industry and reduce consumption of consumer tobacco products and demand for our services.**

The Tobacco Control Act ("TCA"), which amended the Food, Drug, and Cosmetic Act, extended the authority of the Food and Drug Administration ("FDA") to regulate tobacco products and authorized the FDA to adopt product standards for tobacco products, including the level of nicotine yield and the reduction or elimination of other constituents of the products, along with provisions for the testing of products against these standards. The TCA: (i) enhanced restrictions on the advertising of tobacco products; (ii) authorized the FDA to limit the sales of tobacco products to face-to-face transactions permitting the verification of the age of the purchaser; (iii) authorized a study to determine whether the minimum age for the purchase of tobacco products should be increased; and (iv) requires submission of reports from manufacturers of tobacco products to the FDA regarding product ingredients and other matters, including reports on health, toxicological, behavioral, or physiologic effects of tobacco products and their constituents. For packaging, the TCA also mandates warning labels and requires manufacturers to indicate

------

the percentage of domestically and foreign-grown tobacco in the product. The FDA has adopted regulations under the TCA establishing requirements for the sale, distribution, and marketing of cigarettes, as well as package warnings and advertising limitations.

The TCA also directed the FDA to promulgate regulations requiring that the methods used in, and the facilities and controls used for, the manufacture, preproduction design validation, packing, and storage of a tobacco product conform to current good manufacturing practices. Except for our U.S. cut rag processing facility, regulations under the TCA do not apply to tobacco leaf that is not in the possession of a manufacturer of tobacco consumer products, or to the producers of tobacco leaf, including tobacco suppliers, tobacco warehouses, and tobacco supplier cooperatives unless those entities are controlled by a tobacco product manufacturer.

Reports with respect to the harmful physical effects of cigarette smoking have been publicized for many years, and the sale, promotion, and use of cigarettes continue to be subject to increasing governmental regulation. Since 1964, the Surgeon General of the U.S. and the Secretary of Health and Human Services have released several reports linking cigarette smoking with a broad range of health hazards, including various types of cancer, coronary heart disease, and chronic lung disease, and recommending various governmental measures to reduce the incidence of smoking. More recent reports focus on the addictive nature of cigarettes, the effects of smoking cessation, the decrease in smoking in the U.S., the economic and regulatory aspects of smoking in the Western Hemisphere, and cigarette smoking by adolescents, particularly the addictive nature of cigarette smoking in adolescence. Numerous state and municipal governments have taken, and others may take, actions to diminish the social acceptance of smoking of tobacco products, including banning smoking in certain public and private locations.

Several countries have also taken steps to restrict or prohibit cigarette advertising and promotion, to increase taxes on cigarettes to discourage cigarette smoking and to ban flavored tobacco products. In some cases, such restrictions are more onerous than those in the U.S. For example, advertising and promotion of cigarettes has been banned or severely restricted in Australia, Canada, Finland, France, Italy, Singapore and other countries and menthol and other flavored cigarettes are banned in the European Union and the United Kingdom. Further, in February 2005, the World Health Organization ("WHO") treaty, the Framework Convention for Tobacco Control ("FCTC"), entered into force. This treaty, which the WHO reported was signed or otherwise ratified by 183 nations, requires party nations to enact legislation that would require, among other things, specific actions to prevent youth smoking; restrict or prohibit tobacco product marketing; inform the public about the health consequences of smoking and the benefits of quitting; regulate the content of tobacco products; impose new package warning requirements including the use of pictorial or graphic images; eliminate cigarette smuggling and counterfeit cigarettes; restrict smoking in public places; increase and harmonize cigarette excise taxes; abolish duty-free tobacco sales; and permit and encourage litigation against tobacco product manufacturers.

Due to the present regulatory and legislative environment globally, a substantial risk exists that tobacco product sales may decline. A significant decrease in worldwide tobacco consumption brought about by existing or future governmental laws and regulations would reduce demand for tobacco products and services and could have a material adverse effect on our results of operations.

**The impact of potential regulations to prohibit the sale of cigarettes in the U.S., other than low-nicotine cigarettes, if they are adopted and become effective, is uncertain, but they could materially adversely affect our business, results of operations, and financial condition.**

On January 15, 2025, the FDA published a proposed rule that would limit the nicotine level at 0.7 milligrams per gram of tobacco in cigarettes and certain other combusted tobacco products, which is significantly lower than the average concentration in these products on the market today. The FDA's proposal would apply to cigarettes, cigarette tobacco, roll-your-own tobacco, most cigars (including little cigars, cigarillos, and most large cigars), and pipe tobacco. The FDA's proposal does not include e-cigarettes, nicotine pouches, noncombusted cigarettes (such as heated tobacco products that meet the definition of a cigarette), waterpipe tobacco (hookah), smokeless tobacco products, or premium cigars.

The proposal is subject to public comment prior to being adopted by the FDA, which closed on September 15, 2025. Accordingly, the terms of any such final rule and potential date of their effectiveness are uncertain. While the FDA announced that reducing the nicotine levels of cigarettes would reduce consumption of cigarettes by future generations and facilitate current smokers to stop consuming cigarettes, it is uncertain whether their proposal, if it is adopted and becomes effective, will have such effect. While the impact of the FDA's proposal on the Company is also uncertain, regulations consistent with those set forth in the proposed rule, if they are adopted and become effective, could materially adversely affect our business, volume, results of operations, cash flows, and financial condition.

------

**Government actions can have a significant effect on the sourcing of tobacco. If some of the current efforts are successful, we could have difficulty obtaining sufficient tobacco to meet our customers' requirements, which could have an adverse effect on our performance and results of operations.**

A variety of government actions in certain jurisdictions can have a significant effect on the sourcing and production of leaf tobacco. If some of the current proposed efforts are successful, we could have increased barriers to meeting our customers' requirements, which could have an adverse effect on our performance and results of operations.

The WHO, through the FCTC, has specifically issued policy options and recommendations to promote crop diversification initiatives and alternatives to growing leaf tobacco in countries whose economies depend upon tobacco production. If certain countries were to follow these policy recommendations and seek to eliminate or significantly reduce leaf tobacco production, we could encounter difficulty in sourcing leaf tobacco from these regions to fulfill customer requirements, which could have an adverse effect on our results of operations.

Certain recommendations by the WHO, through the FCTC, may also cause shifts in customer usage of certain styles of tobacco. In countries such as Canada and Brazil and in the European Union, efforts have been taken to eliminate certain ingredients from the manufacturing process for tobacco products. The FCTC and national governments have also discussed formulating a strategy to place limitations on the level of nicotine allowed in tobacco and tobacco smoke. Such decisions could cause a change in requirements for certain styles of tobacco in particular countries. Shifts in customer demand from one type of tobacco to another could create sourcing challenges as requirements move from one origin to another.

Regulations impacting our customers that change the requirements for leaf tobacco or restrict their ability to sell their products would inherently impact our business. We have implemented a proprietary "track and trace" system that gathers data on leaf product beginning at the farm level to assist our customers' collection of raw material information to support leaf traceability and customer testing requirements. Additionally, given our global presence, we also have the ability to source different types and styles of tobacco for our customers should their needs change due to regulation. Despite our capabilities, the extent to which governmental actions will affect our business, financial condition, results of operations, and demand for our products and services will depend on future developments, which are highly uncertain and cannot be predicted.

In addition, continued government and public emphasis on environmental issues, including climate change, conservation, and natural resource management, could result in new or more stringent forms of regulatory oversight of industry activities, which may lead to increased levels of expenditures for environmental controls, land use restrictions affecting us or our suppliers, and other conditions that could have a material adverse effect on our business, financial condition, and results of operations. For example, certain aspects of our business generate carbon emissions. Regulatory restrictions on greenhouse gas emissions have been proposed in certain countries in which we operate. These may include limitations on such emissions, taxes or emission allowance fees on such emissions, various restrictions on industrial operations, and other measures that could affect land-use decisions, the cost of agricultural production, and the cost and means of processing and transporting our products. These actions could adversely affect our business, financial condition, and results of operations.

**Certain of our predecessor companies have been subject to governmental investigations into, and litigation concerning, leaf tobacco industry buying and other payment practices.**

The leaf tobacco industry, from time to time, has been the subject of government investigations regarding trade practices. For example, certain of our predecessor companies were the subject of an investigation by the Antitrust Division of the U.S. Department of Justice into certain buying practices alleged to have occurred in the industry, were named defendants in an antitrust class action litigation alleging a conspiracy to rig bids in the tobacco auction markets, and were the subject of an administrative investigation into certain tobacco buying and selling practices alleged to have occurred within the leaf tobacco industry in some countries within the European Union, including Italy, Greece, Spain, and potentially other countries.

**<u>Item 1B. Unresolved Staff Comments</u>**

None.

**<u>Item 1C. Cybersecurity</u>**

***Risk Management and Strategy***

The Company recognizes the importance of maintaining cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our data. Our information security framework leverages information and guidance from external sources and is managed by an internal team, led by the Cybersecurity Manager. This team provides updates on the overall effectiveness of the cybersecurity framework, including information on cyber threats and incidents, to the Information Services leadership team consisting of the Executive Vice President ("EVP") – Global Business & Information Services, Vice President ("VP") – Global Business Systems, VP – Global Information Technology Operations and Governance,

------

and Senior Director – Data Insights and Innovation. We utilize a multi-layered, risk-based approach to our security controls to prevent, detect, and respond to cybersecurity threats. Our capabilities, processes, and security measures include, and are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reactive endpoint protection to detect and prevent virus and malware threats,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• network perimeter firewalls, including malware prevention,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• e-mail scanning to prevent spam and phishing campaigns,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• vulnerability scanning and remediation of vulnerabilities based on priority,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• logical access controls, including multi-factor authentication,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• incident response procedures, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disaster recovery protocols.

The Company educates its workforce as part of our security awareness program to understand the risks and potential impacts of cybersecurity threats on our business, and ways employees can remain vigilant to prevent cybersecurity incidents from occurring. The program includes annual employee acknowledgement of security related policies, ongoing communication about prevalent vulnerabilities, security awareness training, and simulated phishing campaigns.

We maintain strategic partnerships with third-party service providers to enhance our security measures and improve resilience against cybersecurity threats. Annual penetration tests are conducted by a third party to evaluate existing security measures and identify improvements. Additionally, the Company engages a managed detection and response service to monitor our end points, identify suspicious activity, and perform actions to prevent or stop attacks.

The Company maintains a cybersecurity insurance policy that provides coverage for potential losses arising from a cybersecurity incident. Although we maintain cybersecurity insurance, there can be no guarantee that our policy will cover all losses or all types of claims that may arise from such incidents.

***Governance***

Our processes for assessing, identifying, and managing material risks from cybersecurity are included in our Enterprise Risk Management ("ERM") program. Oversight of the Company's ERM program resides with the Audit Committee and our Board of Directors. The Audit Committee regularly reviews the results from the Company's ERM program with management. The Board of Directors receives updates from the EVP – Global Business & Information Services regarding cybersecurity framework developments and information that may impact the Company's cybersecurity posture.

The Company's EVP – Global Business & Information Services reports to the Chief Executive Officer and has 37 years of experience leading information technology functions, which includes information security and incident management prevention and response. Under the direction of the EVP – Global Business & Information Services and the Chief Executive Officer, an internal team within the Company's Information Services department analyzes cybersecurity risks, considers industry trends, and implements controls, as appropriate, to mitigate these risks.

***Impact of Cybersecurity Risks and Threats***

As of the date of this Annual Report on Form 10-K, we are not aware of cybersecurity incidents that have materially affected or are reasonably likely to materially affect our business strategy, results of operations, or financial condition. However, there can be no assurance that a material cybersecurity incident will not occur in the future. Additional information on cybersecurity risks is discussed in "<u>[Item 1A. Risk Factors](#i6f44eae8422d46cd9f377051509c10a4_22)</u>," which should be read in conjunction with the foregoing information.

------

**<u>Item 2. Properties</u>**

Our corporate headquarters are leased and located in Morrisville, North Carolina. We operate our leaf tobacco processing facilities for seven to nine months per year corresponding with the applicable harvesting seasons. We continually compare our production capacity and organization with the transitions occurring in global sourcing of tobacco. We believe our domestic production facilities and certain foreign production facilities have the capacity to process additional volumes of tobacco if required by customer demand. The following is a listing of the principal physical properties owned or leased that are material to our leaf tobacco operations as of March 31, 2026:

---

| | | |
|:---|:---|:---|
| **Location** | **Use** | **Owned or Leased** |
| <u>North America</u> | | |
| &nbsp;&nbsp;&nbsp;Wilson, North Carolina, USA | Factory / Storage | Owned |
| &nbsp;&nbsp;&nbsp;Farmville, North Carolina, USA | Storage | Owned |
| <u>South America</u> | | |
| &nbsp;&nbsp;&nbsp;Venancio Aires, Brazil | Factory / Storage | Owned |
| &nbsp;&nbsp;&nbsp;El Carril, Argentina | Storage | Owned |
| <u>Europe</u> | | |
| &nbsp;&nbsp;&nbsp;Kavadarci, North Macedonia | Factory / Storage | Leased |
| &nbsp;&nbsp;&nbsp;Aqaba, Jordan | Factory / Storage | Leased |
| <u>Africa</u> | | |
| &nbsp;&nbsp;&nbsp;Lilongwe, Malawi | Factory / Storage | Owned |
| &nbsp;&nbsp;&nbsp;Morogoro, Tanzania | Factory / Storage | Owned |
| &nbsp;&nbsp;&nbsp;Harare, Zimbabwe | Factory / Storage | Owned |
| <u>Asia</u> | | |
| &nbsp;&nbsp;&nbsp;Ngoro, Indonesia | Factory / Storage | Owned |

---

**<u>Item 3. Legal Proceedings</u>**

See "<u>[Note 22. Contingencies and Other Information](#i6f44eae8422d46cd9f377051509c10a4_196)</u>" to the "Notes to Consolidated Financial Statements" for additional information with respect to legal proceedings, which is incorporated by reference herein.

**<u>Item 4. Mine Safety Disclosures</u>**

Not applicable.

**PART II**

**<u>Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</u>**

Pyxus' common stock is traded on the OTCID Basic Market maintained by the OTC Markets Group, Inc., under the symbol "PYYX." Over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions. As of March 31, 2026, the outstanding shares of our common stock were held by one shareholder of record and there were approximately 600 beneficial holders of our common stock.

**Issuer Purchase of Equity Securities**

The Company did not repurchase any of its equity securities during the three months ended March 31, 2026.

On August 15, 2024, the Board of Directors authorized a program to repurchase up to $10,000,000 plus fees and expenses of our common stock in the open market or through privately negotiated transactions, subject to limitations under the Company's debt agreements (which currently limit the aggregate amount that may be applied to repurchase shares of common stock to $1,000,000). The repurchase by the Company, on August 21, 2024, of shares of its common stock for approximately $1,000,000, inclusive of brokerage fees, was applied to this limit. This program expires on August 15, 2027. If current restrictions under applicable debt agreements are modified to permit further repurchases of common stock by the Company, the number, price, structure and timing of any further share repurchases will be at the Company's sole discretion, and any such future repurchases of our common stock are dependent on market conditions, liquidity needs, and certain restrictions under our debt arrangements, among other factors.

------

No cash dividends on shares of common stock of Pyxus were paid to shareholders during the fiscal year ended March 31, 2026. The declaration and payment of such dividends is at the discretion of our Board of Directors and subject to our results of operations, financial condition, cash requirements, and other factors, as well as restrictions under applicable law, and our debt agreements.

**<u>Item 6. [Reserved]</u>**

**<u>Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>**

***Forward-Looking Statements***

Readers are cautioned that the statements contained in this report regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which are based on current expectations of future events, may be identified by the use of words such as "strategy," "expects," "continues," "plans," "anticipates," "believes," "will," "estimates," "intends," "projects," "goals," "targets," and other words of similar meaning. These statements also may be identified by the fact that they do not relate strictly to historical or current facts. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from those anticipated, estimated, or projected. Some of these risks and uncertainties include the risks, uncertainties, and other factors set forth in this Annual Report, including in "<u>[Item 1A. Risk Factors](#i6f44eae8422d46cd9f377051509c10a4_22)</u>" and in our other filings with the Securities and Exchange Commission. Any forward-looking statement is qualified by reference to these cautionary statements. It is not possible to predict or identify all risks and uncertainties relevant to these forward-looking statements. Consequently, the risks and uncertainties identified in this Annual Report should not be considered a complete discussion of all potential risks or uncertainties. We do not undertake to update any forward-looking statement that we may make from time to time except as may be required by law.

***Non-GAAP Financial Measure***

Our financial statements are prepared in accordance with accounting principles generally accepted in the U.S. ("U.S. GAAP") However, we use net debt, a non-GAAP financial measure, to evaluate our financial condition. We believe that the presentation of this non-GAAP financial measure, when viewed as a supplement to our indebtedness reflected on our balance sheets prepared in accordance with U.S. GAAP, provides useful information to investors in evaluating our indebtedness. In addition, this non-GAAP measure addresses questions we routinely receive from analysts and investors and, to ensure that investors have access to similar data, we make this data available to the public. This non-GAAP measure should not be considered as an alternative to total debt or any other measure derived in accordance with U.S. GAAP. This non-GAAP measure has important limitations as an analytical tool and should not be considered in isolation or as a substitute for financial measures presented in accordance with U.S. GAAP. The presentation of our non-GAAP financial measures may change from time to time, including from changed business conditions, new accounting rules, or otherwise. Further, our use of "net debt" may vary from the use of similarly titled measures by other companies due to the potential inconsistencies in the method of calculation and differences due to items subject to interpretation.

***Executive Summary***

Fiscal 2026 results were influenced by larger crops in several of our key operating origins, notably those in Africa and South America, a consistent factor throughout the fiscal year. Larger crops generally reduce the per-unit cost of procuring green tobacco and provide us with opportunities to source higher volumes from our global supplier base. Lower purchasing costs, together with increased processing volumes, contributed to current year cost efficiencies, including the dilution of conversion costs on a per-kilo basis.

During fiscal 2026, the global tobacco market transitioned from an undersupply position at the beginning of the fiscal year to an oversupply by its conclusion on March 31, 2026. Against this evolving market backdrop, which also included the introduction of new tariff regulations and the continuation of geopolitical conflicts, our consolidated results continued to include gross profit expansion and increased operating income when compared to the prior year. Our financial performance demonstrates our team's ability to adapt to changing, and sometimes challenging, market conditions, by leveraging our globally diversified footprint, supporting our suppliers, and working with our customers to ensure their requirements are met.

The Company enters fiscal year 2027 with a total of $786.7 million of tobacco inventories on hand, higher than the $732.2 million at the same time a year ago. The higher tobacco inventories are expected to result in more carry-over sales versus fiscal 2026. Crop purchases have commenced in our key sourcing origins within the Southern Hemisphere, and for the second consecutive year we are observing the production of large crops across most of these origins. We are taking a measured approach in our buying strategy to ensure we are procuring the volumes necessary to meet our customers' needs.

------

***Overview***

Pyxus is a global agricultural company with businesses having more than 150 years of experience delivering value-added products and services to businesses and customers. The Company is a trusted provider of responsibly sourced, independently verified, sustainable, and traceable products and ingredients. The Company has one reportable segment for financial reporting purposes: Leaf. An All Other category is included for purposes of reconciliation of the results of the Leaf reportable segment to the consolidated results. See "<u>[Note 26. Segment Information](#i6f44eae8422d46cd9f377051509c10a4_211)</u>" to the "Notes to the Consolidated Financial Statements" for additional information.

------

**Results of Operations** 

**Years Ended March 31, 2026 and 2025**

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| ***Consolidated*** |  |  | Change |
| *(in millions, except per kilo amounts)* | 2026 | 2025 | $% |
| Sales and other operating revenues | $2413.0 | $2481.3 | (2.8) |
| Cost of goods and services sold | 2065.3 | 2138.3 | (3.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 347.7 | 343.0 | 1.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit as a percent of sales | 14.4% | 13.8% |  |
| Selling, general, and administrative expenses | $162.9 | $171.0 | (4.7) |
| Other expense, net | 19.2 | 16.4 | 17.1 |
| Restructuring and asset impairment charges | 2.9 | 2.3 | 26.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 162.7 | 153.3 | 6.1 |
| Gain on debt retirement |  | 8.2 | (100.0) |
| Gain on pension settlement | 0.3 |  | 100.0 |
| Interest expense, net | 134.4 | 128.0 | 5.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes and other items | 28.6 | 33.5 | (14.6) |
| Income tax expense | 30.3 | 25.1 | 20.7 |
| Income from unconsolidated affiliates, net | 17.4 | 8.1 | 114.8 |
| Net income attributable to noncontrolling interests | 1.1 | 1.4 | (21.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Pyxus International, Inc.\* | $14.6 | $15.2 | (3.9) |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| Leaf: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenues | $2235.8 | $2335.1 | (99.3) | (4.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tobacco costs | 1808.0 | 1905.5 | (97.5) | (5.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Transportation, storage, and other period costs | 115.8 | 108.5 | 7.3 | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total product cost of goods sold | 1923.8 | 2014.0 | (90.2) | (4.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Product gross profit | 312.0 | 321.1 | (9.1) | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Product gross profit as a percent of sales | 14.0% | 13.8% |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kilos sold | 381.7 | 383.4 | (1.7) | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp; Average price per kilo | $5.86 | $6.09 | (0.23) | (3.8) |
| &nbsp;&nbsp;&nbsp;&nbsp; Average cost per kilo | 5.04 | 5.25 | (0.21) | (4.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average gross profit per kilo | 0.82 | 0.84 | (0.02) | (2.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Processing and other revenues | $169.3 | $135.9 | 33.4 | 24.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Processing and other costs of services sold | 135.3 | 111.8 | 23.5 | 21.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Processing and other gross profit | 34.0 | 24.1 | 9.9 | 41.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Processing and other gross profit as a percent of sales | 20.1% | 17.7% |  |  |
| All Other: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and other operating revenues | $7.9 | $10.3 | (2.4) | (23.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods and services sold | 6.2 | 12.5 | (6.3) | (50.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) | 1.7 | (2.2) | 3.9 | 177.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) as a percent of sales | 21.5% | (21.4)% |  |  |
| *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* |

---

------

Sales and other operating revenues decreased $68.3 million, or 2.8%, to $2,413.0 million for the year ended March 31, 2026 from $2,481.3 million for the year ended March 31, 2025. This decrease was a result of a 3.8% decrease in average price per kilo, primarily in Africa, with pricing reflective of the lower costs to purchase the crop in the current fiscal year, and lower leaf product revenues driven by a decline in value-added tobacco products sales volumes. The decrease in leaf product revenues was partially offset by volume growth in processing and other revenues mainly from Africa and North America.

Cost of goods and services sold decreased $73.0 million, or 3.4%, to $2,065.3 million for the year ended March 31, 2026 from $2,138.3 million for the year ended March 31, 2025, corresponding to the reduction in sales and other operating revenues, principally driven by lower costs incurred to purchase and process the current crop.

Gross profit increased $4.7 million, or 1.4%, to $347.7 million for the year ended March 31, 2026 from $343.0 million for the year ended March 31, 2025, mainly attributable to increased leaf product sales volumes in South America and higher volumes from processing and other revenues in Africa and North America. The larger processing and other revenues contributed to the improvement in gross profit as a percent of sales to 14.4%, compared to 13.8% in the prior fiscal year.

Selling, general, and administrative expenses decreased $8.1 million, or 4.7%, to $162.9 million for the year ended March 31, 2026 from $171.0 million for the year ended March 31, 2025, primarily driven by a lower accrual for variable incentive compensation and less equity-based compensation expense due to the non-recurrence of modifications to restricted stock awards effected in the prior fiscal year, partially offset by increased personnel costs.

Gain on debt retirement of $8.2 million for the year ended March 31, 2025 was due to the repurchase of $10.3 million of aggregate principal amount of the Pyxus Term Loans for $9.1 million, a 12.0% discount to par, and the repurchase of $34.2 million aggregate principal amount of the 2027 Notes for $26.3 million, a 23.0% discount to par. There were no repurchases of senior secured notes or term loans during the year ended March 31, 2026. See "<u>[Note 25. Related Party Transactions](#i6f44eae8422d46cd9f377051509c10a4_208)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

Interest expense, net increased $6.4 million, or 5.0%, to $134.4 million for the year ended March 31, 2026 from $128.0 million for the year ended March 31, 2025 due to higher average balances outstanding on our foreign seasonal lines of credit primarily in Africa and South America, partially offset by a decrease in weighted average interest rates on our foreign seasonal lines of credit and senior secured term loans.

Income tax expense increased $5.2 million, or 20.7%, to $30.3 million for the year ended March 31, 2026 from $25.1 million for the year ended March 31, 2025 mainly due to the partial release of the valuation allowance applied against certain U.S. deferred tax assets in the prior fiscal year.

***Comparison of the Fiscal Year Ended March 31, 2025 to the Fiscal Year Ended March 31, 2024***

For a comparison of our results of operations for the years ended March 31, 2025 to March 31, 2024, see "Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our annual report on <u>[Form 10-K for the fiscal year ended March 31, 2025](https://www.sec.gov/ix?doc=/Archives/edgar/data/0000939930/000093993025000035/pyx-20250331.htm)</u>, filed with the SEC on June 10, 2025.

------

**Liquidity and Capital Resources**

***Overview***

Our primary sources of liquidity are cash generated from operations, short-term borrowings under our foreign seasonal lines of credit, availability under our ABL Credit Facility, and cash collections from our securitized receivables. Our liquidity requirements are affected by various factors from our tobacco leaf business, including crop seasonality, foreign currency and interest rates, green tobacco prices, customer mix, crop size, and quality. Our leaf tobacco business is seasonal, and purchasing, processing, and selling activities have several associated peaks where cash on-hand and outstanding indebtedness may vary significantly compared to year end. The first two quarters of our fiscal year generally represent the peak of our working capital requirements.

We believe our sources of liquidity will be sufficient to fund our anticipated operating needs for the next twelve months. During such time, our liquidity needs for operations may approach the levels of our anticipated available cash and permitted borrowings under our credit facilities. Unanticipated developments affecting our liquidity needs, including with respect to the foregoing factors, and sources of liquidity, including impacts affecting our cash flows from operations and the availability of capital resources (including an inability to renew or refinance seasonal lines of credit), may result in a deficiency in liquidity. To address a potential liquidity deficiency, we may undertake plans to minimize cash outflows, which could include exiting operations that do not generate positive cash flow. It is possible that, depending on the occurrence of events affecting our liquidity needs and sources of liquidity, such plans may not be sufficient to adequately or timely address a liquidity deficiency.

***Debt Financing***

We continue to finance our business with a combination of short-term and long-term seasonal credit lines, the long-term debt instruments and securities, advances from customers, and cash from operations when available. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for a summary of our short-term and long-term debt.

We continuously monitor and, as available, adjust funding sources as needed to enhance and drive various business opportunities. From time to time, we may take steps to reduce our debt or otherwise improve our financial position. Such actions could include prepayments, open market debt repurchases, negotiated repurchases, other redemptions or retirements of outstanding debt, and refinancing of debt. The amount of prepayments or the amount of debt that may be repurchased, refinanced, or otherwise retired, if any, will depend on market condition, trading levels of our debt, our cash position, compliance with debt covenants, and other considerations.

***Senior Secured Debt***

*ABL Credit Facility*

The Company's wholly owned subsidiary, Pyxus Holdings, Inc. ("Pyxus Holdings"), certain subsidiaries of Pyxus Holdings (together with Pyxus Holdings, the "Borrowers"), and the Company and its wholly owned subsidiary, Pyxus Parent, Inc. ("Pyxus Parent"), as parent guarantors, entered into an ABL Credit Agreement (as amended, the "ABL Credit Agreement"), dated as of February 8, 2022, by and among Pyxus Holdings, as Borrower Agent, the Borrowers and parent guarantors party thereto, the lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Collateral Agent (the "ABL Agent"), which was subsequently amended on January 5, 2023, May 23, 2023, October 24, 2023, and May 12, 2025.

The ABL Credit Agreement establishes the ABL Credit Facility, an asset-based revolving credit facility the proceeds of which may be used to provide for the ongoing working capital and general corporate purposes of the Borrowers, the Company, Pyxus Parent, and their subsidiaries, and for other permitted purposes described in the ABL Credit Agreement. The ABL Credit Facility may be used for revolving credit loans and letters of credit from time to time up to a maximum principal amount of $150.0 million, subject to the borrowing base limitations described below in this paragraph. The ABL Credit Facility includes a $20.0 million uncommitted accordion feature that permits Pyxus Holdings, under certain conditions, to solicit the lenders under the ABL Credit Facility to provide additional revolving loan commitments to increase the aggregate amount of the revolving loan commitments under the ABL Credit Facility not to exceed a maximum principal amount of $170.0 million. The amount available under the ABL Credit Facility is limited by a borrowing base consisting of certain eligible accounts receivable and the value of inventory, as reduced by specified reserves, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 85% of the book value of eligible accounts receivable, plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the lesser of (i) 85% of the book value of Eligible Extended Terms Receivables (as defined in the ABL Credit Agreement) and (ii) $5.0 million plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 90% of eligible credit insured accounts receivable (to the extent the ABL Agent is named as a beneficiary or loss payee with respect to the applicable policy), plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the lesser of (i) 70% of eligible inventory valued at the lower of cost (based on a first-in first-out basis) and market value thereof (net of intercompany profits) or (ii) 85% of the net-orderly-liquidation value percentage of eligible inventory, plus

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the least of (i) 70% of the eligible foreign in-transit inventory valued at the lower of cost (based on a first-in first-out basis) and market value thereof (net of intercompany profits), (ii) 85% of the net-orderly-liquidation value percentage of eligible foreign in-transit inventory, and (iii) $10.0 million, minus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• applicable reserves established by the ABL Agent from time to time.

At March 31, 2026, no borrowings under the ABL Credit Facility were outstanding and $150.0 million was available for borrowing under the ABL Credit Facility. Weighted average borrowings outstanding under the ABL Credit Facility during the fiscal year ended March 31, 2026 were $47.4 million.

The ABL Credit Facility permits both base rate borrowings and borrowings based upon the Secured Overnight Financing Rate ("SOFR"). Borrowings under the ABL Credit Facility bear interest at an annual rate equal to one, three, or six-month reserve-adjusted SOFR Rate plus 275 basis points or 175 basis points above base rate, as applicable, with a fee on unutilized commitments at an annual rate of 25.0 basis points.

The ABL Credit Facility may be prepaid from time to time, in whole or in part, without prepayment or premium, subject to a termination fee upon the permanent reduction of some or all of the commitments under the ABL Credit Facility in the amount of (i) 2% of the amount of commitments permanently reduced on or prior to May 12, 2026 and (ii) 1% of the amount of commitments permanently reduced on or prior to May 12, 2027 but after May 12, 2026. No such termination fee is payable for reductions after May 12, 2027. In addition, customary mandatory prepayments of the loans under the ABL Credit Facility are required upon the occurrence of certain events including, without limitation, outstanding borrowing exposures exceeding the borrowing base, certain dispositions of assets outside of the ordinary course of business in respect of certain collateral securing the ABL Credit Facility and certain casualty and condemnation events. With respect to base rate loans, accrued interest is payable monthly in arrears and, with respect to SOFR loans, accrued interest is payable monthly and on the last day of any applicable interest period.

The Borrowers' obligations under the ABL Credit Facility (and certain related obligations) are (a) guaranteed by Pyxus Parent, and the Company and all of Pyxus Holdings' wholly owned domestic subsidiaries, and each of Pyxus Holdings' future wholly owned domestic subsidiaries is required to guarantee the ABL Credit Facility on a senior secured basis (collectively, the "ABL Loan Parties") and (b) secured by the collateral, as described below, which is owned by the ABL Loan Parties.

*Cash Dominion.* Under the terms of the ABL Credit Facility, if (i) an event of default has occurred and is continuing, (ii) excess borrowing availability under the ABL Credit Facility (based on the lesser of the commitments thereunder and the borrowing base) (the "Excess Availability") falls below the greater of $12.5 million and 10% of the lesser of total revolving loan commitments under the ABL Credit Facility at such time and the borrowing base at such time, or (iii) Domestic Availability (as defined in the ABL Credit Agreement) being less than the greater of $25.0 million and 20% of the lesser of total revolving loan commitments under the ABL Credit Facility at such time and the borrowing base at such time, the ABL Loan Parties will become subject to cash dominion, which will require daily prepayment of loans under the ABL Credit Facility with the cash deposited in certain deposit accounts of the ABL Loan Parties, including concentration accounts, and will restrict the ABL Loan Parties' ability to transfer cash from their concentration accounts to their disbursement accounts. Such cash dominion period (a "Dominion Period") shall end when (i) if arising as a result of a continuing event of default, such event of default ceases to exist, (ii) if arising as a result of non-compliance with the Excess Availability threshold, no event of default is continuing and, for a period of 30 consecutive days, Excess Availability is equal to or greater than the greater of $12.5 million and 10% of the lesser of total revolving loan commitments under the ABL Credit Facility and the borrowing base, or (iii) if arising as a result of Domestic Availability being less than the threshold, no event of default is continuing and, for a period of 30 consecutive days, Domestic Availability is greater than $25.0 million and 20% of the lesser of total revolving loan commitments under the ABL Credit Facility and the borrowing base.

*Covenants.* The ABL Credit Agreement governing the ABL Credit Facility contains a covenant requiring that the Company's fixed charge coverage ratio be no less than 1.10 to 1.00 during any Dominion Period.

The ABL Credit Agreement governing the ABL Credit Facility contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's ability to, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• incur additional indebtedness or issue disqualified stock or preferred stock,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• make investments,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pay dividends and make other restricted payments,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sell certain assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• create liens,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into sale and leaseback transactions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• consolidate, merge, sell or otherwise dispose of all or substantially all of the Company's assets,

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into transactions with affiliates,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• engage directly or indirectly in any business other than the businesses engaged in by the Company,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• directly or indirectly open, maintain or otherwise have accounts other than permitted accounts under the ABL Credit Agreement, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• designate subsidiaries as Unrestricted Subsidiaries (as defined in the ABL Credit Agreement).

*Maturity.* The ABL Credit Facility matures on May 12, 2030 or, if earlier, 90 days prior to the earliest maturity date of (i) the Company's existing senior secured notes and the senior secured term loans (each scheduled to mature on December 31, 2027) in the event any such notes or loans remain outstanding or (ii) any indebtedness that refinances any of the foregoing.

On March 31, 2026, the Borrowers were in compliance with the covenants under the ABL Credit Agreement. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

*Intabex Term Loans*

Pursuant to (i) an exchange offer (the "DDTL Facility Exchange") made to, and accepted by, holders of 100.0% of the outstanding term loans (the "DDTL Term Loans") under the Amended and Restated Term Loan Credit Agreement, effectuated pursuant to that certain Amendment and Restatement Agreement, dated as of June 2, 2022 (the "DDTL Credit Agreement"), by and among Intabex Netherlands B.V., as borrower ("Intabex"), the guarantors party thereto, the administrative agent and collateral agent thereunder, and the several lenders from time to time party thereto and (ii) an exchange offer (the "Exit Facility Exchange") made to, and accepted by, holders of 100.0% of the outstanding term loans (the "Exit Term Loans") under the Exit Term Loan Credit Agreement, dated as of August 24, 2020 (the "Exit Term Loan Credit Agreement"), by and among Pyxus Holdings, as borrower, the guarantors party thereto, the administrative agent and collateral agent thereunder, and the several lenders from time to time party thereto, on February 6, 2023, Pyxus Holdings entered into the Intabex Term Loan Credit Agreement, dated as of February 6, 2023 (the "Intabex Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus (US) LLC ("Alter Domus"), as administrative agent and senior collateral agent. The Intabex Term Loan Credit Agreement established a term loan credit facility in an aggregate principal amount of approximately $189.0 million (the "Intabex Credit Facility"), under which term loans in the full aggregate principal amount of the Intabex Credit Facility (the "Intabex Term Loans") were deemed made in exchange for (i) $100.0 million principal amount of the DDTL Term Loans, plus an additional $2.0 million on account of the exit fee payable under the DDTL Credit Agreement and (ii) approximately $87.0 million principal amount of Exit Term Loans, representing 40.0% of the outstanding principal amount thereof (including the applicable accrued and unpaid PIK interest thereon).

The Intabex Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Intabex Term Loans are stated to mature on December 31, 2027.

The Intabex Term Loans may be prepaid from time to time, in whole or in part, without prepayment or penalty. With respect to alternate base rate loans, accrued interest is payable quarterly in arrears on the last business day of each calendar quarter and, with respect to SOFR loans, accrued interest is payable on the last day of each applicable interest period but no less frequently than every three months.

The Intabex Term Loan Credit Agreement contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; designate subsidiaries as unrestricted subsidiaries; and, in the case of Intabex, undertake business activities and sell certain subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors under the Intabex Term Loan Credit Agreement were in compliance with the covenants under the Intabex Term Loan Credit Agreement. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

*Pyxus Term Loans*

Pursuant to the Exit Facility Exchange, on February 6, 2023, Pyxus Holdings entered into the Pyxus Term Loan Credit Agreement, dated as of February 6, 2023 (the "Pyxus Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus, as administrative agent and senior collateral agent, to establish a term loan credit facility in an aggregate principal amount of approximately $130.6 million (the "Pyxus Credit Facility"), under which term loans in the full aggregate principal amount of the Pyxus Credit Facility (the "Pyxus Term Loans" and, together with the Intabex Term Loans, the "Senior Secured Term Loans") were deemed made in exchange for 60.0% of the outstanding principal amount of Exit Term Loans (including the applicable accrued and unpaid PIK interest thereon).

------

The Pyxus Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Pyxus Term Loans are stated to mature on December 31, 2027.

The Pyxus Term Loans may be prepaid from time to time, in whole or in part, without prepayment or penalty. With respect to alternate base rate loans, accrued interest is payable quarterly in arrears on the last business day of each calendar quarter and, with respect to SOFR loans, accrued interest is payable on the last day of each applicable interest period but no less frequently than every three months.

The Pyxus Term Loan Credit Agreement contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors under the Pyxus Term Loan Credit Agreement were in compliance with the covenants under the Pyxus Term Loan Credit Agreement.

*8.50% Senior Secured Notes due 2027*

Pursuant to an exchange offer (the "Notes Exchange" and, together with the DDTL Facility Exchange and the Exit Facility Exchange, the "Debt Exchange Transactions") made by Pyxus Holdings and accepted by holders of approximately 92.7% of the aggregate principal amount of the outstanding 10.0% Senior Secured First Lien Notes due 2024 issued by Pyxus Holdings (the "2024 Notes") pursuant to that certain Indenture, dated as of August 24, 2020 (the "2024 Notes Indenture"), by and among Pyxus Holdings, the guarantors party thereto and the trustee, collateral agent, registrar and paying agent thereunder, on February 6, 2023, Pyxus Holdings issued approximately $260.5 million in aggregate principal amount of 8.5% Senior Secured Notes due December 31, 2027 (the "2027 Notes" and, together with the Senior Secured Term Loans, the "Senior Secured Term Debt") to the exchanging holders of the 2024 Notes for an equal principal amount of 2024 Notes. The 2027 Notes were issued pursuant to the Indenture, dated as of February 6, 2023 (the "2027 Notes Indenture"), among Pyxus Holdings, the guarantors party thereto, and Wilmington Trust, National Association, as trustee, and Alter Domus, as collateral agent.

The 2027 Notes bear interest at a rate of 8.5% per annum, which interest is computed based on a 360-day year comprised of twelve 30-day months. Interest accrues on the 2027 Notes from the date of issuance and is payable semi-annually in arrears on June 15 and December 15 of each year, commencing on June 15, 2023. The 2027 Notes are stated to mature on December 31, 2027.

At any time, Pyxus Holdings may redeem the 2027 Notes, in whole or in part, at a redemption price equal to 100.0% of the principal amount of 2027 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date.

The 2027 Notes Indenture contains customary affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors of the 2027 Notes were in compliance with the covenants under the 2027 Notes Indenture.

*Guarantees and Collateral*

The obligations of Pyxus Holdings under the ABL Credit Agreement and the Senior Secured Term Debt are fully and unconditionally guaranteed by the Company, Pyxus Parent and all of the Company's domestic subsidiaries and certain of the Company's foreign subsidiaries, subject to certain limitations (the "Senior Secured Debt Obligors"). In addition, under the Intabex Term Loan Credit Facility, Intabex and Alliance One International Tabak B.V. (which were obligors under the DDTL Term Loans) also guarantee the Intabex Credit Facility (together, the "Specified Intabex Obligors") but do not guarantee the 2027 Notes, the Pyxus Term Loans or obligations under the ABL Credit Agreement. In addition, certain assets of the Specified Intabex Obligors (which were pledged as collateral for the DDTL Term Loans) are pledged as collateral to secure the Intabex

------

Term Loans (the "Intabex Collateral") but do not secure the 2027 Notes, the Pyxus Term Loans, or obligations under the ABL Credit Agreement. On March 27, 2024, Alliance One International Tabak B.V. was merged with and into Intabex.

The Senior Secured Debt Obligors' obligations under the ABL Credit Agreement are secured by (i) a first-priority senior lien the ABL Priority Collateral (as defined in the ABL/Senior Secured Term Debt Intercreditor Agreement (as defined below)), which includes certain accounts receivable and inventory and certain related intercompany notes, cash, deposit accounts, related general intangibles and instruments, certain other related assets and proceeds of the foregoing of the Senior Secured Debt Obligors, and (ii) a junior-priority lien on substantially all assets of the Senior Secured Debt Obligors other than certain exclusions and the ABL Priority Collateral. The Senior Secured Term Debt is secured by (i) a first-priority senior lien on substantially all assets of the Senior Secured Debt Obligors other than certain exclusions and the ABL Priority Collateral and (ii) a junior-priority lien on the ABL Priority Collateral. The Intabex Term Loans are further secured by a first-priority lien on the Intabex Collateral.

The obligations under the Senior Secured Term Debt share a single lien, held by Alter Domus, as senior collateral agent (the "Senior Collateral Agent"), on the Collateral (as defined below) subject to the payment waterfall pursuant to the intercreditor arrangements described below. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

*Intercreditor Agreements* 

The priority of the obligations under the ABL Credit Agreement and the Senior Secured Term Debt are set forth in the two intercreditor agreements entered into in connection with consummation of the DDTL Facility Exchange, the Exit Facility Exchange and the Notes Exchange.

*ABL/Senior Secured Term Debt Intercreditor Agreement*. On February 6, 2023, Pyxus Holdings, Inc., the guarantors party thereto, PNC Bank, National Association, as ABL Agent, Alter Domus, as Pyxus Term Loan Administrative Agent, Intabex Term Loan Administrative Agent and Senior Collateral Agent, and Wilmington Trust, National Association, as Senior Notes Trustee entered into an Amended and Restated ABL Intercreditor Agreement, dated as of February 6, 2023 (the "ABL/Senior Secured Term Debt Intercreditor Agreement") to provide for the intercreditor relationship between, (i) on one hand, the holders of obligations under the ABL Credit Facility, the guarantees thereof and certain related obligations and (ii) on the other hand, the holders of obligations under the Senior Secured Term Debt, the guarantees thereof and certain related obligations. Pursuant to the terms of the ABL/Term Loan/Notes Intercreditor Agreement, Pyxus Holdings' obligations under the ABL Credit Facility, the guarantees thereof and certain related obligations have first-priority senior liens on the ABL Priority Collateral, which includes certain accounts receivable and inventory and certain related intercompany notes, cash, deposit accounts, related general intangibles and instruments, certain other related assets of the foregoing entities and proceeds of the foregoing, with the obligations under the Senior Secured Term Debt having junior-priority liens on the ABL Priority Collateral. Pursuant to the ABL/Senior Secured Term Debt Intercreditor Agreement, Pyxus Holdings' collective obligations under the Senior Secured Term Debt, the guarantees thereof and certain related obligations have first-priority senior liens on the collateral that is not ABL Priority Collateral, including owned material real property in the U.S., capital stock of subsidiaries owned directly by Pyxus Holdings or a guarantor (other than the Intabex Collateral), existing and after acquired intellectual property rights, equipment, related general intangibles and instruments and certain other assets related to the foregoing and proceeds of the foregoing, with the obligations under the ABL Credit Facility having junior-priority liens on such collateral, other than real property. The ABL Credit Facility is not secured by real property.

*Secured Debt Intercreditor Agreement*. On February 6, 2023, the Senior Secured Debt Obligors, together with the representative for the holders of the Senior Secured Term Debt and the Senior Collateral Agent, entered into the Intercreditor and Collateral Agency Agreement, dated as of February 6, 2023 (the "Senior Secured Term Debt Intercreditor Agreement"), pursuant to which the Senior Collateral Agent, serves as joint collateral agent for the benefit of the holders of the 2027 Notes, the Pyxus Term Loans and the Intabex Term Loans with respect to all common collateral securing such indebtedness (the "Collateral," which excludes Intabex Collateral). The Senior Secured Term Debt Intercreditor Agreement provides that Collateral or proceeds thereof received in connection with or upon the exercise of secured creditor remedies will be distributed (subject to the provisions described in the next paragraph) first to holders of the Senior Secured Term Debt on a pro rata basis based on the aggregate principal amount of each class of Senior Secured Term Debt, and then to holders of future junior debt secured by such Collateral on a pro rata basis based on the aggregate principal amount of each class of future junior debt (and in each case permitted refinancing indebtedness thereof).

Exercise of rights and remedies against the Collateral and certain rights in a bankruptcy or insolvency proceeding (including the right to object to debtor-in-possession financing or to credit bid) by the Senior Collateral Agent will be controlled first by the holders of a majority in principal amount of the Senior Secured Term Loans (including, in any event, each holder holding at least 20.0% of the Senior Secured Term Loans as of February 6, 2023, provided such holder holds at least 15.0% of the Senior Secured Term Loans as of the date of determination), second, after repayment in full of the Senior Secured Term Loans, by the

------

holders of a majority in principal amount of the 2027 Notes and last, after repayment in full of the Senior Secured Term Loans and the 2027 Notes, by holders of a majority in principal amount of any future junior debt secured by the Collateral. Any such future junior debt will be subject to certain customary waivers of rights in a bankruptcy or insolvency proceeding in favor of the Senior Collateral Agent, including, but not limited to, with respect to debtor-in-possession financing, adequate protection, and credit bidding. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

***Foreign Seasonal Lines of Credit***

Excluding long-term credit arrangements, the Company typically finances its foreign operations with committed and uncommitted short-term foreign seasonal lines of credit arrangements with a number of banks. These operating lines are generally seasonal in nature, typically extending for a term of 180 to 365 days corresponding to the tobacco crop cycle in that location. For uncommitted facilities, the lenders have the right to cease making loans and demand repayment of loans at any time or at specified dates. These loans are generally renewed at the outset of each tobacco season. Certain of the foreign seasonal lines of credit are guaranteed by the Company and certain of its subsidiaries. At March 31, 2026, the total borrowing capacity under individual foreign seasonal lines of credit range up to $170.0 million. Certain of the foreign seasonal lines of credit, with aggregate outstanding borrowings at March 31, 2026 of approximately $106.9 million, are secured by trade receivables and inventories as collateral. At March 31, 2026, the Company and its subsidiaries were in compliance with the covenants associated with its short-term foreign seasonal lines of credit.

Seasonal liquidity beyond cash flow from operations is provided by our foreign seasonal lines of credit, advances from customers, and sales of accounts receivable. Our average short-term borrowings, peak quarter-end short-term borrowings outstanding, and weighted-average interest rate on short-term borrowings were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| *(in millions)* | 2026 | 2026 | 2025 | 2025 |
| Average short-term borrowings | $| 807.1 | $| 624.7 |
| Peak quarter-end short-term borrowings outstanding | $| 908.0 | $| 744.8 |
| Weighted-average interest rate on short-term borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4% |

---

Peak quarter-end borrowings for the year ended March 31, 2026 were at the end of the second quarter, which was driven by outstanding borrowings in Africa and South America. The increase in average and peak quarter-end borrowings when compared to the prior year is due to the larger crops the Company procured from our origins within those same regions. Borrowings during the prior year and in the current year were repaid with cash provided by operating activities. For further information on our debt financing as of March 31, 2026, see "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

The following summarizes our total borrowing capacity under our short-term and long-term credit lines and letter of credit facilities and the remaining available amount after the reduction for outstanding borrowings and amounts reserved for outstanding letters of credit:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2025 | March 31, 2025 |
| *(in millions)* | Total Borrowing Capacity | Remaining Amount Available | Total Borrowing Capacity | Remaining Amount Available |
| Senior Secured Credit Facilities: |  |  |  |  |
| &nbsp;&nbsp;ABL Credit Facility | $150.0 | $150.0 | $120.0 | $120.0 |
| Foreign seasonal lines of credit | 1053.4 | 594.3 | 906.2 | 525.4 |
| Other long-term debt |  |  | 0.4 | 0.4 |
| Letters of credit | 11.0 | 3.0 | 12.2 | 4.4 |
| &nbsp;&nbsp;Total | $1214.4 | $747.3 | $1038.8 | $650.2 |

---

The total borrowing capacity under the ABL Credit Facility increased $30.0 million when compared to the prior year as a result of the Fourth Amendment to the ABL Credit Agreement entered into on May 12, 2025, which among other things, increased the aggregate amount of revolving loan commitments from $120.0 million to $150.0 million. The amounts presented as available under the ABL Credit Facility are subject to further limitations from the borrowing base consisting of certain eligible accounts receivable and inventory, reduced by specified reserves.

------

The total borrowing capacity of our foreign seasonal lines of credit increased $147.2 million when compared to the prior year and were primarily utilized to purchase larger volumes of green tobacco. The amounts presented as the total borrowing capacity and the remaining amount available for borrowing under the foreign seasonal lines of credit are subject to limitations based on the level of receivables and inventories as collateral and by certain restrictive covenants, including covenants under the ABL Credit Agreement and the agreements governing the Senior Secured Term Debt.

***Net Debt***

We refer to "Net debt," a non-GAAP measure, as total debt liabilities less cash and cash equivalents. We believe this non-GAAP financial measure is useful to monitor leverage and to evaluate changes to the Company's capital structure. A limitation associated with using net debt is that it subtracts cash and cash equivalents, and therefore, may imply that management intends to use cash and cash equivalents to reduce outstanding debt and that cash held in certain jurisdictions can be applied to repay obligations owing in other jurisdictions and without reduction for applicable taxes. In addition, net debt suggests that our debt obligations are less than the most comparable GAAP measure indicates. The following summarizes the computation of net debt:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| *(in millions)* | 2026 | 2025 |
| Notes payable | $477.1 | $395.0 |
| Long-term debt<sup>(1)</sup> | 455.8 | 454.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt liabilities | $932.9 | $849.9 |
| Less: Cash and cash equivalents | 134.3 | 78.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net debt | $798.6 | $771.6 |
| <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility. Weighted average borrowings outstanding under the ABL Credit Facility were $47.4 million for the fiscal year ended March 31, 2026. | <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility. Weighted average borrowings outstanding under the ABL Credit Facility were $47.4 million for the fiscal year ended March 31, 2026. | <sup>(1)</sup> Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility. Weighted average borrowings outstanding under the ABL Credit Facility were $47.4 million for the fiscal year ended March 31, 2026. |

---

***Working Capital***

The following summarizes our working capital:

---

| | | | |
|:---|:---|:---|:---|
| | March 31, | March 31, | Change |
| *(in millions except for current ratio)* | 2026 | 2025 | $% |
| Cash, cash equivalents, and restricted cash | $137.7 | $85.5 | 61.1 |
| Trade and other receivables, net | 264.9 | 204.3 | 29.7 |
| Inventories and advances to tobacco suppliers, net | 854.3 | 792.7 | 7.8 |
| Recoverable income taxes | 2.9 | 6.6 | (56.1) |
| Prepaid expenses and other current assets | 70.8 | 69.0 | 2.6 |
| &nbsp;&nbsp;Total current assets\* | $1330.5 | $1158.2 | 14.9 |
| Notes payable | $477.1 | $395.0 | 20.8 |
| Accounts payable | 146.8 | 132.9 | 10.5 |
| Advances from customers | 175.0 | 135.6 | 29.1 |
| Accrued expenses and other current liabilities | 114.8 | 90.9 | 26.3 |
| Income taxes payable | 9.1 | 11.0 | (17.3) |
| Operating leases payable | 9.9 | 8.5 | 16.5 |
| &nbsp;&nbsp;Total current liabilities\* | $932.8 | $773.9 | 20.5 |
| Current ratio | 1.4 to 1 | 1.5 to 1 |  |
| Working capital | $397.7 | $384.3 | 3.5 |
| *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* | *\*Amounts may not equal column totals due to rounding.* |

---

Working capital increased $13.4 million, or 3.5%, to $397.7 million as of March 31, 2026 from $384.3 million as of March 31, 2025. The improvement in working capital reflects increased inventories and advances to tobacco suppliers, net from larger crops in Africa and South America, the timing and related impact of higher sales during the three months ended March 31, 2026 versus the same period a year ago, and an increase in cash and cash equivalents primarily from financing activities. The

------

increase in these current asset balances were partially offset by increased borrowings under foreign seasonal lines of credit to capture the higher crop volumes primarily in our Southern Hemisphere origins, an increase in advances from customers for future shipments of tobacco, and higher accrued expenses due to the timing of certain accruals, including an increase for accrued freight costs.

***Inventories***

The following summarizes inventory committed to a customer and uncommitted inventory balances for processed tobacco:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| *(in millions)* | 2026 | 2025 |
| Committed | $462.2 | $482.8 |
| Uncommitted | 45.2 | 7.6 |
| &nbsp;&nbsp;Total processed tobacco | $507.4 | $490.4 |

---

Total processed tobacco increased $17.0 million, or 3.5%, to $507.4 million as of March 31, 2026 from $490.4 million as of March 31, 2025. The increase primarily reflects larger crop volumes purchased and processed in Africa. We expected an increase in our uncommitted inventories when compared to the prior fiscal year, a consistent trend since the second quarter of fiscal year 2026, and the increase at March 31, 2026 is indicative of the shift to an oversupply position in the global tobacco market as we enter fiscal 2027. See "<u>[Note 1. Basis of Presentation and Summary of Significant Accounting Policies](#i6f44eae8422d46cd9f377051509c10a4_136)</u>" and "<u>[Note 9. Inventories, Net](#i6f44eae8422d46cd9f377051509c10a4_157)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

***Sources and Uses of Cash***

We have typically financed our foreign tobacco operations with committed and uncommitted short-term seasonal lines of credit. These lines of credit are generally seasonal in nature, normally extending for a term of 180 to 365 days, corresponding to the tobacco crop cycle in that market. For uncommitted facilities, the lenders have the right to cease making loans and demand repayment of loans. These short-term seasonal lines of credit are typically renewed at the outset of each tobacco season. We maintain various other financing arrangements to meet the cash requirements of our businesses. See "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

We utilize capital in excess of cash flow from operations to finance accounts receivable, inventory, and advances to tobacco suppliers in foreign countries. In addition, we may periodically elect to purchase, redeem, repay, retire, or cancel indebtedness prior to stated maturity under our various foreign seasonal credit lines.

As of March 31, 2026, our cash, cash equivalents, and restricted cash was $137.7 million, of which $99.4 million was held in foreign jurisdictions for working capital needs, a majority of which is subject to exchange controls and a portion of which is subject to tax consequences upon repatriation, which could limit our ability to fully repatriate these funds. Fluctuation of the U.S. dollar versus many of the currencies in which we incur costs may have an impact on our working capital requirements. We will continue to monitor and hedge foreign currency costs, as needed.

------

The following summarizes the sources and uses of our cash flows:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| *(in millions)* | 2026 | 2025 | 2024 |
| Net income | $15.7 | $16.5 | $3.2 |
| Trade and other receivables | (254.9) | (208.4) | (167.6) |
| Inventories and advances to suppliers | (60.4) | 156.3 | (136.0) |
| Payables and accrued expenses | 31.5 | (49.2) | 17.5 |
| Advances from customers | 34.8 | 45.9 | 55.3 |
| Other | 24.8 | 25.5 | 12.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(208.5) | $(13.4) | $(215.0) |
| Collections from beneficial interests in securitized trade receivables | 200.7 | 188.3 | 175.9 |
| Other | (9.3) | (17.7) | (16.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | $191.4 | $170.6 | $159.4 |
| Net proceeds (repayments) from short-term borrowings | 77.3 | (102.6) | 122.5 |
| Repayments of long-term borrowings |  | (55.8) | (60.3) |
| Net repayments of revolving loan facilities |  |  | (25.0) |
| Other | (4.8) | (8.9) | (11.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | $72.5 | $(167.3) | $25.6 |
| Effect of exchange rate changes on cash | (3.4) | (4.2) | (9.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in cash, cash equivalents, and restricted cash\* | $52.1 | $(14.2) | $(39.1) |
| *\*Amounts may not equal totals due to rounding.* |  |  |  |

---

The change in cash, cash equivalents, and restricted cash for the fiscal year ended March 31, 2026 compared to the fiscal year ended March 31, 2025 increased by $66.3 million. The increase was due to higher net proceeds received from foreign seasonal lines of credit and the non-recurrence of partial repayments made on long-term debt in the prior-year period, partially offset by an increase in cash used to purchase larger crop volumes.

***Planned Capital Expenditures***

We are anticipating $38.4 million in capital investments for fiscal 2027, which includes the new construction of a warehouse in South America and significant refurbishments to an existing warehouse in Africa. Both of these projects are aligned with advancing the Company's strategic initiatives to drive long-term efficiencies and cost optimization. The remainder of our expected capital spend is for the routine replacement of machinery and equipment, and investments in other such assets to enhance our operational effectiveness and to support our ongoing sustainability efforts.

***Securitized Receivables***

We sell trade receivables to unaffiliated financial institutions under multiple revolving trade accounts receivable securitization facilities. Under two of the programs, we receive a discount from the face value of the receivable sold, less contractual dilutions which limit the amount that may be outstanding from any one particular customer and insurance reserves that also have the effect of limiting the risk attributable to any one customer. Our beneficial interests in these two facilities are subordinate to the purchaser of the receivables. Under the other programs, we receive an amount equal to the face value of the receivable sold, less a discount rate tied to a benchmark rate, which varies based on the invoice currency. See "<u>[Note 17. Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

------

***Future Contractual Obligations and Commitments***

The following summarizes our material contractual obligations and commercial commitments as of March 31, 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | Payments / Expirations by Fiscal Year | Payments / Expirations by Fiscal Year | Payments / Expirations by Fiscal Year | Payments / Expirations by Fiscal Year |
| *(in millions)* |<br>Total | 2027 | &nbsp;&nbsp;&nbsp;&nbsp;Years <br>&nbsp;&nbsp;&nbsp;&nbsp;2028-2029 | &nbsp;&nbsp;&nbsp;&nbsp;Years <br>&nbsp;&nbsp;&nbsp;&nbsp;2030-2031 | &nbsp;&nbsp;&nbsp;&nbsp;After <br>&nbsp;&nbsp;&nbsp;&nbsp;2031 |
| Long-Term Debt Obligations | $455.8 | $— | $455.8 | $— | $— |
| Short-Term Debt Obligations<sup>(1)</sup> | 477.1 | 477.1 |  |  |  |
| Interest on Debt Obligations<sup>(2)</sup> | 89.1 | 50.4 | 38.3 | 0.4 |  |
| Pension and Postretirement Obligations | 51.0 | 5.4 | 10.4 | 9.9 | 25.3 |
| Operating Lease Obligations | 42.2 | 14.0 | 15.5 | 7.4 | 5.3 |
| Tobacco and Other Purchase Obligations | 806.1 | 806.1 |  |  |  |
| Amounts Guaranteed for Tobacco Suppliers | 119.7 | 119.7 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $2041.0 | $1472.7 | $520.0 | $17.7 | $30.6 |
| <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. | <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. | <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. | <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. | <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. | <sup>(1)</sup> Short-term debt obligations consist of our foreign seasonal credit lines. |
| <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. | <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. | <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. | <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. | <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. | <sup>(2)</sup> Interest obligations include interest for long-term debt, including indebtedness under the ABL Credit Facility. The projected interest includes both fixed and variable rate debt. The variable rate used in the projections is the rate that was being charged on our variable rate debt as of March 31, 2026. |

---

*Tobacco and Other Purchase Obligations*

Tobacco purchase obligations result from contracts with suppliers to buy either specified quantities of tobacco or the supplier's total tobacco production. Amounts shown as tobacco purchase obligations are estimates based on projected purchase prices of the future crop tobacco. Payment of these obligations is net of our advances to these suppliers. Our tobacco purchase obligations do not exceed our projected requirements over the related terms and are in the normal course of business. Other purchase obligations consist primarily of purchase commitments of agricultural material. Tobacco and other purchase obligations increased $35.4 million, or 4.6%, from $770.7 million to $806.1 million primarily due to higher estimated volumes expected to be sourced from our key origins in South America and Asia, and higher estimated volumes with increased pricing due to inflationary pressures in Europe.

*Amounts Guaranteed for Tobacco Suppliers*

In Africa and South America, we provide guarantees to ensure financing is available to our tobacco suppliers. In the event these suppliers should default, we would be responsible for repayment of the funds provided to these suppliers. We also provide guarantees for the financing of certain unconsolidated subsidiaries in Asia and South America. See "<u>[Note 18. Guarantees](#i6f44eae8422d46cd9f377051509c10a4_184)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

***Tax and Repatriation Matters***

We are subject to income tax laws in the countries in which we do business through wholly owned subsidiaries and through affiliates. We regularly evaluate the status of the accumulated unremitted earnings of each of our foreign subsidiaries. Our ability to repatriate unremitted non-U.S earnings may be limited by local legal restrictions and exchange controls in certain jurisdictions in which we operate. If the undistributed earnings are needed in the U.S., we may be required to pay state income and/or non-U.S local withholding taxes upon repatriation. We provide deferred income taxes, net of creditable foreign taxes, if applicable, on earnings that are not indefinitely invested. See "<u>[Note 5. Income Taxes](#i6f44eae8422d46cd9f377051509c10a4_148)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

**Critical Accounting Estimates**

***Overview***

The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires the use of estimates and assumptions that have an impact on the reported amounts of assets, liabilities, revenues, expenses, and the disclosure of contingent assets and liabilities. Management considers an accounting estimate critical if it: (i) requires us to make judgments and estimates about matters that are inherently uncertain, (ii) it is important to an understanding of our financial condition or operating results, and (iii) has a material impact to the financial statements.

We base our estimates on currently available information, historical experience, and various other assumptions we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates. Management has discussed the development, selection, and disclosure of our critical accounting estimates with the Audit Committee of the Board of Directors.

------

Management believes the following accounting estimates are most critical to our business operations and to an understanding of our financial condition and results of operations and reflect the more significant estimates and assumptions used in the preparation of our consolidated financial statements.

***Income Taxes***

Our annual effective income tax rate is based on our jurisdictional mix of pretax income, statutory tax rates, exchange rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Tax laws are complex, subject to change, and subject to different interpretations by the taxpayer and respective governmental taxing authorities. Significant judgment is required in determining our tax expense and in evaluating our tax positions including evaluating uncertainties under ASC 740. We record unrecognized tax benefits in multiple jurisdictions and evaluate the future potential outcomes of tax positions, based upon our interpretation of the country-specific tax law, and the likelihood of future settlement. We review our tax positions quarterly and adjust the balances as new information becomes available.

Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. Such assets arise from temporary differences between the financial reporting and tax bases of assets and liabilities and from net operating loss and tax credit carryforwards. We evaluate the recoverability of these future tax deductions by assessing the impact from changes in or issuance of new tax law and the adequacy of future expected taxable income from all sources, including reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. These sources of income inherently rely on estimates. To provide insight, we use our historical experience along with our short and long-range business forecasts. In addition, we adjust historical data for objectively verifiable information where appropriate.

We believe it is more likely than not that a portion of the deferred income tax assets may expire as unused and have established a valuation allowance against them. Although realization is not assured for the remaining deferred income tax assets, we believe it is more likely than not such remaining deferred tax assets will be fully recoverable within the applicable statutory expiration periods. However, deferred tax assets could be reduced in the near term if estimates of taxable income are significantly reduced, or available tax planning strategies are no longer viable. See "<u>[Note 5. Income Taxes](#i6f44eae8422d46cd9f377051509c10a4_148)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

***Pensions and Postretirement Health Care and Life Insurance Benefits***

The valuation of our pension and other postretirement health care and life insurance plans requires the use of assumptions and estimates that are used to develop actuarial valuations of expenses, assets, and liabilities. These assumptions include discount rates, investment returns, projected salary increases, benefits, and mortality rates. The significant assumptions used in the calculation of pension and postretirement obligations are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Discount rate: The discount rate is based on investment yields available at the measurement date on high-quality fixed income obligations, such as those included in the Moody's Aa bond index.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Salary increase assumption: The salary increase assumption reflects our expectations with respect to long-term salary increases of our workforce. Historical pay increases, expectations for the future, and anticipated inflation and promotion rates are considered in developing this assumption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash balance crediting rate: Interest is credited on cash balance accounts based on the yield on one-year Treasury Constant Maturities plus 1%. The assumed crediting rate thus considers the discount rate, current treasury rates, current inflation rates, and expectations for the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mortality rates: Mortality rates are based on gender-distinct group annuity mortality tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected return on plan assets: The expected return reflects asset allocations, investment strategy, and our historical actual returns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Termination and retirement rates: Termination and retirement rates are based on standard tables reflecting past experience and anticipated future experience under the plan. No early retirement rates are used since benefits provided are actuarially equivalent and there are not early retirement subsidies in the plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Inflation: The inflation assumption is based on an evaluation of external market indicators, including real gross domestic product growth and central bank inflation targets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Expected contributions: The expected amount and timing of contributions are based on an assessment of minimum requirements, cash availability, and other considerations (e.g., funded status, avoidance of regulatory premiums, and levies, and tax efficiency).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Health care cost trends: The health care cost trend assumptions are developed based on historical cost data, the near-term outlook, and an assessment of likely long-term trends.

Assumptions are set at each year end and are generally not changed during the year unless there is a major plan event such as a curtailment or settlement that would trigger a plan remeasurement.

Management periodically reviews actual demographic experience as it compares to the actuarial assumptions. Changes in assumptions are made if there are significant deviations or if future expectations change significantly. Based upon anticipated

------

changes in assumptions, pension and postretirement expense for the year ending March 31, 2027 is expected to be consistent with the year ended March 31, 2026. The contribution to our employee benefit plans during the year ended March 31, 2026 was $4.3 million and is expected to be $4.5 million in fiscal 2027.

The effect of actual results differing from our assumptions are accumulated and amortized over future periods. Changes in other assumptions and future investment returns could potentially have a material impact on our pension and postretirement expenses and related funding requirements. The effect of a change in certain assumptions is shown below:

---

| | | |
|:---|:---|:---|
| *(in thousands)* | Estimated Change <br>in Projected<br>Benefit Obligation <br>Increase (Decrease) | Estimated Change in <br>Annual Expense <br>Increase (Decrease) |
| ***Change in Assumption (Pension and Postretirement Plans)*** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% increase in discount rate | $(4015) | $2 |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% decrease in discount rate | $4529 | $224 |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% increase in salary rate | $172 | $52 |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% decrease in salary rate | $(161) | $(46) |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% increase in rate of return on assets | Not applicable | $(194) |
| &nbsp;&nbsp;&nbsp;&nbsp; 1% decrease in rate of return on assets | Not applicable | $194 |

---

Changes in assumptions for other postretirement benefits are no longer applicable as the benefit is capped and no longer subject to inflation. See "<u>[Note 21. Pension and Other Postretirement Benefits](#i6f44eae8422d46cd9f377051509c10a4_193)</u>" to the "Notes to Consolidated Financial Statements" for additional information.

**Recent Accounting Pronouncements Not Yet Adopted**

Information with respect to recent accounting pronouncements not yet adopted is included in "<u>[Note 2. New Accounting Standards](#i6f44eae8422d46cd9f377051509c10a4_139)</u>" to the "Notes to Consolidated Financial Statements," which information is incorporated by reference herein.

**<u>Item 7A. Quantitative and Qualitative Disclosures About Market Risk</u>**

**Derivatives policies**

Hedging foreign exchange exposure using forward contracts are specifically contemplated to manage risk in accordance with management's policies and reduce the risks inherent in currency fluctuations. We do not utilize derivatives for speculative purposes or enter into market risk sensitive instruments for trading purposes. Derivatives are transaction specific such that a specific contract or invoice determines the amount, maturity, and other specifics of the hedge.

**Foreign exchange rates**

Our sales transactions are generally conducted in USD, as is the business of the global tobacco industry. However, local country operating costs, including the purchasing and processing costs for tobaccos, are subject to the effects of exchange fluctuations of the local currency against the USD. We attempt to minimize such currency risks by matching the timing of our working capital borrowing needs against the tobacco purchasing and processing funds requirements in the currency of the country where the tobacco is grown. Also, in some cases, our sales pricing arrangements with our customers allow adjustments for the effect of currency exchange fluctuations on local purchasing and processing costs. Fluctuations in the value of foreign currencies can significantly affect our operating results. In our cost of goods and services sold, we have recognized exchange losses of $4.6 million, $6.0 million, and $3.7 million for the years ended March 31, 2026, 2025, and 2024, respectively. We recognized exchange losses of $0.2 million, $1.1 million, and $0.1 million related to income tax balances within income tax expense for the years ended March 31, 2026, 2025, and 2024, respectively. In addition, foreign currency fluctuations in the Euro, Macedonian Denar, and Pound Sterling can significantly impact the currency translation adjustment component of accumulated other comprehensive income. We recognized gains (losses) of $0.9 million, $(0.4) million, and $0.7 million for the years ended March 31, 2026, 2025, and 2024, respectively, as a result of fluctuations in these currencies.

Our consolidated SG&A expenses denominated in foreign currencies are subject to translation risks from currency exchange fluctuations. These foreign denominated expenses accounted for approximately $57.8 million, or 35.5%, of our total SG&A expenses for the year ended March 31, 2026. A 10% change in the value of the USD relative to those currencies would have caused the reported value of those expenses to increase or decrease by approximately $5.8 million.

------

**Interest rates**

We manage our exposure to interest rate risk through the proportion of fixed rate and variable rate debt in our total debt portfolio. A 1% change in variable interest rates would have increased or decreased our reported interest cost for the year ended March 31, 2026 by approximately $11.3 million. A substantial portion of our borrowings are denominated in USD and bear interest at commonly quoted rates.

------

**<u>Item 8.</u> <u>Financial Statements and Supplementary Data</u>**

---

| | |
|:---|:---|
| **Table of Contents** | **Table of Contents** |
| | **<u>Page No.</u>** |
| <u>[Consolidated Statements of Operations](#i6f44eae8422d46cd9f377051509c10a4_115)</u> | <u>[39](#i6f44eae8422d46cd9f377051509c10a4_115)</u> |
| <u>[Consolidated Statements of Comprehensive Income](#i6f44eae8422d46cd9f377051509c10a4_118)</u> | <u>[40](#i6f44eae8422d46cd9f377051509c10a4_118)</u> |
| <u>[Consolidated Balance Sheets](#i6f44eae8422d46cd9f377051509c10a4_121)</u> | <u>[41](#i6f44eae8422d46cd9f377051509c10a4_121)</u> |
| <u>[Consolidated Statements of Stockholders' Equity](#i6f44eae8422d46cd9f377051509c10a4_124)</u> | <u>[42](#i6f44eae8422d46cd9f377051509c10a4_124)</u> |
| <u>[Consolidated Statements of Cash Flows](#i6f44eae8422d46cd9f377051509c10a4_127)</u> | <u>[43](#i6f44eae8422d46cd9f377051509c10a4_127)</u> |
| <u>[Notes to Consolidated Financial Statements](#i6f44eae8422d46cd9f377051509c10a4_133)</u> | <u>[44](#i6f44eae8422d46cd9f377051509c10a4_133)</u> |
| <u>[Report of Independent Registered Public Accounting Firm](#i6f44eae8422d46cd9f377051509c10a4_226)</u> <u>(PCAOB ID No. 34)</u> | <u>[84](#i6f44eae8422d46cd9f377051509c10a4_226)</u> |

---

------

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Operations**

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| *(in thousands, except per share data)* | 2026 | 2025 | 2024 |
| Sales and other operating revenues | $2413000 | $2481260 | $2032559 |
| Cost of goods and services sold | 2065321 | 2138276 | 1720224 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 347679 | 342984 | 312335 |
| Selling, general, and administrative expenses | 162934 | 170998 | 160910 |
| Other expense, net | 19193 | 16410 | 9439 |
| Restructuring and asset impairment charges | 2852 | 2259 | 4799 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 162700 | 153317 | 137187 |
| Gain on debt retirement |  | 8178 | 15914 |
| Gain (loss) on pension settlement | 283 |  | (12008) |
| Interest expense, net | 134353 | 128041 | 125620 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes and other items | 28630 | 33454 | 15473 |
| Income tax expense | 30344 | 25053 | 27281 |
| Income from unconsolidated affiliates, net | 17371 | 8132 | 14992 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | 15657 | 16533 | 3184 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interests | 1088 | 1367 | 521 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Pyxus International, Inc. | $14569 | $15166 | $2663 |
| Earnings per share: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.56 | $0.59 | $0.11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.56 | $0.59 | $0.11 |
| Weighted average number of shares outstanding: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 25790 | 25643 | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 25957 | 25667 | 25000 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |  |

---

------

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Comprehensive Income**

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| *(in thousands)* | 2026 | 2025 | 2024 |
| Net income | $15657 | $16533 | $3184 |
| Other comprehensive (loss) income, net of tax: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 936 | (353) | 700 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement benefit plans | (2307) | (250) | 4419 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedges | 164 | 132 | (2860) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive (loss) income, net of tax | $(1207) | $(471) | $2259 |
| Total comprehensive income | 14450 | 16062 | 5443 |
| Comprehensive income attributable to noncontrolling interests | 1088 | 1367 | 509 |
| &nbsp;&nbsp;&nbsp;&nbsp;Comprehensive income attributable to Pyxus International, Inc. | $13362 | $14695 | $4934 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |  |

---

------

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| *(in thousands)* | 2026 | 2025 |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $134337 | $78254 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 3316 | 7290 |
| &nbsp;&nbsp;&nbsp;Trade receivables, net | 239456 | 189239 |
| &nbsp;&nbsp;&nbsp;Other receivables | 25451 | 15040 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 817950 | 761951 |
| &nbsp;&nbsp;&nbsp;Advances to suppliers, net | 36337 | 30745 |
| &nbsp;&nbsp;&nbsp;Recoverable income taxes | 2886 | 6616 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 49000 | 47151 |
| &nbsp;&nbsp;&nbsp;Other current assets | 21751 | 21874 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1330484 | 1158160 |
| Investments in unconsolidated affiliates | 105863 | 96928 |
| Intangible assets, net | 24076 | 28507 |
| Deferred income taxes, net | 14507 | 13567 |
| Long-term recoverable income taxes | 9467 | 5669 |
| Other noncurrent assets | 35424 | 33094 |
| Right-of-use assets | 31717 | 29742 |
| Property, plant, and equipment, net | 143154 | 138176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1694692 | $1503843 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable | $477132 | $395030 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 146828 | 132871 |
| &nbsp;&nbsp;&nbsp;Advances from customers | 174995 | 135607 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 114760 | 90912 |
| &nbsp;&nbsp;&nbsp;Income taxes payable | 9145 | 11001 |
| &nbsp;&nbsp;&nbsp;Operating leases payable | 9915 | 8514 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt |  | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 932775 | 773947 |
| Long-term taxes payable | 4112 | 5187 |
| Long-term debt | 455757 | 454850 |
| Deferred income taxes | 11961 | 8818 |
| Liability for unrecognized tax benefits | 28074 | 18635 |
| Long-term leases | 21020 | 19584 |
| Pension, postretirement, and other long-term liabilities | 59886 | 57052 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $1513585 | $1338073 |
| Commitments and contingencies |  |  |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;Common stock—no par value: |  |  |
| &nbsp;&nbsp;&nbsp;Authorized shares (250,000 for all periods) |  |  |
| &nbsp;&nbsp;&nbsp;Issued and outstanding shares (24,608 for all periods) | $393921 | $392899 |
| &nbsp;&nbsp;&nbsp;Retained deficit | (225556) | (240125) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 6123 | 7315 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity of Pyxus International, Inc. | 174488 | 160089 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | 6619 | 5681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 181107 | 165770 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1694692 | $1503843 |
| *See accompanying notes to consolidated financial statements.* |  |  |

---

------

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Stockholders' Equity**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | | |
| | | | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | | |
| *(in thousands)* | Common<br>Stock | Retained<br>Deficit | Currency<br>Translation<br>Adjustment | Pensions,<br>Net of Tax | Derivatives,<br>Net of Tax | Noncontrolling<br>Interests | Total<br>Stockholders'<br>Equity |
| Balance, March 31, 2025 | $392899 | $(240125) | $(6045) | $12516 | $844 | $5681 | $165770 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income |  | (15825) |  |  |  | 562 | (15263) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 237 |  |  |  |  |  | 237 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax |  |  | 2039 |  | 1457 |  | 3496 |
| Balance, June 30, 2025 | $393136 | $(255950) | $(4006) | $12516 | $2301 | $6243 | $154240 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss |  | (879) |  |  |  | (23) | (902) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends |  |  |  |  |  | (135) | (135) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 256 |  |  |  |  |  | 256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive loss, net of tax |  |  | (477) |  | (1016) |  | (1493) |
| Balance, September 30, 2025 | $393392 | $(256829) | $(4483) | $12516 | $1285 | $6085 | $151966 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 16903 |  |  |  | 259 | 17162 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 272 |  |  |  |  |  | 272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax |  |  | 154 | (1521) | (444) |  | (1811) |
| Balance, December 31, 2025 | $393664 | $(239926) | $(4329) | $10995 | $841 | $6344 | $167589 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 14370 |  |  |  | 290 | 14660 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 257 |  |  |  |  |  | 257 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income, net of tax |  |  | (780) | (771) | 167 | (15) | (1399) |
| Balance, March 31, 2026 | $393921 | $(225556) | $(5109) | $10224 | $1008 | $6619 | $181107 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |

---

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Stockholders' Equity (continued)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | | |
| | | | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | | |
| *(in thousands)* | Common<br>Stock | Retained<br>Deficit | Currency<br>Translation<br>Adjustment | Pensions,<br>Net of Tax | Derivatives,<br>Net of Tax | Noncontrolling<br>Interests | Total<br>Stockholders'<br>Equity |
| Balance, March 31, 2024 | $389789 | $(255291) | $(5692) | $12766 | $712 | $4539 | $146823 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 4642 |  |  |  | 310 | 4952 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 3031 |  |  |  |  |  | 3031 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax |  |  | 543 |  | (2237) |  | (1694) |
| Balance, June 30, 2024 | $392820 | $(250649) | $(5149) | $12766 | $(1525) | $4849 | $153112 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss |  | (3227) |  |  |  | (46) | (3273) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends |  |  |  |  |  | (225) | (225) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 601 |  |  |  |  |  | 601 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share repurchases | (1000) |  |  |  |  |  | (1000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax |  |  | 278 |  | 1266 |  | 1544 |
| Balance, September 30, 2024 | $392421 | $(253876) | $(4871) | $12766 | $(259) | $4578 | $150759 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 18898 |  |  |  | 512 | 19410 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 267 |  |  |  |  |  | 267 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive loss, net of tax |  |  | (976) |  | (2453) |  | (3429) |
| Balance, December 31, 2024 | $392688 | $(234978) | $(5847) | $12766 | $(2712) | $5090 | $167007 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income |  | (5147) |  |  |  | 591 | (4556) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 211 |  |  |  |  |  | 211 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income, net of tax |  |  | (198) | (250) | 3556 |  | 3108 |
| Balance, March 31, 2025 | $392899 | $(240125) | $(6045) | $12516 | $844 | $5681 | $165770 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |

---

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Stockholders' Equity (continued)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | Attributable to Pyxus International, Inc. | | |
| | | | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | Accumulated Other Comprehensive Income | | |
| *(in thousands)* | Common<br>Stock | Retained<br>Deficit | Currency<br>Translation<br>Adjustment | Pensions,<br>Net of Tax | Derivatives,<br>Net of Tax | Noncontrolling<br>Interest | Total<br>Stockholders'<br>Equity |
| Balance, March 31, 2023 | $390290 | $(257954) | $(6392) | $8335 | $3572 | $3979 | $141830 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  | 804 |  |  |  | (34) | 770 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income, net of tax |  |  | 707 |  | 862 |  | 1569 |
| Balance, June 30, 2023 | $390290 | $(257150) | $(5685) | $8335 | $4434 | $3945 | $144169 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  | 8095 |  |  |  | (199) | 7896 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  |  |  |  |  | 493 | 493 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive loss, net of tax |  |  | (1545) |  | (1000) |  | (2545) |
| Balance, September 30, 2023 | $390290 | $(249055) | $(7230) | $8335 | $3434 | $4239 | $150013 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  | 3835 |  |  |  | 344 | 4179 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (501) |  |  |  |  | 8 | (493) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends |  |  |  |  |  | (450) | (450) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax |  |  | 2185 | 3511 | (1288) |  | 4408 |
| Balance, December 31, 2023 | $389789 | $(245220) | $(5045) | $11846 | $2146 | $4141 | $157657 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (loss) income |  | (10071) |  |  |  | 410 | (9661) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income, net of tax |  |  | (647) | 920 | (1434) | (12) | (1173) |
| Balance, March 31, 2024 | $389789 | $(255291) | $(5692) | $12766 | $712 | $4539 | $146823 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |

---

------

**Pyxus International, Inc. and Subsidiaries**

**Consolidated Statements of Cash Flows**

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| *(in thousands)* | 2026 | 2025 | 2024 |
| **Operating activities:** |  |  |  |
| &nbsp;&nbsp;Net income | $15657 | $16533 | $3184 |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash used in operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 20893 | 20334 | 19250 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt amortization/interest | 10567 | 11235 | 8559 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt retirement |  | (8178) | (15914) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign currency transactions | 6554 | 4922 | 4009 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on pension settlement | (283) |  | 12008 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 1022 | 4110 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from unconsolidated affiliates, net of dividends | (8935) | 4317 | (506) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities, net: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other receivables | (254881) | (208374) | (167600) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories and advances to suppliers | (60350) | 156309 | (136010) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred items | 11539 | 1052 | 3240 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recoverable income taxes | (1486) | (4721) | (2689) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payables and accrued expenses | 31512 | (49190) | 17531 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advances from customers | 34798 | 45937 | 55302 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (1642) | 8943 | (4506) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (2182) | 2719 | (8207) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating assets and liabilities | (1221) | (8419) | 4114 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | (10013) | (10915) | (6735) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | $(208451) | $(13386) | $(214970) |
| **Investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment | $(22051) | $(23028) | $(21043) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of property, plant, and equipment | 5215 | 3770 | 4312 |
| &nbsp;&nbsp;&nbsp;Collections from beneficial interests in securitized trade receivables | 200684 | 188312 | 175911 |
| &nbsp;&nbsp;&nbsp;Other, net | 7575 | 1584 | 269 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by investing activities | $191423 | $170638 | $159449 |
| **Financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net proceeds (repayments) from short-term borrowings | $77293 | $(102550) | $122483 |
| &nbsp;&nbsp;&nbsp;Proceeds from revolving loan facilities | 281000 | 363000 | 331000 |
| &nbsp;&nbsp;&nbsp;Repayment of revolving loan facilities | (281000) | (363000) | (356000) |
| &nbsp;&nbsp;&nbsp;Repayment of long-term borrowings |  | (55822) | (60342) |
| &nbsp;&nbsp;&nbsp;Debt issuance costs | (5350) | (9106) | (11751) |
| &nbsp;&nbsp;&nbsp;Other, net | 580 | 217 | 171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | $72523 | $(167261) | $25561 |
| Effect of exchange rate changes on cash | (3386) | (4240) | (9156) |
| Increase (decrease) in cash, cash equivalents, and restricted cash | 52109 | (14249) | (39116) |
| Cash and cash equivalents at beginning of period | 78254 | 92569 | 136733 |
| Restricted cash at beginning of period | 7290 | 7224 | 2176 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash, cash equivalents, and restricted cash at end of period | $137653 | $85544 | $99793 |
| Other information: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes, net | $20440 | $31101 | $22501 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes related to debt exchange |  |  | 12543 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest, net | 119470 | 115009 | 109518 |
| Noncash investing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncash amounts obtained as a beneficial interest in exchange for transferring trade receivables in a securitization transaction | 198567 | 241069 | 160041 |
| *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* | *See accompanying notes to consolidated financial statements.* |  |

---

------

---

| | | |
|:---|:---|:---|
| **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** | **Pyxus International, Inc. and Subsidiaries** |
| **Notes to Consolidated Financial Statements** | **Notes to Consolidated Financial Statements** | **Notes to Consolidated Financial Statements** |
| *(in thousands, except per share data)* | *(in thousands, except per share data)* | **<u>Page No.</u>** |
| <u>[Note 1](#i6f44eae8422d46cd9f377051509c10a4_136)</u> | <u>[Basis of Presentation and Summary of Significant Accounting Policies](#i6f44eae8422d46cd9f377051509c10a4_136)</u> | <u>[45](#i6f44eae8422d46cd9f377051509c10a4_136)</u> |
| <u>[Note 2](#i6f44eae8422d46cd9f377051509c10a4_139)</u> | <u>[New Accounting Standards](#i6f44eae8422d46cd9f377051509c10a4_139)</u> | <u>[51](#i6f44eae8422d46cd9f377051509c10a4_139)</u> |
| <u>[Note 3](#i6f44eae8422d46cd9f377051509c10a4_142)</u> | <u>[Revenue Recognition](#i6f44eae8422d46cd9f377051509c10a4_142)</u> | <u>[52](#i6f44eae8422d46cd9f377051509c10a4_142)</u> |
| <u>[Note 4](#i6f44eae8422d46cd9f377051509c10a4_145)</u> | <u>[Other Expense, Net](#i6f44eae8422d46cd9f377051509c10a4_145)</u> | <u>[52](#i6f44eae8422d46cd9f377051509c10a4_145)</u> |
| <u>[Note 5](#i6f44eae8422d46cd9f377051509c10a4_148)</u> | <u>[Income Taxes](#i6f44eae8422d46cd9f377051509c10a4_148)</u> | <u>[53](#i6f44eae8422d46cd9f377051509c10a4_148)</u> |
| <u>[Note 6](#i6f44eae8422d46cd9f377051509c10a4_151)</u> | <u>[Earnings](#i6f44eae8422d46cd9f377051509c10a4_151)[Per Share](#i6f44eae8422d46cd9f377051509c10a4_151)</u> | <u>[57](#i6f44eae8422d46cd9f377051509c10a4_151)</u> |
| <u>[Note 7](#i6f44eae8422d46cd9f377051509c10a4_154)</u> | <u>[Restricted Cash](#i6f44eae8422d46cd9f377051509c10a4_154)</u> | <u>[57](#i6f44eae8422d46cd9f377051509c10a4_154)</u> |
| <u>[Note 8](#i6f44eae8422d46cd9f377051509c10a4_2161)</u> | <u>[Trade Receivables, Net](#i6f44eae8422d46cd9f377051509c10a4_2161)</u> | <u>[57](#i6f44eae8422d46cd9f377051509c10a4_2161)</u> |
| <u>[Note 9](#i6f44eae8422d46cd9f377051509c10a4_157)</u> | <u>[Inventories, Net](#i6f44eae8422d46cd9f377051509c10a4_157)</u> | <u>[58](#i6f44eae8422d46cd9f377051509c10a4_157)</u> |
| <u>[Note 10](#i6f44eae8422d46cd9f377051509c10a4_160)</u> | <u>[Advances to Suppliers, Net](#i6f44eae8422d46cd9f377051509c10a4_160)</u> | <u>[58](#i6f44eae8422d46cd9f377051509c10a4_160)</u> |
| <u>[Note 11](#i6f44eae8422d46cd9f377051509c10a4_163)</u> | <u>[Equity Method Investments](#i6f44eae8422d46cd9f377051509c10a4_163)</u> | <u>[58](#i6f44eae8422d46cd9f377051509c10a4_163)</u> |
| <u>[Note 12](#i6f44eae8422d46cd9f377051509c10a4_166)</u> | <u>[Variable Interest Entities](#i6f44eae8422d46cd9f377051509c10a4_166)</u> | <u>[59](#i6f44eae8422d46cd9f377051509c10a4_166)</u> |
| <u>[Note 13](#i6f44eae8422d46cd9f377051509c10a4_169)</u> | <u>[Intangible Assets, Net](#i6f44eae8422d46cd9f377051509c10a4_169)</u> | <u>[59](#i6f44eae8422d46cd9f377051509c10a4_169)</u> |
| <u>[Note 14](#i6f44eae8422d46cd9f377051509c10a4_172)</u> | <u>[Leases](#i6f44eae8422d46cd9f377051509c10a4_172)</u> | <u>[60](#i6f44eae8422d46cd9f377051509c10a4_172)</u> |
| <u>[Note 15](#i6f44eae8422d46cd9f377051509c10a4_175)</u> | <u>[Property, Plant, and Equipment, Net](#i6f44eae8422d46cd9f377051509c10a4_175)</u> | <u>[61](#i6f44eae8422d46cd9f377051509c10a4_175)</u> |
| <u>[Note 16](#i6f44eae8422d46cd9f377051509c10a4_178)</u> | <u>[Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u> | <u>[62](#i6f44eae8422d46cd9f377051509c10a4_178)</u> |
| <u>[Note 17](#i6f44eae8422d46cd9f377051509c10a4_181)</u> | <u>[Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u> | <u>[67](#i6f44eae8422d46cd9f377051509c10a4_181)</u> |
| <u>[Note 18](#i6f44eae8422d46cd9f377051509c10a4_184)</u> | <u>[Guarantees](#i6f44eae8422d46cd9f377051509c10a4_184)</u> | <u>[68](#i6f44eae8422d46cd9f377051509c10a4_184)</u> |
| <u>[Note 19](#i6f44eae8422d46cd9f377051509c10a4_187)</u> | <u>[Derivative Financial Instruments](#i6f44eae8422d46cd9f377051509c10a4_187)</u> | <u>[68](#i6f44eae8422d46cd9f377051509c10a4_187)</u> |
| <u>[Note 20](#i6f44eae8422d46cd9f377051509c10a4_190)</u> | <u>[Fair Value Measurements](#i6f44eae8422d46cd9f377051509c10a4_190)</u> | <u>[69](#i6f44eae8422d46cd9f377051509c10a4_190)</u> |
| <u>[Note 21](#i6f44eae8422d46cd9f377051509c10a4_193)</u> | <u>[Pension and Other Postretirement Benefits](#i6f44eae8422d46cd9f377051509c10a4_193)</u> | <u>[70](#i6f44eae8422d46cd9f377051509c10a4_193)</u> |
| <u>[Note 22](#i6f44eae8422d46cd9f377051509c10a4_196)</u> | <u>[Contingencies and Other Information](#i6f44eae8422d46cd9f377051509c10a4_196)</u> | <u>[75](#i6f44eae8422d46cd9f377051509c10a4_196)</u> |
| <u>[Note 23](#i6f44eae8422d46cd9f377051509c10a4_199)</u> | <u>[Accumulated Other Comprehensive](#i6f44eae8422d46cd9f377051509c10a4_199)[Income](#i6f44eae8422d46cd9f377051509c10a4_199)</u> | <u>[76](#i6f44eae8422d46cd9f377051509c10a4_199)</u> |
| <u>[Note 24](#i6f44eae8422d46cd9f377051509c10a4_205)</u> | <u>[Equity-Based Compensation](#i6f44eae8422d46cd9f377051509c10a4_205)</u> | <u>[77](#i6f44eae8422d46cd9f377051509c10a4_205)</u> |
| <u>[Note 25](#i6f44eae8422d46cd9f377051509c10a4_208)</u> | <u>[Related Party Transactions](#i6f44eae8422d46cd9f377051509c10a4_208)</u> | <u>[79](#i6f44eae8422d46cd9f377051509c10a4_208)</u> |
| <u>[Note 26](#i6f44eae8422d46cd9f377051509c10a4_211)</u> | <u>[Segment Information](#i6f44eae8422d46cd9f377051509c10a4_211)</u> | <u>[80](#i6f44eae8422d46cd9f377051509c10a4_211)</u> |
| <u>[Note 27](#i6f44eae8422d46cd9f377051509c10a4_214)</u> | <u>[Subsequent Events](#i6f44eae8422d46cd9f377051509c10a4_214)</u> | <u>[83](#i6f44eae8422d46cd9f377051509c10a4_214)</u> |

---

------

**1. Basis of Presentation and Summary of Significant Accounting Policies**

Pyxus International, Inc. (the "Company," "Pyxus," "we," "us," or "our") is a global agricultural company with businesses having more than 150 years of experience delivering value-added products and services to businesses and customers. Pyxus and its subsidiaries are trusted providers of responsibly sourced, independently verified, sustainable, and traceable products and ingredients. The Company has a diversified geographic footprint with operations in Africa, Asia, Europe, North America, and South America.

As the context requires, the "Company" and "Pyxus" also includes the consolidated subsidiaries of Pyxus International, Inc. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission applicable to annual reporting on Form 10-K.

***Principles of Consolidation***

The consolidated financial statements include the accounts of the Company and its majority-owned and controlled subsidiaries. Intercompany accounts and transactions have been eliminated.

***Equity Method Investments***

The Company's equity method investments and its cost method investments are non-marketable securities. When not required to consolidate its investment in another entity, the Company uses the equity method if it (i) can exercise significant influence over the other entity, and (ii) holds common stock and/or in-substance common stock of the other entity. Under the equity method, investments are carried at cost, plus or minus the Company's equity in the increases or decreases of the investee's net assets after the date of acquisition. The Company continually monitors its equity method investments for factors indicating other-than-temporary impairment. The Company's proportionate share of the net income or loss of these entities is included in income from unconsolidated affiliates, net within the consolidated statements of operations. Dividends received from the investee reduce the carrying amount of the investment. Distributions from equity method investees are accounted for based on the cumulative earnings approach to determine whether they represent a return of investment or a return on investment.

***Variable Interest Entities***

The Company holds variable interests in multiple variable interest entities, which primarily procure or process inventory on behalf of the Company or are securitization entities. These variable interests relate to equity investments, receivables, guarantees, and securitized receivables. The Company is not the primary beneficiary of most of these entities as it does not have the power to direct the activities that most significantly impact the economic performance of these entities, due to these entities' management and board of directors' structure. As a result, most of these variable interest entities are not consolidated. Creditors of the Company's variable interest entities do not have recourse against the general credit of the Company.

The Company's investments in unconsolidated variable interest entities are classified as investments in unconsolidated affiliates in the consolidated balance sheets. The Company's assets and liabilities with variable interest entities are classified as related party balances. The Company's maximum exposure to loss in these variable interest entities is represented by the investments, receivables, guarantees, and the deferred purchase price on the sale of securitized receivables.

***Use of Estimates***

The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. These estimates and assumptions also affect the reported amounts of revenues and expenses during the reporting period. Actual results may differ from the Company's estimates and assumptions. Estimates are used in accounting for, among other things, revenue recognition, pension and postretirement health care benefits, inventory reserves, credit loss reserves, bank loan guarantees to suppliers and unconsolidated subsidiaries, reserves for advances to suppliers, useful lives for depreciation and amortization, future cash flows associated with impairment testing for long-lived assets, deferred tax assets and uncertain income tax positions, intrastate tax credits, incremental borrowing rates for the present value of lease payments, fair value determinations of financial assets and liabilities, including derivatives, securitized beneficial interests, and counterparty risk.

***Reclassifications***

Certain prior-period amounts were reclassified to conform to the current-year presentation in the consolidated statements of cash flows and the segment information footnote disclosure.

***Revenue Recognition***

The Company's revenue consists primarily of the sale of processed tobacco and fees charged for processing and related services to the manufacturers of tobacco products. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company's performance obligations are satisfied when the transfer of control of the distinct

------

product or service to the customer occurs. For products, control is transferred, and revenue is recognized, at a point in time, in accordance with the shipping terms of the contract. For processing and related services, control is transferred, and revenue is recognized, over time using the input method based on a kilogram of packed tobacco. A kilogram of processed tobacco (or tobacco processing services resulting in a kilogram of processed tobacco) is the only material and distinct performance obligation for the Company's tobacco revenue streams. The Company does not disclose information related to its unsatisfied performance obligations with an expected original duration of one year or less. Contract costs primarily include labor, material, shipping and handling, and overhead expenses.

The transaction price is the amount of consideration to which the Company expects to be entitled to receive in exchange for transferring goods or providing services under the contract. The transaction price consists of fixed cash consideration, which is the invoiced amount, and an estimate for variable consideration. The Company's variable consideration includes price adjustments for claims resulting from tobacco that does not meet customer specifications due to various reasons such as shrinkage, improper blend, or chemical makeup, etc. The Company's process to handle customer claims includes a claims allowance that is assessed quarterly and recorded within accrued expenses and other current liabilities in the consolidated balance sheets and as contra-revenue within sales and other operating revenues. The Company estimates expected claims using the expected value method due to the large number of contracts with similar characteristics that we enter into with customers, the high volumes of tobacco we sell each year, and our actual history of past claims.

Warehousing fees for storing customer-controlled tobacco until the customer requests shipment represents another form of variable consideration present in certain contracts with our customers. Warehousing fees are either included in the transaction price for tobacco based on the customers' best estimate of the date they will request shipment, or is separately charged using a per-day storage rate. When the Company enters into a contract with a customer, the price communicated is the amount of consideration the Company expects to receive.

*Taxes Collected from Customers*

Certain subsidiaries are subject to value-added taxes on local sales. Value-added taxes on local sales are recorded in sales and other operating revenues and cost of goods and services sold in the consolidated statements of operations.

*Shipping and Handling*

The Company elected to account for shipping and handling as activities to fulfill its performance obligations, regardless of when control transfers. Shipping and handling fees that are billed to customers are recognized in sales and other operating revenues and the associated shipping and handling costs are recognized in cost of goods and services sold in the consolidated statements of operations.

***Advances From Customers***

On occasion, the Company receives advances and deposits from customers for future promises to deliver goods or services. These cash advance payments are refundable to the customer without penalty. The balance in advances from customers is reduced as the Company satisfies performance obligations under the contract with the customer and the criteria for revenue recognition is met.

***Income Taxes***

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities reflect the expected future tax consequences of events that are recognized in the consolidated financial statements in different periods than they are recognized for tax purposes. Deferred tax assets and liabilities are established using enacted tax rates in effect for the year in which these items are expected to reverse.

The realization of deferred tax assets is dependent on generating sufficient taxable income in the appropriate jurisdiction prior to the expiration of the carryforward periods. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. When assessing the need for a valuation allowance, the Company considers carryback potential, historical earnings, future reversals of existing taxable temporary differences (including liabilities for unrecognized tax benefits), forecasted operating profits and tax planning strategies.

The Company's provision for income taxes is based on pre-tax income, statutory tax rates, and tax planning opportunities available in the various jurisdictions in which it operates. Tax laws are complex and subject to different interpretations by the taxpayer and respective governmental taxing authorities. The Company recognizes tax benefits from uncertainties if it believes it is more-likely-than-not it will be sustained based on the technical merits. Penalties and interest related to income taxes, if incurred, are included in income tax expense.

------

***Earnings Per Share***

The calculations of basic and diluted earnings per share are based on net income divided by the basic weighted average number of common shares and diluted weighted average number of common shares outstanding, respectively. Under the treasury stock method, restricted stock units will have a dilutive effect when the respective period's average market price of the Company's common stock exceeds the assumed exercise proceeds, and the average amount of cost not yet recognized. Performance based stock units are included in diluted earnings per share if the performance targets have been met at the end of the reporting period. Share-based payment awards that provide contingently issuable shares upon a performance or market condition are included in basic and diluted earnings per share only if the condition is met as of the end of the reporting period.

***Cash, Cash Equivalents, and Restricted Cash***

Cash and cash equivalents include cash in banks and highly liquid investments with original maturities of three months or less and are stated at cost, which approximates fair value. Cash that is subject to legal restrictions for withdrawal or use in our operations is classified as restricted cash, and primarily relates to amounts held in escrow for customs or performance bonds.

***Trade Receivables, Net***

Trade receivables are recorded at the invoiced amount less an estimated allowance for expected credit losses. The Company's trade receivables do not bear interest. Payment terms and conditions vary by contract, although terms generally include a requirement of payment within 30 to 60 days. In addition to estimating an allowance based on specific identification of certain receivables that have a higher probability of not being paid, the Company also records an estimate for expected credit losses for the remaining receivables in the aggregate using a loss-rate method that considers historical bad debts, age of customer receivable balances, and current customer receivable balances. The Company has elected the practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the customer receivable. Balances are written-off when determined to be uncollectible. The provision for expected credit losses is recorded in selling, general, and administrative expenses in the consolidated statements of operations.

***Securitized Receivables***

The Company sells trade receivables to unaffiliated financial institutions under multiple accounts receivable securitization facilities. Under these facilities, receivables sold for cash are removed from the consolidated balance sheets. Under some of the facilities, a portion of the purchase price for the receivables is paid by the unaffiliated financial institutions in cash and the balance is a deferred purchase price receivable, which is paid as payments on the receivables are collected from account debtors.

The net cash proceeds received by the Company at the time of sale are disclosed as an operating activity in the consolidated statements of cash flows. The deferred purchase price receivable represents a continuing involvement and a beneficial interest in the transferred financial assets and is recognized at fair value as part of the sale transaction. The deferred purchase price receivables are included in trade and other receivables, net in the consolidated balance sheets and are valued using unobservable inputs (i.e., Level 3 inputs), primarily discounted cash flow. The net cash proceeds received by the Company as deferred purchase price are disclosed as an investing activity in the consolidated statements of cash flows. Additionally, beneficial interests received in exchange for transferring trade receivables in a securitization transaction are disclosed as a noncash investing activity in the consolidated statements of cash flows.

The difference between the carrying amount of the receivables sold under these facilities and the sum of the cash and fair value of the other assets received at the time of transfer is recognized as a loss on sale of the related receivables and recorded in other expense, net in the consolidated statements of operations. Program costs are recorded in other expense, net in the consolidated statements of operations.

***Inventories, Net***

Costs in inventory include processed tobacco inventory, unprocessed tobacco inventory, and other inventory. Costs of unprocessed tobacco inventories are determined by the average cost method, which include the cost of green tobacco. Costs of processed tobacco inventories are determined by the average cost method, which include both the cost of unprocessed tobacco, as well as direct and indirect costs related to processing the product. Costs of other inventory are determined by the first-in, first-out method, which include costs of packing materials, agricultural supplies such as seed, fertilizer, herbicides, and pesticides, and non-tobacco agricultural products.

Inventories are carried at the lower of cost and net realizable value ("NRV"). NRV represents the estimated selling price in the ordinary course of business for similar grades of tobacco for uncommitted inventories, and the expected selling price to the customer for committed inventories, less reasonably predictable costs of completion, disposal, and transportation. If the NRV is estimated to be less than the cost, the Company writes down the carrying value of its inventories to NRV. When valuing its inventories, the Company also takes into consideration obsolescence based on the age and quality of the tobacco. Inventory write-downs resulting from NRV adjustments or due to obsolescence are recorded in cost of goods and services sold in the consolidated statements of operations.

------

***Advances to Tobacco Suppliers, Net***

The Company purchases seeds, fertilizer, pesticides, and other products related to growing tobacco and advances them to tobacco suppliers to assist in crop production. These seasonal advances are short term, represent prepaid inventory, and are recorded as advances to tobacco suppliers. Upon delivery of tobacco, part of the purchase price to the supplier is paid in cash and part through a reduction of the advance balance. The advances applied to the delivery are reclassified from advances to unprocessed inventory.

The Company also has noncurrent advances, which generally represent the cost of advances to tobacco suppliers for infrastructure, such as curing barns, recovered through the delivery of tobacco to the Company by the tobacco suppliers. Tobacco suppliers may not be able to settle the entirety of advances due each year. In these situations, the Company may allow the farmers to deliver tobacco over future crop years to recover its advances. Noncurrent advances to tobacco suppliers are recorded in other noncurrent assets in the consolidated balance sheets.

The Company accounts for its advances to tobacco suppliers using a cost accumulation model, which reports advances at the lower of cost or recoverable amounts, exclusive of the mark-up and interest. The mark-up and interest on its advances are recognized upon delivery of tobacco as a decrease in the cost of the current crop. A provision for tobacco supplier bad debts is recorded in cost of goods and services sold in the consolidated statements of operations for abnormal yield adjustments or unrecovered advances. Normal yield adjustments are capitalized into the cost of the current crop and are recorded in cost of goods and services sold as that crop is sold.

***Intangible Assets, Net***

The Company has intangible assets with definite useful lives. These intangible assets are assessed annually and tested for impairment whenever factors indicate the carrying amount may not be recoverable. The trade name, customer relationship, and technology intangibles are amortized on a straight-line basis over fourteen, nine to twelve years, and eight years, respectively. The amortization period is the term of the contract or, if no term is specified in the contract, management's best estimate of the useful life based on experience. Technology includes internally developed software that is amortized on a straight-line basis over three to five years. Amortization commences once substantial testing activities are completed, and the software is ready for its intended use. Events and changes in circumstance may either result in a revision in the estimated useful life or impairment of an intangible. Amortization expense associated with finite-lived intangible assets is recorded in selling, general, and administrative expenses in the consolidated statements of operations.

***Leases***

The Company has operating leases for land, buildings, automobiles, and other equipment that expire at various dates through fiscal year 2040. The Company does not have material finance leases. Leases for real estate generally have initial terms ranging from two to thirteen years, excluding renewal options. Leases for equipment generally have initial terms ranging from two to five years excluding renewal options. Most leases have fixed rentals, with many of the real estate leases requiring additional payments for real estate taxes. These lease terms may include optional renewals, terminations, or purchases, which are considered in the Company's assessments when such options are reasonably certain to be exercised.

The Company measures right-of-use assets and related lease liabilities based on the present value of remaining lease payments, including in-substance fixed payments, the current payment amount when payments depend on an index or rate (e.g., inflation adjustments, market renewals), and the amount the Company believes is probable to be paid to the lessor under residual value guarantees, when applicable. Lease contracts may include fixed payments for non-lease components, such as maintenance, which are included in the measurement of lease liabilities for certain asset classes based on the Company's election to combine lease and non-lease components. Certain of our leases contain variable lease payments that are not known at the commencement date and are determinable based on the performance or use of the underlying asset. Variable lease payments are not included in the consolidated balance sheets and are expensed as incurred. The Company does not recognize short-term leases, those lease contracts with durations of twelve months or less, in the consolidated balance sheets, and the related lease payments are expensed on a straight-line basis over the lease term.

As applicable borrowing rates are not typically implied within the lease arrangements, the Company discounts lease payments based on its estimated incremental borrowing rate at lease commencement, or modification, which is based on the Company's estimated credit rating, the lease term at commencement, and the contract currency of the lease arrangement.

***Property, Plant, and Equipment, Net***

Property, plant, and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets. Buildings are depreciated over a range of nine to forty years. Machinery and equipment are depreciated over a range of two to nineteen years. Repairs and maintenance costs are expensed as incurred. The cost of major improvements is capitalized. Upon sale or disposition of an asset, the cost and related accumulated depreciation are removed from the balance sheet accounts and the resulting gain or loss is included in other expense, net in the consolidated statements of operations.

------

Long-lived assets are tested for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The evaluation is performed at the lowest level of identifiable cash flows at which the asset could be bought or sold in a current transaction between willing parties and may be estimated using several techniques, including quoted market prices or valuations, present value techniques based on estimates of cash flows, or multiples of earnings or revenue performance measures.

***Guarantees***

The Company's guarantees are primarily related to bank loans to suppliers for crop production financing. The Company also guarantees bank loans of certain unconsolidated subsidiaries primarily in Asia and South America. Under longer-term arrangements, the Company may guarantee financing on suppliers' construction of curing barns or other tobacco production assets. Guaranteed loans are generally repaid concurrent with the delivery of tobacco to the Company. The Company is obligated to repay guaranteed loans should the supplier default. If default occurs, the Company has recourse against its various suppliers and their production assets. The fair value of the Company's guarantees is recorded in accrued expenses and other current liabilities in the consolidated balance sheets and included in crop costs, except for the joint venture in Brazil, which are included in other receivables.

In Brazil, certain suppliers obtain government subsidized rural credit financing from local banks that is guaranteed by the Company. Upon delivery of tobacco, the Company remits payments to the local banks on behalf of the suppliers before paying the supplier. Amounts owed to suppliers are recorded in accounts payable in the consolidated balance sheets. Rural credit financing repayment is due to local banks based on contractual due dates.

***Derivative Financial Instruments***

We are exposed to foreign currency exchange rate risk due to the scope of the Company's international operations. To manage fluctuations in foreign currency exchange rates, the Company may enter into forward or option currency contracts. These derivative financial instruments are either designated as cash flow hedges of forecasted transactions, including purchases of green tobacco, other processing-related costs, and selling, general, and administrative expenses, or are not designated as hedging instruments and are used to partially offset the immediate earnings impact of foreign currency exchange rate fluctuations on certain foreign currency denominated transactions, or monetary assets and liabilities. The Company does not enter into derivative instruments for speculative or trading purposes.

Derivative assets and liabilities are recorded in other current assets and accrued expenses and other current liabilities, respectively, within the consolidated balance sheets and are measured at fair value. Changes in fair value are recognized in earnings, unless the derivative is designated and qualifies to be in a hedge accounting relationship. For derivatives designated in a hedge accounting relationship, the Company evaluates hedge effectiveness at inception and on an ongoing basis. If a hedge relationship is no longer expected to be effective, the derivative in that relationship is de-designated and hedge accounting is discontinued.

Changes in fair value of foreign currency derivatives designated in cash flow hedging relationships are recorded in accumulated other comprehensive income in the consolidated balance sheets and reclassified to earnings when the hedged item affects earnings. Cash flows from derivatives are classified in the consolidated statements of cash flows in the same category as the cash flows from the underlying hedged items. The Company has elected not to offset fair value amounts recognized for derivative instruments with the same counterparty under a master netting agreement.

***Pension and Other Postretirement Benefits***

*Retirement Benefits*

The Company maintains various excess benefit and supplemental plans that provide additional benefits to certain individuals in key positions and individuals whose compensation and the resulting benefits that would have been paid are limited by regulations imposed by the Internal Revenue Code. In addition, a Supplemental Retirement Account Plan defined contribution plan is maintained. Additional non-U.S. plans sponsored by certain subsidiaries cover certain current and former employees.

*Postretirement Health and Life Insurance Benefits*

The Company provides certain health and life insurance benefits to retired U.S. employees (and their eligible dependents) who meet specified age and service requirements. The plan excludes new employees after September 2005 and caps the Company's annual cost commitment to postretirement benefits for retirees. The Company retains the right, subject to existing agreements, to modify or eliminate these postretirement health and life insurance benefits in the future. The Company provides certain health and life insurance benefits to retired Brazilian directors and certain retirees located in Europe including their eligible dependents who meet specified requirements.

------

*Plan Assets*

The Company's policy is to contribute amounts to the plans sufficient to meet or exceed funding requirements of local governmental rules and regulations. The Company's investment objectives for plan assets are to generate consistent total investment return to pay anticipated plan benefits, while minimizing long-term costs and portfolio volatility. The financial objectives underlying this policy include maintaining plan contributions at a reasonable level relative to benefits provided and assuring unfunded obligations do not grow to a level that would adversely affect the Company's financial health. Portfolio performance is measured against investment objectives and objective benchmarks. The portfolio objective is to exceed the actuarial return on assets assumption. The Company is exploring partial risk transfers and/or full plan terminations and has implemented a Liability Driven Investment ("LDI") strategy to maintain the high funded status and immunize the portfolio from excessive market volatility. Management and the plan's consultant regularly review portfolio allocations and periodically rebalance the portfolio to the targeted allocations according to the guidelines set forth in the Company's investment policy. Equity securities do not include the Company's common stock. The Company's diversification and risk control processes serve to minimize the concentration and experience of risk. There are no significant concentrations of risk, in terms of sector, industry, geography, or individual company or companies.

The Company's plan assets primarily consist of cash and cash equivalents, GBP Sterling denominated fixed income securities, and real estate investments. The Plan has transitioned to a LDI strategy, which consists of high-quality sovereign and corporate bonds whose interest rate sensitivity matches that of the plans' liabilities. Plan assets are measured at fair value annually on March 31, the measurement date. The following are descriptions, valuation methodologies, and inputs used to determine the fair value of each major category of plan assets:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash and cash equivalents include short-term investment funds, primarily in diversified portfolios of investment grade money market instruments that are valued using quoted market prices or other valuation methods and classified as Level 1 or Level 2 in the fair value hierarchy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Investments in equity and fixed income mutual funds are publicly traded and valued primarily using quoted market prices and generally classified as Level 1 in the fair value hierarchy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fixed income securities are diversified and publicly traded, and are valued using quoted market prices or other valuation methods classified as Level 1 or Level 2 in the fair value hierarchy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Real estate investments include those in private limited partnerships that invest in various domestic and international commercial and residential real estate projects and publicly traded REIT securities. The fair values of private real estate assets are typically determined by using income and/or cost approaches or comparable sales approach, taking into consideration discount and capitalization rates, financial conditions, local market conditions, and the status of the capital markets, and are generally classified as Level 3 in the fair value hierarchy. Publicly traded REIT securities are valued primarily using quoted market prices and are generally classified as Level 1 in the fair value hierarchy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diversified investments include mutual funds with an absolute return strategy. Mutual fund investments with absolute return strategies are publicly traded and valued using quoted market prices and are generally classified as Level 1 in the fair value hierarchy.

***Foreign Currency Translation and Remeasurement***

The Company translates assets and liabilities of its foreign subsidiaries from their respective functional currencies to USD using exchange rates in effect at period end. The Company's results of operations and its cash flows are translated using average exchange rates for each reporting period. Resulting currency translation adjustments are reflected as a separate component of accumulated other comprehensive income in the consolidated balance sheets.

The financial statements of foreign subsidiaries, for which the USD is the functional currency, and which have certain transactions denominated in a local currency, are remeasured into USD. The remeasurement of local currencies into USD results in remeasurement adjustments that are included in net income.

Realized and unrealized foreign currency exchange gains and losses resulting from remeasurement and settlement of foreign currency transactions denominated in a currency other than the functional currency of an entity are recorded in cost of goods and services sold and other expense, net within the consolidated statements of operations.

***Equity-Based Compensation***

The Company's Board of Directors adopted the 2020 Incentive Plan on November 18, 2020 (the "Incentive Plan"), and on March 21, 2024 and March 19, 2025, the Board of Directors amended and restated the Company's Incentive Plan to increase the number of shares of the Company's common stock authorized to be issued thereunder. The Incentive Plan provides the Company the flexibility to grant a variety of equity-based awards including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance share awards, and incentive awards to its officers, directors, and employees. For equity-based awards without performance conditions, the Company recognizes equity-based compensation cost on a straight-line basis over the vesting period of the award. For equity-based awards with performance conditions, the Company recognizes equity-based compensation cost using the accelerated attribution method over the requisite service period

------

when the Company determines it is probable that the performance condition will be satisfied. The Company recognizes forfeitures of equity-based awards as they occur. Equity-based compensation expense is recorded in selling, general, and administrative expenses within the consolidated statements of operations.

**2. New Accounting Standards**

***Recently Adopted Accounting Pronouncements***

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09, *Income Taxes: Improvements to Income Tax Disclosures*, to provide more disaggregation of income tax information mainly related to the effective tax rate reconciliation and the income taxes paid disclosure requirements. Under the new accounting rules, the tabular effective tax rate reconciliation must include specific categories with certain reconciling items based on the expected tax further disaggregated by nature and/or jurisdiction. Income taxes paid, net of refunds received, must be broken out by federal, state, and foreign taxes, and further disaggregated by individual jurisdictions based on total income taxes paid. The Company adopted these new and enhanced annual income tax disclosures on a retrospective basis beginning with the fiscal year ended March 31, 2026. Prior period disclosures have been recast to reflect the new disclosure requirements. The adoption of this new rule resulted in expanded income tax disclosures, which are included in "<u>[Note 5. Income Taxes](#i6f44eae8422d46cd9f377051509c10a4_148)</u>," and did not have an impact on the Company's financial condition, results of operations, or cash flows.

In July 2025, the FASB issued ASU No. 2025-05, *Financial Instruments - Credit Losses: Measurement of Credit Losses for Accounts Receivable and Contract Assets*, to include a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets. This new practical expedient allows an entity to assume current economic conditions as of the balance sheet date will not change for the life of the asset, thereby eliminating the need for an entity to develop and consider reasonable and supportable forecasts of future economic conditions. This amendment is effective for the Company's fiscal year beginning April 1, 2026, with early adoption permitted. The Company early adopted this new ASU in the fourth quarter of fiscal year 2026 and elected to apply the practical expedient. The adoption of this practical expedient did not have a material impact on the Company's financial condition, results of operations, or cash flows.

***Accounting Pronouncements Not Yet Adopted***

In November 2024, the FASB issued ASU No. 2024-03, *Disaggregation of Income Statement Expenses*, which requires a tabular disclosure of relevant expense captions into prescribed natural expense categories. The annual disclosure requirements are effective for the Company's fiscal year ending March 31, 2028, and the interim period disclosure requirements are effective beginning April 1, 2028. Early adoption is permitted. This new standard will result in additional disclosures within the footnotes to the financial statements, and is not expected to have an impact on the Company's financial condition, results of operations, or cash flows.

In September 2025, the FASB issued ASU No. 2025-06, *Intangibles - Goodwill and Other - Internal-Use Software: Targeted Improvements to the Accounting for Internal-Use Software*, changing the existing model used to determine when cost capitalization is to occur based on various project stages of software development with a more modern approach that introduces a probable-to-complete recognition threshold. The scope of this new guidance also includes the costs an entity incurs to implement a cloud computing arrangement as a customer. This amendment is effective for the Company's annual and interim periods beginning April 1, 2028. Early adoption is permitted. The Company is currently evaluating the impact this new accounting standard will have on its financial condition, results of operations, and cash flows.

In November 2025, the FASB issued ASU No. 2025-09, *Hedge Accounting Improvements*, to clarify certain aspects of existing hedge accounting guidance, and to more closely align hedge accounting with the economics of an entity's risk management activities. This amendment is effective for the Company's annual and interim periods beginning April 1, 2027 and requires adoption on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact this new accounting standard will have on its financial condition, results of operations, and cash flows.

In December 2025, the FASB issued ASU No. 2025-10, *Accounting for Government Grants Received by Business Entities,* to establish guidance on the recognition, measurement, and presentation of government grants received by business entities. This new guidance is effective for the Company's fiscal year beginning April 1, 2029, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact this new accounting standard will have on its financial condition, results of operations, and cash flows.

------

**3. Revenue Recognition**

Product revenues are primarily processed tobacco sold to the customer. Processing and other revenues are mainly contracts to process customer-owned green tobacco. During such processing, ownership remains with the customers. All Other revenue is primarily composed of revenue from the sale of non-tobacco agricultural products. The following disaggregates sales and other operating revenues by major source, with the All Other category being included for purposes of reconciliation of the respective balances below of the Leaf segment (the Company's sole reportable segment) to the consolidated financial statements:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Leaf: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenues | $2235763 | $2335107 | $1912438 |
| &nbsp;&nbsp;&nbsp;&nbsp;Processing and other revenues | 169310 | 135877 | 117177 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leaf sales and other operating revenues | 2405073 | 2470984 | 2029615 |
| All Other: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Other sales and other operating revenues | 7927 | 10276 | 2944 |
| Total sales and other operating revenues | $2413000 | $2481260 | $2032559 |

---

The following summarizes activity in the claims allowance:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Balance, beginning of period | $2436 | $3313 | $2350 |
| &nbsp;&nbsp;&nbsp;Additions | 8318 | 2010 | 6191 |
| &nbsp;&nbsp;&nbsp;Payments and other adjustments | (4846) | (2887) | (5228) |
| Balance, end of period | $5908 | $2436 | $3313 |

---

***Taxes Collected from Customers***

Value-added taxes were $50,656, $43,298, and $34,905 for the years ended March 31, 2026, 2025, and 2024, respectively.

**4. Other Expense, Net**

The following summarizes the components of other expense, net:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Losses on sale of receivables<sup>(1)</sup> | $14101 | $19565 | $13121 |
| Foreign currency losses (gains) | 1739 | (2121) | 251 |
| Loss on resolution of customs matter | 6440 |  |  |
| Gain on sale of fixed assets | (3114) | (2423) | (2300) |
| Miscellaneous expense (income), net | 27 | 1389 | (1633) |
| &nbsp;&nbsp;Total | $19193 | $16410 | $9439 |
| <sup>(1)</sup> See "<u>[Note 17. Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" for additional information. | <sup>(1)</sup> See "<u>[Note 17. Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" for additional information. | <sup>(1)</sup> See "<u>[Note 17. Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" for additional information. | <sup>(1)</sup> See "<u>[Note 17. Securitized Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" for additional information. |

---

------

**5. Income Taxes**

***Income Tax Provision***

The components of income before income taxes and other items consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| &nbsp;&nbsp;Domestic | $(20603) | $(4579) | $(17697) |
| &nbsp;&nbsp;Foreign | 49233 | 38033 | 33170 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $28630 | $33454 | $15473 |

---

The details of the amount shown for income taxes in the consolidated statements of operations are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Current: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal | $1323 | $6837 | $5319 |
| &nbsp;&nbsp;&nbsp;&nbsp;State | (280) | 261 | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign | 26522 | 23611 | 24385 |
| Total Current | 27565 | 30709 | 29645 |
| Deferred: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal<sup>(1)</sup> | (151) | (10307) | 968 |
| &nbsp;&nbsp;&nbsp;&nbsp;State | 6 | (155) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign | 2924 | 4806 | (3323) |
| Total Deferred | 2779 | (5656) | (2364) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | $30344 | $25053 | $27281 |
| <sup>(1)</sup> Deferred federal expense for fiscal year 2025 was primarily due to release of a valuation allowance in the U.S. from improved profitability. | <sup>(1)</sup> Deferred federal expense for fiscal year 2025 was primarily due to release of a valuation allowance in the U.S. from improved profitability. | <sup>(1)</sup> Deferred federal expense for fiscal year 2025 was primarily due to release of a valuation allowance in the U.S. from improved profitability. | <sup>(1)</sup> Deferred federal expense for fiscal year 2025 was primarily due to release of a valuation allowance in the U.S. from improved profitability. |

---

------

The difference between income tax expense based on income before income taxes and other items and the amount computed by applying the U.S. statutory federal income tax rate to income are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| | $% | $% | $% |
| U.S. federal statutory tax rate | 21.0 | 21.0 | 21.0 |
| State and local income taxes, net of federal income tax effect<sup>(1)</sup> | (0.7) | 0.2 | (0.7) |
| Foreign tax effects |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Argentina |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances | 5.9 | 16.6 | 3.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange effects and currency translation | (1.4) | (7.7) | 9.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (1.2) | (7.4) | (5.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Brazil |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange effects and currency translation | (4.7) | 19.8 | (14.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hybrid dividends | (10.7) | (9.4) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax on unremitted foreign earnings | 4.1 | (6.8) | (2.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 8.9 | 9.1 | 16.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Malawi |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances | 0.1 | (14.2) | 49.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange effects and currency translation | 2.5 | 17.1 | (30.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 6.7 | 8.9 | (2.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tanzania |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nondeductible interest | 12.7 | 4.0 | 4.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 4.7 | 4.8 | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Zambia |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in valuation allowances | (10.1) | (7.3) | 17.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange effects and currency translation | 8.1 | (1.1) | (5.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 8.2 | 3.6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other foreign jurisdictions | 11.1 | 8.5 | (3.6) |
| Effect of cross-border tax laws |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Global intangible low-taxed income | 23.9 | 21.2 | 29.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. taxes on foreign earnings | 8.6 | 1.5 | 27.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 3.0 | 1.3 | 7.9 |
| Tax credits |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign tax credits | (25.4) | (12.9) | (32.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other |  | (0.1) | (0.3) |
| Changes in valuation allowances | 1.8 | (22.6) | 26.5 |
| Nontaxable or nondeductible items | 5.2 | (3.7) | (15.5) |
| Changes in unrecognized tax benefits | 26.6 | 26.3 | 61.9 |
| Other, net | (2.9) | 4.3 | 14.1 |
| Income tax expense | 106.0 | 74.9 | 176.3 |
| <sup>(1)</sup> The effects of individual state and local jurisdictions are immaterial.  | <sup>(1)</sup> The effects of individual state and local jurisdictions are immaterial.  | <sup>(1)</sup> The effects of individual state and local jurisdictions are immaterial.  | <sup>(1)</sup> The effects of individual state and local jurisdictions are immaterial.  |

---

------

The following summarizes the components of deferred tax assets (liabilities):

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Deferred tax assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-deductible interest carryforward | $37406 | $34940 |
| &nbsp;&nbsp;&nbsp;&nbsp;Original issue discount | 7165 | 10439 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reserves and accruals | 26520 | 22691 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax loss carryforwards | 17393 | 16653 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized exchange losses |  | 1448 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease obligations | 7333 | 6511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 12608 | 9971 |
| Gross deferred tax assets | 108425 | 102653 |
| &nbsp;&nbsp;&nbsp;&nbsp;Valuation allowance | (60632) | (60302) |
| Total deferred tax assets | $47793 | $42351 |
| Deferred tax liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unremitted earnings of foreign subsidiaries | $(31607) | $(27560) |
| &nbsp;&nbsp;&nbsp;&nbsp;Right of use asset | (7567) | (7050) |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized exchange gains | (4176) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (1894) | (2989) |
| Total deferred tax liabilities | $(45244) | $(37599) |
| Net deferred tax assets | $2549 | $4752 |

---

The following summarizes the change in the valuation allowance for deferred tax assets:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Balance, beginning of period | $60302 | $70391 | $59506 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes to expenses<sup>(1)</sup> | 632 | (10081) | 10727 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes to other comprehensive income | (302) | (8) | 158 |
| Balance, end of period | $60632 | $60302 | $70391 |
| <sup>(1)</sup> For the years ended March 31, 2025 and 2024, respectively, the change was primarily driven by a reduction in the valuation allowance in the U.S. and an increase in the valuation allowances across various African jurisdictions. | <sup>(1)</sup> For the years ended March 31, 2025 and 2024, respectively, the change was primarily driven by a reduction in the valuation allowance in the U.S. and an increase in the valuation allowances across various African jurisdictions. | <sup>(1)</sup> For the years ended March 31, 2025 and 2024, respectively, the change was primarily driven by a reduction in the valuation allowance in the U.S. and an increase in the valuation allowances across various African jurisdictions. | <sup>(1)</sup> For the years ended March 31, 2025 and 2024, respectively, the change was primarily driven by a reduction in the valuation allowance in the U.S. and an increase in the valuation allowances across various African jurisdictions. |

---

As of March 31, 2026, the Company had foreign net operating loss carryforwards of $55,740, of which $34,096 relates to jurisdictions with definite lived carryforward periods and $21,644 relates to jurisdictions with indefinite lived carryforward periods.

Under current U.S. tax regulations, in general, repatriation of foreign earnings to the U.S. can be completed without incurring material incremental U.S. tax. However, repatriation of foreign earnings could subject the Company to domestic, state, or foreign jurisdictional taxes (including withholding taxes) on distributions or sales of minority owned investments.

The Company has not recorded a deferred tax liability for U.S. federal, U.S. state, or foreign tax from foreign subsidiary unremitted earnings and profits where an indefinite reinvestment assertion was made on the basis that this group of foreign subsidiaries does not expect to have available excess cash and cash equivalents to remit in the foreseeable future or has specific needs for available excess cash. The unrecorded tax liability associated with indefinitely reinvested foreign subsidiary earnings is not practicable to estimate due to the inherent complexity of the Company's global operations.

------

***Accounting for Uncertainty in Income Taxes***

The following summarizes the changes to unrecognized tax benefits and related interest and penalties:

---

| | | |
|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 |
| Balance at April 1 | $12806 | $16892 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase for prior year tax positions | 5208 | 2989 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase for current year tax positions | 3319 | 4854 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reduction for settlements | (331) | (8020) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of changes in exchange rates | (123) | (210) |
| &nbsp;&nbsp;&nbsp;&nbsp;Reduction of statute of limitation expirations | (36) | (3699) |
| Balance at March 31<sup>(1)</sup> | $20843 | $12806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 3253 | 1929 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued penalties | 5277 | 3900 |
| Balance at March 31<sup>(1)</sup> | $29373 | $18635 |
| <sup>(1)</sup> As of March 31, 2026, $29,680 would impact the Company's effective tax rate, if recognized. This includes indirect effects such as related valuation allowance releases. | <sup>(1)</sup> As of March 31, 2026, $29,680 would impact the Company's effective tax rate, if recognized. This includes indirect effects such as related valuation allowance releases. | <sup>(1)</sup> As of March 31, 2026, $29,680 would impact the Company's effective tax rate, if recognized. This includes indirect effects such as related valuation allowance releases. |

---

&nbsp;&nbsp;&nbsp;&nbsp;

Due to the Company's global operations, numerous tax audits may be ongoing throughout the world at any point in time. The Company's income tax liabilities are based on estimates of potential income taxes due upon the conclusion of such audits and are updated to reflect changes in facts and circumstances, as they become known. Due to the uncertain and complex application of tax regulations, it is possible that the resolution of audits may result in liabilities which could be materially different from these estimates. The Company will record additional income tax expense or benefit in the period in which such resolution occurs or if estimates or judgments change.

The Company and its subsidiaries file a U.S. federal consolidated income tax return as well as returns in several U.S. states and a number of foreign jurisdictions. As of March 31, 2026, the Company's earliest open tax year for U.S. federal income tax purposes relate to tax periods ending in 2022. Open tax years in state and foreign jurisdictions generally range from three to six years. In applicable jurisdictions, the Company's tax attributes from prior periods remain subject to adjustment.

***Cash Paid for Income Taxes, Net***

The following summarizes cash paid for income taxes (net of refunds) by jurisdiction:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| U.S. federal | $1621 | $2300 | $6438 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt exchange |  |  | 12543 |
| U.S. state and local | (42) | 92 | 299 |
|  | 1579 | 2392 | 19280 |
| Foreign |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Brazil | $3462 | $3895 | $(1359) |
| &nbsp;&nbsp;&nbsp;&nbsp;Indonesia | 1753 | 2110 | 3184 |
| &nbsp;&nbsp;&nbsp;&nbsp;Malawi | 3027 | 1402 | 542 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tanzania | 973 | 5389 | 1235 |
| &nbsp;&nbsp;&nbsp;&nbsp;Turkey | 3180 | 3265 | 3823 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(1)</sup> | 6466 | 12648 | 8339 |
|  | $18861 | $28709 | $15764 |
| Total | $20440 | $31101 | $35044 |
| <sup>(1)</sup> Includes amounts paid to settle certain income tax matters that were subject to litigation in various jurisdictions. | <sup>(1)</sup> Includes amounts paid to settle certain income tax matters that were subject to litigation in various jurisdictions. | <sup>(1)</sup> Includes amounts paid to settle certain income tax matters that were subject to litigation in various jurisdictions. | <sup>(1)</sup> Includes amounts paid to settle certain income tax matters that were subject to litigation in various jurisdictions. |

---

------

**6. Earnings Per Share**

The following summarizes the computation of earnings per share:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Net income attributable to Pyxus International, Inc. | $14569 | $15166 | $2663 |
| Basic weighted average shares outstanding | 25790 | 25643 | 25000 |
| Plus: Dilutive equity awards | 167 | 24 |  |
| Diluted weighted average shares outstanding | 25957 | 25667 | 25000 |
| Earnings per share: |  |  |  |
| &nbsp;&nbsp;Basic | $0.56 | $0.59 | $0.11 |
| &nbsp;&nbsp;Diluted | $0.56 | $0.59 | $0.11 |

---

**7. Restricted Cash**

The following summarizes the composition of restricted cash:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Compensating balance for short-term borrowings | $107 | $542 |
| Escrow | 1953 | 3534 |
| Grants | 458 | 3116 |
| Other | 798 | 98 |
| &nbsp;&nbsp;Total | $3316 | $7290 |

---

**8. Trade Receivables, Net**

Trade receivables are net of an allowance for expected credit losses. The following summarizes activity in the allowance for expected credit losses:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Balance, beginning of period | $(24035) | $(23940) | $(24730) |
| &nbsp;&nbsp;&nbsp;Additions | (160) | (1299) | (1535) |
| &nbsp;&nbsp;&nbsp;Write-offs and other adjustments | 7316 | 1204 | 2325 |
| Balance, end of period | (16879) | (24035) | (23940) |
| Trade receivables | 256335 | 213274 | 192704 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade receivables, net | $239456 | $189239 | $168764 |

---

------

**9. Inventories, Net**

The following summarizes the composition of inventories, net with the All Other category primarily composed of non-tobacco agricultural products:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Processed tobacco | $507380 | $490410 |
| Unprocessed tobacco | 279348 | 241832 |
| Other tobacco related | 26883 | 25643 |
| All Other | 4339 | 4066 |
| &nbsp;&nbsp;Total | $817950 | $761951 |

---

**10. Advances to Suppliers, Ne**t

The following summarizes the composition of advances to suppliers, net:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Advances to tobacco suppliers, net | $33257 | $29144 |
| Advances to non-tobacco suppliers | 3080 | 1601 |
| &nbsp;&nbsp;&nbsp;Total in current assets | 36337 | 30745 |
| Long-term advances to tobacco suppliers, net | 6928 | 4980 |
| &nbsp;&nbsp;Total current and long-term | $43265 | $35725 |

---

The mark-up and interest on advances to tobacco suppliers, net capitalized, or to be capitalized into inventory for the current crop, were $20,732 and $17,066 for the year ended March 31, 2026 and 2025, respectively. Unrecoverable advances and other costs capitalized, or to be capitalized into the current crop, were $10,911 and $11,833 as of March 31, 2026 and 2025, respectively.

**11. Equity Method Investments**

The following summarizes the Company's equity method investments as of March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Investee Name | Location | Primary Purpose | Ownership Percentage | Basis Difference<sup>(1)</sup> |
| Adams International Ltd. | Thailand | Purchase and process tobacco | 49% | $(4526) |
| Alliance One Industries India Private Ltd. | India | Purchase and process tobacco | 49% | (5770) |
| China Brasil Tabacos Exportadora S.A. | Brazil | Purchase and process tobacco | 49% | 43000 |
| Oryantal Tütün Paketleme Sanayi ve Ticaret A.Ş. | Turkey | Process tobacco | 50% | (416) |
| Purilum, LLC | U.S. | Produce flavor formulations and consumable nicotine products | 50% | 4589 |
| Siam Tobacco Export Corporation Ltd. | Thailand | Purchase and process tobacco | 49% | (6098) |
| <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. | <sup>(1)</sup> Basis differences for the Company's equity method investments are due to fair value adjustments recorded during fiscal 2021. |

---

------

The following summarizes aggregate financial information for these equity method investments:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Statement of operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales | $581169 | $611152 | $505262 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 80965 | 70208 | 82614 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | 35780 | 16851 | 33101 |

---

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Balance sheet: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets | $457219 | $419192 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment and other assets | 65716 | 49243 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current liabilities | 362790 | 328818 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term obligations and other liabilities | 6333 | 4560 |

---

**12. Variable Interest Entities**

The following summarizes the Company's financial relationships with its unconsolidated variable interest entities:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Investments in variable interest entities | $99239 | $90239 |
| Guaranteed amounts to variable interest entities (not to exceed) | 18483 | 15995 |

---

See "<u>[Note 25. Related Party Transactions](#i6f44eae8422d46cd9f377051509c10a4_208)</u>" for the asset and liability balances associated with our equity investments. See "<u>[Note 17](#i6f44eae8422d46cd9f377051509c10a4_181)[. Secur](#i6f44eae8422d46cd9f377051509c10a4_181)[itized](#i6f44eae8422d46cd9f377051509c10a4_181)[Receivables](#i6f44eae8422d46cd9f377051509c10a4_181)</u>" for the beneficial interests with certain of our securitization facilities.

**13. Intangible Assets, Net**

The gross carrying amount and accumulated amortization of intangible assets consist of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2026 |
| | Weighted Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | 6.4 years | $26101 | $(12144) | $13957 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | 2.4 years | 11618 | (8292) | 3326 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade names | 8.4 years | 11300 | (4507) | 6793 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $49019 | $(24943) | $24076 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | March 31, 2025 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Weighted Average Remaining Useful Life | Gross Carrying Amount | Accumulated Amortization | Intangible Assets, Net |
| Intangibles subject to amortization: |  |  |  |  |
| &nbsp;&nbsp;Customer relationships | 7.4 years | $26101 | $(9969) | $16132 |
| &nbsp;&nbsp;Technology | 3.4 years | 11618 | (6844) | 4774 |
| &nbsp;&nbsp;Trade names | 9.4 years | 11300 | (3699) | 7601 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  | $49019 | $(20512) | $28507 |

---

The following summarizes amortization expense for definite-lived intangible assets:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Amortization expense | $4431 | $4532 | $4631 |

---

The following summarizes the estimated intangible asset amortization expense for the next five fiscal years and beyond:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Customer Relationships | Technology<sup>(1)</sup> | Trade Names | Total |
| 2027 | $2175 | $1378 | $807 | $4360 |
| 2028 | 2175 | 1375 | 807 | 4357 |
| 2029 | 2175 | 573 | 807 | 3555 |
| 2030 | 2175 |  | 807 | 2982 |
| 2031 | 2175 |  | 807 | 2982 |
| Thereafter | 3082 |  | 2758 | 5840 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $13957 | $3326 | $6793 | $24076 |
| <sup>(1)</sup> Estimated amortization expense for technology is based on costs accumulated as of March 31, 2026. These estimates will change as new costs are incurred and until the software is placed into service. | <sup>(1)</sup> Estimated amortization expense for technology is based on costs accumulated as of March 31, 2026. These estimates will change as new costs are incurred and until the software is placed into service. | <sup>(1)</sup> Estimated amortization expense for technology is based on costs accumulated as of March 31, 2026. These estimates will change as new costs are incurred and until the software is placed into service. | <sup>(1)</sup> Estimated amortization expense for technology is based on costs accumulated as of March 31, 2026. These estimates will change as new costs are incurred and until the software is placed into service. | <sup>(1)</sup> Estimated amortization expense for technology is based on costs accumulated as of March 31, 2026. These estimates will change as new costs are incurred and until the software is placed into service. |

---

**14. Leases**

The following summarizes lease costs:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Operating lease costs | $14998 | $14199 | $16028 |
| Variable and short-term lease costs | 19640 | 14848 | 8964 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease costs | $34638 | $29047 | $24992 |

---

The following summarizes the measurement of remaining operating lease terms and discount rates:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Weighted average remaining lease term | 4.3 years | 4.8 years |
| Weighted average discount rate | 16.1% | 15.4% |

---

------

The following summarizes supplemental cash flow information related to operating leases:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows used for operating leases | $14664 | $14145 | $15764 |
| Noncash investing activity: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Right-of-use assets obtained in exchange for new operating lease liabilities | 12164 | 3964 | 10444 |

---

Future minimum lease payments required under operating lease agreements, including those with extended lease term options that are reasonably certain of being exercised, as of March 31, 2026 are summarized by fiscal year as follows:

---

| | |
|:---|:---|
| | Operating Leases |
| 2027 | $13971 |
| 2028 | 9798 |
| 2029 | 5793 |
| 2030 | 4409 |
| 2031 | 2960 |
| Thereafter | 5265 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total future minimum lease payments | 42196 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: amounts related to imputed interest | 11261 |
| &nbsp;&nbsp;&nbsp;&nbsp;Present value of lease liabilities<sup>(1)</sup> | $30935 |
| <sup>(1)</sup> This amount is comprised of $9,915 and $21,020 of current and noncurrent operating lease liabilities, respectively, included in the consolidated balance sheets. | <sup>(1)</sup> This amount is comprised of $9,915 and $21,020 of current and noncurrent operating lease liabilities, respectively, included in the consolidated balance sheets. |

---

**15. Property, Plant, and Equipment, Net**

The following summarizes property, plant, and equipment, net:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Land | $27434 | $26815 |
| Buildings | 47512 | 45982 |
| Machinery and equipment | 122820 | 109247 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 197766 | 182044 |
| Less: accumulated depreciation <sup>(1)</sup> | (54612) | (43868) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total property, plant, and equipment, net | $143154 | $138176 |
| <sup>(1)</sup> This balance was partially reduced by the disposition of certain fully depreciated assets during the year ended March 31, 2026. | <sup>(1)</sup> This balance was partially reduced by the disposition of certain fully depreciated assets during the year ended March 31, 2026. | <sup>(1)</sup> This balance was partially reduced by the disposition of certain fully depreciated assets during the year ended March 31, 2026. |

---

The following summarizes the classification of depreciation expense recorded in the consolidated statements of operations:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Depreciation expense recorded in cost of goods and services sold | $14220 | $13264 | $11806 |
| Depreciation expense recorded in selling, general, and administrative expenses | 2036 | 2380 | 2646 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total depreciation expense | $16256 | $15644 | $14452 |

---

------

**16. Debt Arrangements**

The following summarizes debt and notes payable:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | Outstanding | Outstanding | | | | | | |
| | | March 31, | March 31, | Long-Term Debt Repayment Schedule by Fiscal Year | Long-Term Debt Repayment Schedule by Fiscal Year | Long-Term Debt Repayment Schedule by Fiscal Year | Long-Term Debt Repayment Schedule by Fiscal Year | Long-Term Debt Repayment Schedule by Fiscal Year | Long-Term Debt Repayment Schedule by Fiscal Year |
| |<br>Interest<br>Rate<sup>(1)</sup> | 2026 | 2025 | 2027 | 2028 | 2029 | 2030 | 2031 | Later |
| Senior secured credit facility: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;ABL Credit Facility | 7.0% | $— | $— | $— | $— | $— | $— | $— | $— |
| Senior secured notes: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;8.5% Notes Due 2027<sup>(2)</sup> | 8.5% | 146662 | 145820 |  | 146662 |  |  |  |  |
| Senior secured term loans: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Intabex Term Loans<sup>(3)</sup> | 12.4% | 187752 | 187144 |  | 187752 |  |  |  |  |
| &nbsp;&nbsp;Pyxus Term Loans<sup>(4)</sup> | 12.4% | 121343 | 121886 |  | 121343 |  |  |  |  |
| Other debt: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Other long-term debt | 8.8% |  | 12 |  |  |  |  |  |  |
| &nbsp;&nbsp;Notes payable<sup>(5)</sup> | 8.8% | 477132 | 395030 | 477132 |  |  |  |  |  |
| &nbsp;&nbsp; Total debt |  | $932889 | $849892 | $477132 | $455757 | $— | $— | $— | $— |
| Short-term<sup>(5)</sup> |  | $477132 | $395030 |  |  |  |  |  |  |
| Long-term: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Current portion of long-term debt | &nbsp;&nbsp;Current portion of long-term debt | $— | $12 |  |  |  |  |  |  |
| &nbsp;&nbsp;Long-term debt |  | 455757 | 454850 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total |  | $455757 | $454862 |  |  |  |  |  |  |
| Letters of credit |  | $8024 | $7790 |  |  |  |  |  |  |
| <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. | <sup>(1)</sup> Weighted average stated rate for the trailing twelve months ended March 31, 2026 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding. |
| <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. | <sup>(2)</sup> Balance of $146,662 is net of a debt discount of $1,677. Total repayment at maturity is $148,339. |
| <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. | <sup>(3)</sup> Balance of $187,752 is net of a debt discount of $1,281. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment. |
| <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. | <sup>(4)</sup> Balance of $121,343 is net of a debt premium of $1,138. Total repayment at maturity is $120,205. |
| <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. | <sup>(5)</sup> Primarily foreign seasonal lines of credit. |

---

***Outstanding Senior Secured Debt***

*ABL Credit Facility*

The Company's wholly owned subsidiary, Pyxus Holdings, Inc. ("Pyxus Holdings"), certain subsidiaries of Pyxus Holdings (together with Pyxus Holdings, the "Borrowers"), and the Company and its wholly owned subsidiary, Pyxus Parent, Inc. ("Pyxus Parent"), as parent guarantors, entered into an ABL Credit Agreement (as amended, the "ABL Credit Agreement"), dated as of February 8, 2022, by and among Pyxus Holdings, as Borrower Agent, the Borrowers and parent guarantors party thereto, the lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Collateral Agent (the "ABL Agent"), which was subsequently amended on January 5, 2023, May 23, 2023, October 24, 2023, and May 12, 2025.

The ABL Credit Agreement establishes the ABL Credit Facility, an asset-based revolving credit facility the proceeds of which may be used to provide for the ongoing working capital and general corporate purposes of the Borrowers, the Company, Pyxus Parent, and their subsidiaries, and for other permitted purposes described in the ABL Credit Agreement. The ABL Credit Facility may be used for revolving credit loans and letters of credit from time to time up to a maximum principal amount of $150,000, subject to the borrowing base limitations described below in this paragraph. The ABL Credit Facility includes a $20,000 uncommitted accordion feature that permits Pyxus Holdings, under certain conditions, to solicit the lenders under the ABL Credit Facility to provide additional revolving loan commitments to increase the aggregate amount of the revolving loan commitments under the ABL Credit Facility not to exceed a maximum principal amount of $170,000. The amount available under the ABL Credit Facility is limited by a borrowing base consisting of certain eligible accounts receivable and the value of inventory, as reduced by specified reserves, as follows:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 85% of the book value of eligible accounts receivable, plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the lesser of (i) 85% of the book value of Eligible Extended Terms Receivables (as defined in the ABL Credit Agreement) and (ii) $5,000, plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 90% of eligible credit insured accounts receivable (to the extent the ABL Agent is named as a beneficiary or loss payee with respect to the applicable policy), plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the lesser of (i) 70% of eligible inventory valued at the lower of cost (based on a first-in first-out basis) and market value thereof (net of intercompany profits) or (ii) 85% of the net-orderly-liquidation value percentage of eligible inventory, plus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the least of (i) 70% of the eligible foreign in-transit inventory valued at the lower of cost (based on a first-in first-out basis) and market value thereof (net of intercompany profits), (ii) 85% of the net-orderly-liquidation value percentage of eligible foreign in-transit inventory, and (iii) $10,000, minus

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• applicable reserves established by the ABL Agent from time to time.

At March 31, 2026, no borrowings under the ABL Credit Facility were outstanding and $150,000 was available for borrowing under the ABL Credit Facility. Weighted average borrowings outstanding under the ABL Credit Facility during the fiscal year ended March 31, 2026 were $47,373.

The ABL Credit Facility permits both base rate borrowings and borrowings based upon the Secured Overnight Financing Rate ("SOFR"). Borrowings under the ABL Credit Facility bear interest at an annual rate equal to one, three, or six-month reserve-adjusted SOFR Rate plus 275 basis points or 175 basis points above base rate, as applicable, with a fee on unutilized commitments at an annual rate of 25.0 basis points.

The ABL Credit Facility may be prepaid from time to time, in whole or in part, without prepayment or premium, subject to a termination fee upon the permanent reduction of some or all of the commitments under the ABL Credit Facility in the amount of (i) 2% of the amount of commitments permanently reduced on or prior to May 12, 2026 and (ii) 1% of the amount of commitments permanently reduced on or prior to May 12, 2027 but after May 12, 2026. No such termination fee is payable for reductions after May 12, 2027. In addition, customary mandatory prepayments of the loans under the ABL Credit Facility are required upon the occurrence of certain events including, without limitation, outstanding borrowing exposures exceeding the borrowing base, certain dispositions of assets outside of the ordinary course of business in respect of certain collateral securing the ABL Credit Facility and certain casualty and condemnation events. With respect to base rate loans, accrued interest is payable monthly in arrears and, with respect to SOFR loans, accrued interest is payable monthly and on the last day of any applicable interest period.

The Borrowers' obligations under the ABL Credit Facility (and certain related obligations) are (a) guaranteed by Pyxus Parent, and the Company and all of Pyxus Holdings' wholly owned domestic subsidiaries, and each of Pyxus Holdings' future wholly owned domestic subsidiaries is required to guarantee the ABL Credit Facility on a senior secured basis (collectively, the "ABL Loan Parties") and (b) secured by the collateral, as described below, which is owned by the ABL Loan Parties.

*Cash Dominion.* Under the terms of the ABL Credit Facility, if (i) an event of default has occurred and is continuing, (ii) excess borrowing availability under the ABL Credit Facility (based on the lesser of the commitments thereunder and the borrowing base) (the "Excess Availability") falls below the greater of $12,500 and 10% of the lesser of total revolving loan commitments under the ABL Credit Facility at such time and the borrowing base at such time, or (iii) Domestic Availability (as defined in the ABL Credit Agreement) being less than the greater of $25,000 and 20% of the lesser of total revolving loan commitments under the ABL Credit Facility at such time and the borrowing base at such time, the ABL Loan Parties will become subject to cash dominion, which will require daily prepayment of loans under the ABL Credit Facility with the cash deposited in certain deposit accounts of the ABL Loan Parties, including concentration accounts, and will restrict the ABL Loan Parties' ability to transfer cash from their concentration accounts to their disbursement accounts. Such cash dominion period (a "Dominion Period") shall end when (i) if arising as a result of a continuing event of default, such event of default ceases to exist, (ii) if arising as a result of non-compliance with the Excess Availability threshold, no event of default is continuing and, for a period of 30 consecutive days, Excess Availability is equal to or greater than the greater of $12,500 and 10% of the lesser of total revolving loan commitments under the ABL Credit Facility and the borrowing base, or (iii) if arising as a result of Domestic Availability being less than the threshold, no event of default is continuing and, for a period of 30 consecutive days, Domestic Availability is greater than the greater of $25,000 and 20% of the lesser of total revolving loan commitments under the ABL Credit Facility and the borrowing base.

*Covenants.* The ABL Credit Agreement governing the ABL Credit Facility contains a covenant requiring that the Company's fixed charge coverage ratio be no less than 1.10 to 1.00 during any Dominion Period.

------

The ABL Credit Agreement governing the ABL Credit Facility contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's ability to, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• incur additional indebtedness or issue disqualified stock or preferred stock,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• make investments,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pay dividends and make other restricted payments,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• sell certain assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• create liens,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into sale and leaseback transactions,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• consolidate, merge, sell or otherwise dispose of all or substantially all of the Company's assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into transactions with affiliates,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• engage directly or indirectly in any business other than the businesses engaged in by the Company,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• directly or indirectly open, maintain or otherwise have accounts other than permitted accounts under the ABL Credit Agreement, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• designate subsidiaries as Unrestricted Subsidiaries (as defined in the ABL Credit Agreement).

*Maturity.* The ABL Credit Facility matures on May 12, 2030 or, if earlier, 90 days prior to the earliest maturity date of (i) the Company's existing senior secured notes and the senior secured term loans (each scheduled to mature on December 31, 2027) in the event any such notes or loans remain outstanding or (ii) any indebtedness that refinances any of the foregoing.

On March 31, 2026, the Borrowers were in compliance with the covenants under the ABL Credit Agreement.

*Intabex Term Loans*

Pursuant to (i) an exchange offer (the "DDTL Facility Exchange") made to, and accepted by, holders of 100.0% of the outstanding term loans (the "DDTL Term Loans") under the Amended and Restated Term Loan Credit Agreement, effectuated pursuant to that certain Amendment and Restatement Agreement, dated as of June 2, 2022 (the "DDTL Credit Agreement"), by and among Intabex Netherlands B.V., as borrower ("Intabex"), the guarantors party thereto, the administrative agent and collateral agent thereunder, and the several lenders from time to time party thereto and (ii) an exchange offer (the "Exit Facility Exchange") made to, and accepted by, holders of 100.0% of the outstanding term loans (the "Exit Term Loans") under the Exit Term Loan Credit Agreement, dated as of August 24, 2020 (the "Exit Term Loan Credit Agreement"), by and among Pyxus Holdings, as borrower, the guarantors party thereto, the administrative agent and collateral agent thereunder, and the several lenders from time to time party thereto, on February 6, 2023, Pyxus Holdings entered into the Intabex Term Loan Credit Agreement, dated as of February 6, 2023 (the "Intabex Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus (US) LLC ("Alter Domus"), as administrative agent and senior collateral agent. The Intabex Term Loan Credit Agreement established a term loan credit facility in an aggregate principal amount of approximately $189,033 (the "Intabex Credit Facility"), under which term loans in the full aggregate principal amount of the Intabex Credit Facility (the "Intabex Term Loans") were deemed made in exchange for (i) $100,000 principal amount of the DDTL Term Loans, plus an additional $2,000 on account of the exit fee payable under the DDTL Credit Agreement and (ii) approximately $87,033 principal amount of Exit Term Loans, representing 40.0% of the outstanding principal amount thereof (including the applicable accrued and unpaid PIK interest thereon).

The Intabex Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Intabex Term Loans are stated to mature on December 31, 2027.

The Intabex Term Loans may be prepaid from time to time, in whole or in part, without prepayment or penalty. With respect to alternate base rate loans, accrued interest is payable quarterly in arrears on the last business day of each calendar quarter and, with respect to SOFR loans, accrued interest is payable on the last day of each applicable interest period but no less frequently than every three months.

The Intabex Term Loan Credit Agreement contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; designate subsidiaries as unrestricted subsidiaries; and, in the case of Intabex, undertake business activities and sell certain subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors under the Intabex Term Loan Credit Agreement were in compliance with the covenants under the Intabex Term Loan Credit Agreement.

------

*Pyxus Term Loans*

Pursuant to the Exit Facility Exchange, on February 6, 2023, Pyxus Holdings entered into the Pyxus Term Loan Credit Agreement, dated as of February 6, 2023 (the "Pyxus Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus, as administrative agent and senior collateral agent, to establish a term loan credit facility in an aggregate principal amount of approximately $130,550 (the "Pyxus Credit Facility"), under which term loans in the full aggregate principal amount of the Pyxus Credit Facility (the "Pyxus Term Loans" and, together with the Intabex Term Loans, the "Senior Secured Term Loans") were deemed made in exchange for 60.0% of the outstanding principal amount of Exit Term Loans (including the applicable accrued and unpaid PIK interest thereon).

The Pyxus Term Loans bear interest, at Pyxus Holdings' option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Pyxus Term Loans are stated to mature on December 31, 2027.

The Pyxus Term Loans may be prepaid from time to time, in whole or in part, without prepayment or penalty. With respect to alternate base rate loans, accrued interest is payable quarterly in arrears on the last business day of each calendar quarter and, with respect to SOFR loans, accrued interest is payable on the last day of each applicable interest period but no less frequently than every three months.

The Pyxus Term Loan Credit Agreement contains customary representations and warranties, affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors under the Pyxus Term Loan Credit Agreement were in compliance with the covenants under the Pyxus Term Loan Credit Agreement.

*8.50% Senior Secured Notes due 2027*

Pursuant to an exchange offer (the "Notes Exchange" and, together with the DDTL Facility Exchange and the Exit Facility Exchange, the "Debt Exchange Transactions") made by Pyxus Holdings and accepted by holders of approximately 92.7% of the aggregate principal amount of the outstanding 10.0% Senior Secured First Lien Notes due 2024 issued by Pyxus Holdings (the "2024 Notes") pursuant to that certain Indenture, dated as of August 24, 2020 (the "2024 Notes Indenture"), by and among Pyxus Holdings, the guarantors party thereto and the trustee, collateral agent, registrar and paying agent thereunder, on February 6, 2023, Pyxus Holdings issued approximately $260,452 in aggregate principal amount of 8.5% Senior Secured Notes due December 31, 2027 (the "2027 Notes" and, together with the Senior Secured Term Loans, the "Senior Secured Term Debt") to the exchanging holders of the 2024 Notes for an equal principal amount of 2024 Notes. The 2027 Notes were issued pursuant to the Indenture, dated as of February 6, 2023 (the "2027 Notes Indenture"), among Pyxus Holdings, the guarantors party thereto, and Wilmington Trust, National Association, as trustee, and Alter Domus, as collateral agent.

The 2027 Notes bear interest at a rate of 8.5% per annum, which interest is computed based on a 360-day year comprised of twelve 30-day months. Interest accrues on the 2027 Notes from the date of issuance and is payable semi-annually in arrears on June 15 and December 15 of each year, commencing on June 15, 2023. The 2027 Notes are stated to mature on December 31, 2027.

At any time, Pyxus Holdings may redeem the 2027 Notes, in whole or in part, at a redemption price equal to 100.0% of the principal amount of 2027 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date.

The 2027 Notes Indenture contains customary affirmative and negative covenants (subject, in each case, to exceptions and qualifications) and events of defaults, including covenants that limit the Company's and its restricted subsidiaries' ability to, among other things, incur additional indebtedness or issue disqualified stock or preferred stock; make investments; pay dividends and make other restricted payments; sell certain assets; incur liens; consolidate, merge, sell or otherwise dispose of all or substantially all their assets; enter into transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries.

On March 31, 2026, Pyxus Holdings and the guarantors of the 2027 Notes were in compliance with the covenants under the 2027 Notes Indenture.

------

*Guarantees and Collateral*

The obligations of Pyxus Holdings under the ABL Credit Agreement and the Senior Secured Term Debt are fully and unconditionally guaranteed by the Company, Pyxus Parent and all of the Company's domestic subsidiaries and certain of the Company's foreign subsidiaries, subject to certain limitations (the "Senior Secured Debt Obligors"). In addition, under the Intabex Term Loan Credit Facility, Intabex and Alliance One International Tabak B.V. (which were obligors under the DDTL Term Loans) also guarantee the Intabex Credit Facility (together, the "Specified Intabex Obligors") but do not guarantee the 2027 Notes, the Pyxus Term Loans or obligations under the ABL Credit Agreement. In addition, certain assets of the Specified Intabex Obligors (which were pledged as collateral for the DDTL Term Loans) are pledged as collateral to secure the Intabex Term Loans (the "Intabex Collateral") but do not secure the 2027 Notes, the Pyxus Term Loans, or obligations under the ABL Credit Agreement. On March 27, 2024, Alliance One International Tabak B.V. was merged with and into Intabex.

The Senior Secured Debt Obligors' obligations under the ABL Credit Agreement are secured by (i) a first-priority senior lien the ABL Priority Collateral (as defined in the ABL/Senior Secured Term Debt Intercreditor Agreement (as defined below)), which includes certain accounts receivable and inventory and certain related intercompany notes, cash, deposit accounts, related general intangibles and instruments, certain other related assets and proceeds of the foregoing of the Senior Secured Debt Obligors, and (ii) a junior-priority lien on substantially all assets of the Senior Secured Debt Obligors other than certain exclusions and the ABL Priority Collateral. The Senior Secured Term Debt is secured by (i) a first-priority senior lien on substantially all assets of the Senior Secured Debt Obligors other than certain exclusions and the ABL Priority Collateral and (ii) a junior-priority lien on the ABL Priority Collateral. The Intabex Term Loans are further secured by a first-priority lien on the Intabex Collateral.

The obligations under the Senior Secured Term Debt share a single lien, held by Alter Domus, as senior collateral agent (the "Senior Collateral Agent"), on the Collateral (as defined below) subject to the payment waterfall pursuant to the intercreditor arrangements described below.

*Intercreditor Agreements* 

The priority of the obligations under the ABL Credit Agreement and the Senior Secured Term Debt are set forth in the two intercreditor agreements entered into in connection with consummation of the DDTL Facility Exchange, the Exit Facility Exchange and the Notes Exchange.

*ABL/Senior Secured Term Debt Intercreditor Agreement*. On February 6, 2023, Pyxus Holdings, Inc., the guarantors party thereto, PNC Bank, National Association, as ABL Agent, Alter Domus, as Pyxus Term Loan Administrative Agent, Intabex Term Loan Administrative Agent and Senior Collateral Agent, and Wilmington Trust, National Association, as Senior Notes Trustee entered into an Amended and Restated ABL Intercreditor Agreement, dated as of February 6, 2023 (the "ABL/Senior Secured Term Debt Intercreditor Agreement") to provide for the intercreditor relationship between, (i) on one hand, the holders of obligations under the ABL Credit Facility, the guarantees thereof and certain related obligations and (ii) on the other hand, the holders of obligations under the Senior Secured Term Debt, the guarantees thereof and certain related obligations. Pursuant to the terms of the ABL/Term Loan/Notes Intercreditor Agreement, Pyxus Holdings' obligations under the ABL Credit Facility, the guarantees thereof and certain related obligations have first-priority senior liens on the ABL Priority Collateral, which includes certain accounts receivable and inventory and certain related intercompany notes, cash, deposit accounts, related general intangibles and instruments, certain other related assets of the foregoing entities and proceeds of the foregoing, with the obligations under the Senior Secured Term Debt having junior-priority liens on the ABL Priority Collateral. Pursuant to the ABL/Senior Secured Term Debt Intercreditor Agreement, Pyxus Holdings' collective obligations under the Senior Secured Term Debt, the guarantees thereof and certain related obligations have first-priority senior liens on the collateral that is not ABL Priority Collateral, including owned material real property in the U.S., capital stock of subsidiaries owned directly by Pyxus Holdings or a guarantor (other than the Intabex Collateral), existing and after acquired intellectual property rights, equipment, related general intangibles and instruments and certain other assets related to the foregoing and proceeds of the foregoing, with the obligations under the ABL Credit Facility having junior-priority liens on such collateral, other than real property. The ABL Credit Facility is not secured by real property.

*Secured Debt Intercreditor Agreement*. On February 6, 2023, the Senior Secured Debt Obligors, together with the representative for the holders of the Senior Secured Term Debt and the Senior Collateral Agent, entered into the Intercreditor and Collateral Agency Agreement, dated as of February 6, 2023 (the "Senior Secured Term Debt Intercreditor Agreement"), pursuant to which the Senior Collateral Agent, serves as joint collateral agent for the benefit of the holders of the 2027 Notes, the Pyxus Term Loans and the Intabex Term Loans with respect to all common collateral securing such indebtedness (the "Collateral," which excludes Intabex Collateral). The Senior Secured Term Debt Intercreditor Agreement provides that Collateral or proceeds thereof received in connection with or upon the exercise of secured creditor remedies will be distributed (subject to the provisions described in the next paragraph) first to holders of the Senior Secured Term Debt on a pro rata basis based on the aggregate principal amount of each class of Senior Secured Term Debt, and then to holders of future junior debt

------

secured by such Collateral on a pro rata basis based on the aggregate principal amount of each class of future junior debt (and in each case permitted refinancing indebtedness thereof).

Exercise of rights and remedies against the Collateral and certain rights in a bankruptcy or insolvency proceeding (including the right to object to debtor-in-possession financing or to credit bid) by the Senior Collateral Agent will be controlled first by the holders of a majority in principal amount of the Senior Secured Term Loans (including, in any event, each holder holding at least 20.0% of the Senior Secured Term Loans as of February 6, 2023, provided such holder holds at least 15.0% of the Senior Secured Term Loans as of the date of determination), second, after repayment in full of the Senior Secured Term Loans, by the holders of a majority in principal amount of the 2027 Notes and last, after repayment in full of the Senior Secured Term Loans and the 2027 Notes, by holders of a majority in principal amount of any future junior debt secured by the Collateral. Any such future junior debt will be subject to certain customary waivers of rights in a bankruptcy or insolvency proceeding in favor of the Senior Collateral Agent, including, but not limited to, with respect to debtor-in-possession financing, adequate protection, and credit bidding.

***Other Outstanding Debt***

*Foreign Seasonal Lines of Credit*

Excluding its long-term credit agreements, the Company has typically financed its foreign operations with committed and uncommitted short-term seasonal lines of credit arrangements with a number of banks. These operating lines are generally seasonal in nature, typically extending for a term of 180 to 365 days corresponding to the tobacco crop cycle in that location. For uncommitted facilities, the lenders have the right to cease making loans and demand repayment of loans at any time or at specified dates. These loans are generally renewed at the outset of each tobacco season. Certain of the seasonal lines of credit are secured by trade receivables and inventories as collateral and are guaranteed by the Company and certain of its subsidiaries. At March 31, 2026, the total borrowing capacity under individual seasonal lines of credit range up to $170,000. At March 31, 2026 and 2025, the Company was permitted to borrow under foreign seasonal lines of credit, including letters of credit, up to a total of $1,064,468 and $918,372, respectively, subject to limitations under the ABL Credit Agreement and the agreements governing the Senior Secured Term Debt. The weighted average variable interest rate for the years ended March 31, 2026 and 2025 was 8.8% and 9.4%, respectively. Certain of the seasonal lines of credit with aggregate outstanding borrowings at March 31, 2026 and 2025 of $106,850 and $93,243, respectively, are secured by trade receivables and inventories as collateral. At March 31, 2026 and 2025, respectively, $107 and $542 of cash was held on deposit as a compensating balance. At March 31, 2026, the Company and its subsidiaries were in compliance with the covenants associated with the short-term foreign seasonal lines of credit.

**17. Securitized Receivables**

The Company sells trade receivables to unaffiliated financial institutions under various accounts receivable securitization facilities, two of which are subject to annual renewal.

Under the first facility, with Finacity Corporation (the "Finacity Facility"), the Company continuously sells a designated pool of trade receivables to a special purpose entity, which sells 100% of the receivables to an unaffiliated financial institution. Following the sale and transfer of the receivables to the special purpose entity, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. This facility requires a minimum level of deferred purchase price be retained by the Company in connection with the sales of the receivables to the unaffiliated financial institution. The Company continues to service, administer, and collect the receivables on behalf of the special purpose entity and receives a servicing fee of 0.5% of serviced receivables per annum. The Company estimates the expected fee it receives in return for its obligation to service these receivables reflects fair value, and accordingly, no servicing assets or liabilities are recognized. Servicing fees are recorded as a reduction of selling, general, and administrative expenses within the consolidated statements of operations. Under this facility, the Company may request a temporary increase in the investment limit up to an additional $40,000, applicable only for the period from January 1, 2026 through May 31, 2026. As of March 31, 2026, the investment limit of this facility was $160,000 of trade receivables, inclusive of the temporary increase.

Under the second facility, the Company offers trade receivables for sale to an unaffiliated financial institution, which are then subject to acceptance by the unaffiliated financial institution. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. Although the Company continues to service, administer, and collect the receivables on behalf of the unaffiliated financial institution, the Company does not receive a servicing fee, and as a result, has established a servicing liability based

------

upon unobservable inputs, primarily discounted cash flow. As of March 31, 2026, the investment limit under the second facility was $160,000 of trade receivables.

As servicer for the Finacity Facility and the second facility, the Company may receive funds that are due to the unaffiliated financial institutions which are net settled on the next settlement date. As of March 31, 2026 and 2025, trade receivables, net in the consolidated balance sheets have been reduced by $13,610 and $2,190 as a result of the net settlement, respectively. See "<u>[Note 20. Fair Value Measurements](#i6f44eae8422d46cd9f377051509c10a4_190)</u>" for additional information.

Under the other facilities, the Company offers trade receivables for sale to unaffiliated financial institutions, which are then subject to acceptance by the unaffiliated financial institutions. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. As of March 31, 2026, the investment limits under these other facilities were variable based on qualifying sales.

The following summarizes the Company's accounts receivable outstanding in the securitization facilities, which represents trade receivables sold into the program that have not been collected from the customer, and related beneficial interests, applicable only to the first and second facilities, which represents the Company's residual interest in receivables sold that have not been collected from the customer:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Receivables outstanding in facility | $341679 | $355246 |
| Beneficial interest | 29034 | 29354 |

---

Cash proceeds from the sale of trade receivables are comprised of an initial cash payment received at the time of transfer and a deferred purchase price receivable, applicable only to the first and second facilities, which represents the Company's right to receive the remaining consideration upon collection of the underlying trade receivables by the purchasers. The following summarizes the Company's cash collections from both the initial cash proceeds and the deferred purchase price receivable:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Cash collections from: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Initial proceeds | $842093 | $981560 | $649680 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred purchase price receivable | 200684 | 188312 | 175911 |

---

**18. Guarantees**

In certain sourcing regions, the Company guarantees bank loans for suppliers to finance their crops. The Company also guarantees bank loans of certain unconsolidated affiliates. See "<u>[Note 20. Fair Value Measurements](#i6f44eae8422d46cd9f377051509c10a4_190)</u>" for the fair value of the Company's guarantee liability and corresponding fair value classification. The following summarizes amounts guaranteed:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Amounts guaranteed (not to exceed) | $119728 | $110660 |
| Amounts outstanding under guarantee<sup>(1)</sup> | 92550 | 80045 |
| Amounts due to local banks on behalf of suppliers for government subsidized rural credit financing | 10204 | 13787 |
| <sup>(1)</sup> Most of the guarantees outstanding at March 31, 2026 expire within one year. | <sup>(1)</sup> Most of the guarantees outstanding at March 31, 2026 expire within one year. | <sup>(1)</sup> Most of the guarantees outstanding at March 31, 2026 expire within one year. |

---

**19. Derivative Financial Instruments**

As of March 31, 2026 and 2025, the Company's derivative financial instruments outstanding were designated as cash flow hedges and were primarily used to hedge Brazilian real denominated purchases of green tobacco and the related processing costs. See "<u>[Note 23. Accumulated Other](#i6f44eae8422d46cd9f377051509c10a4_199)[Comprehensive Income](#i6f44eae8422d46cd9f377051509c10a4_199)</u>" for a summary of cash flow hedging activity within accumulated other comprehensive income. See "<u>[Note 20. Fair Value Measurements](#i6f44eae8422d46cd9f377051509c10a4_190)</u>" for the fair values of the Company's outstanding derivative assets and liabilities and corresponding fair value classifications.

------

The following summarizes the U.S. dollar notional amount of derivative contracts outstanding:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Foreign currency exchange contracts | $54100 | $49500 |

---

The following summarizes the impact of foreign currency exchange contracts designated as cash flow hedges ("hedged derivatives") and non-designated hedges ("non-hedged derivatives") within cost of goods and services sold in the consolidated statements of operations:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Foreign currency exchange contracts gains (losses), net from: | Foreign currency exchange contracts gains (losses), net from: | Foreign currency exchange contracts gains (losses), net from: | Foreign currency exchange contracts gains (losses), net from: |
| &nbsp;&nbsp;Hedged derivatives | $4022 | $(2411) | $6356 |
| &nbsp;&nbsp;Non-hedged derivatives<sup>(1)</sup> | 4887 |  |  |
| <sup>(1)</sup> There were foreign currency exchange contracts not designated as hedging instruments (related to the Malawian kwacha) outstanding during the year ended March 31, 2026, but all had expired or settled by period end. | <sup>(1)</sup> There were foreign currency exchange contracts not designated as hedging instruments (related to the Malawian kwacha) outstanding during the year ended March 31, 2026, but all had expired or settled by period end. | <sup>(1)</sup> There were foreign currency exchange contracts not designated as hedging instruments (related to the Malawian kwacha) outstanding during the year ended March 31, 2026, but all had expired or settled by period end. | <sup>(1)</sup> There were foreign currency exchange contracts not designated as hedging instruments (related to the Malawian kwacha) outstanding during the year ended March 31, 2026, but all had expired or settled by period end. |

---

**20. Fair Value Measurements**

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The inputs used to measure fair value are prioritized based on a three-level valuation hierarchy, which is comprised of observable and non-observable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These three levels of inputs create the following fair value hierarchy:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 inputs are quoted prices in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 inputs include data points that are observable such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other data points that are observable (other than quoted prices) or can be corroborated by observable market data.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 inputs are unobservable data points that are supported by little or no market activity, which requires management of the Company to develop its own assumptions.

&nbsp;&nbsp;&nbsp;&nbsp;

The following summarizes the fair value of the Company's financial assets and liabilities measured on a recurring basis, along with their corresponding level within the fair value hierarchy:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 |
| | Level 2 | Level 3 | Total at Fair Value | Level 2 | Level 3 | Total at Fair Value |
| Financial assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivative financial instruments | $649 | $— | $649 | $982 | $— | $982 |
| &nbsp;&nbsp;&nbsp;Securitized beneficial interests |  | 29034 | 29034 |  | 29354 | 29354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $649 | $29034 | $29683 | $982 | $29354 | $30336 |
| Financial liabilities: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Derivative financial instruments | $— | $— | $— | $57 | $— | $57 |
| &nbsp;&nbsp;Long-term debt<sup>(1)</sup> | 433490 |  | 433490 | 433885 | 12 | 433897 |
| &nbsp;&nbsp;&nbsp;Guarantees |  | 7537 | 7537 |  | 6459 | 6459 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $433490 | $7537 | $441027 | $433942 | $6471 | $440413 |
| <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. | <sup>(1)</sup> This fair value measurement disclosure does not affect the consolidated balance sheets. |

---

------

*Level 2 measurements*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Debt: The fair value of debt is based on the market price for similar financial instruments or model-derived valuations with observable inputs. The primary inputs to the valuation include market expectations, the Company's credit risk, and the contractual terms of the debt instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Derivatives: The fair value of derivatives is based on the discounted cash flow analysis of the expected future cash flows. The primary inputs to the valuation include forward yield curves, implied volatilities, interest rates, and credit valuation adjustments.

*Level 3 measurements*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Guarantees: The fair value of guarantees is based on the discounted cash flow analysis of the expected future cash flows or historical loss rates. The historical loss rate was weighted by the principal balance of the loans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Securitized beneficial interests: The fair value of securitized beneficial interests is based on the present value of future expected cash flows. The discount rate was weighted by the outstanding interest. Payment speed was weighted by the average days outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Debt: The fair value of debt is based on the present value of future payments. The primary inputs to this valuation include treasury notes interest and borrowing rates. The borrowing rates were weighted by average loans outstanding.

The following summarizes the changes in Level 3 instruments measured on a recurring basis.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 |
| | Securitized Beneficial Interests | Long-Term Debt | Guarantees | Securitized Beneficial Interests | Long-Term Debt | Guarantees |
| Balance, beginning of period | $29354 | $12 | $6459 | $15036 | $160 | $5097 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances | 198567 |  | 8026 | 244886 |  | 7639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Settlements | (189786) | (12) | (3798) | (212964) | (148) | (2421) |
| &nbsp;&nbsp;&nbsp;&nbsp;Losses recognized in earnings | (9101) |  | (3150) | (17604) |  | (3856) |
| Balance, end of period | $29034 | $— | $7537 | $29354 | $12 | $6459 |

---

The following summarizes significant unobservable inputs and the valuation techniques utilized:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended March 31, 2026 | Year Ended March 31, 2026 | Year Ended March 31, 2026 |
| | Valuation Technique | Unobservable Input | Range (Weighted Average) |
| Securitized Beneficial Interests | Discounted Cash Flow | Discount Rate | 2.7% to 6.2% |
| Securitized Beneficial Interests | Discounted Cash Flow | Payment Speed | 59 days to 91 days |
| Guarantees | Historical Loss | Historical Loss | 1.2% to 39.1% |
| Guarantees |  |  |  |

---

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended March 31, 2025 | Year Ended March 31, 2025 | Year Ended March 31, 2025 |
| | Valuation Technique | Unobservable Input | Range (Weighted Average) |
| Securitized Beneficial Interests | Discounted Cash Flow | Discount Rate | 3.0% to 6.9% |
| Securitized Beneficial Interests | Discounted Cash Flow | Payment Speed | 64 days to 91 days |
| Guarantees | Historical Loss | Historical Loss | 0.7% to 37.3% |
| Guarantees |  |  |  |

---

**21. Pension and Other Postretirement Benefits**

***Defined Benefit Plans***

The Company terminated one of its defined benefit pension plans in the United Kingdom ("U.K. Pension Plan") during the year ended March 31, 2024. The U.K. Pension Plan was over-funded. During the year ended March 31, 2024, the Company utilized the surplus assets to pay termination fees and received a $1,106 cash distribution from the plan termination. The Company recorded a noncash pension settlement charge of $12,008 during the year ended March 31, 2024, which included the disposition of the U.K. Pension Plan assets and the reclassification of $3,511 unrecognized net pension losses, net of $1,170 tax benefit, within accumulated other comprehensive income into the Company's consolidated statements of operations.

------

The following summarizes benefit obligations, plan assets, and funded status for the defined benefit pension plans:

---

| | | | |
|:---|:---|:---|:---|
| | U.S. Plans | Non-U.S. Plans | Total |
| | March 31, 2026 | March 31, 2026 | March 31, 2026 |
| Benefit obligation, beginning | $32877 | $19571 | $52448 |
| Service cost |  | 211 | 211 |
| Interest cost | 1559 | 1003 | 2562 |
| Plan amendments |  | 15 | 15 |
| Actuarial losses (gains) | 765 | (666) | 99 |
| Plan settlements |  | (1032) | (1032) |
| Effects of currency translation |  | 232 | 232 |
| Benefits paid | (3337) | (1489) | (4826) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit obligation, ending | $31864 | $17845 | $49709 |
| Fair value of plan assets, beginning | $— | $22421 | $22421 |
| Actual return on plan assets |  | (670) | (670) |
| Employer contributions | 3337 | 605 | 3942 |
| Plan settlements |  | (1032) | (1032) |
| Benefits paid | (3337) | (1489) | (4826) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of plan assets, ending | $— | $19835 | $19835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funded status of the plan | $(31864) | $1990 | $(29874) |

---

---

| | | | |
|:---|:---|:---|:---|
| | U.S. Plans | Non-U.S. Plans | Total |
| | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| Benefit obligation, beginning | $33694 | $21266 | $54960 |
| Service cost |  | 235 | 235 |
| Interest cost | 1679 | 1038 | 2717 |
| Actuarial losses (gains) | 838 | (1132) | (294) |
| Plan settlements |  | (224) | (224) |
| Effects of currency translation |  | (51) | (51) |
| Benefits paid | (3334) | (1561) | (4895) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit obligation, ending | $32877 | $19571 | $52448 |
| Fair value of plan assets, beginning | $— | $22380 | $22380 |
| Actual return on plan assets |  | 1011 | 1011 |
| Employer contributions | 3334 | 815 | 4149 |
| Plan settlements |  | (224) | (224) |
| Benefits paid | (3334) | (1561) | (4895) |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of plan assets, ending | $— | $22421 | $22421 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Funded status of the plan | $(32877) | $2850 | $(30027) |

---

The following summarizes amounts reported in the consolidated balance sheets for the defined benefit pension plans:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | U.S. Plans | U.S. Plans | Non-U.S. Plans | Non-U.S. Plans |
| | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2026 | 2025 |
| Noncurrent benefit asset recorded in other noncurrent assets | $— | $— | $7632 | $8752 |
| Accrued current benefit liability recorded in accrued expenses and other current liabilities | (3306) | (3313) | (653) | (729) |
| Accrued noncurrent benefit liability recorded in pension, postretirement, and other long-term liabilities | (28558) | (29564) | (4989) | (5173) |
| &nbsp;&nbsp;&nbsp;&nbsp;Funded status of the plan | $(31864) | $(32877) | $1990 | $2850 |

---

------

The following summarizes pension obligations for the defined benefit pension plans:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | U.S. Plans | U.S. Plans | Non-U.S. Plans<sup>(1)</sup> | Non-U.S. Plans<sup>(1)</sup> |
| | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2026 | 2025 |
| Information for pension plans with accumulated benefit obligation in excess of plan assets: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Projected benefit obligation | $31864 | $32877 | $5642 | $5902 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated benefit obligation | 31864 | 32877 | 4747 | 5448 |
| <sup>(1)</sup> Certain of the Company's non-U.S. defined benefit pension plans in Europe were over-funded as of March 31, 2026 and 2025. | <sup>(1)</sup> Certain of the Company's non-U.S. defined benefit pension plans in Europe were over-funded as of March 31, 2026 and 2025. | <sup>(1)</sup> Certain of the Company's non-U.S. defined benefit pension plans in Europe were over-funded as of March 31, 2026 and 2025. | <sup>(1)</sup> Certain of the Company's non-U.S. defined benefit pension plans in Europe were over-funded as of March 31, 2026 and 2025. | <sup>(1)</sup> Certain of the Company's non-U.S. defined benefit pension plans in Europe were over-funded as of March 31, 2026 and 2025. |

---

The following summarizes activity in accumulated other comprehensive income for the defined benefit plans:

---

| | | | |
|:---|:---|:---|:---|
| | U.S. and Non-U.S. Pension | U.S. and Non-U.S. Post-retirement | Total |
| Prior service cost | $(32) | $— | $(32) |
| Net actuarial gain | 11738 | 1209 | 12947 |
| Deferred taxes | (109) | (40) | (149) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at March 31, 2024 | $11597 | $1169 | $12766 |
| Prior service credit | $13 | $— | $13 |
| Net actuarial (loss) gain | (100) | 28 | (72) |
| Deferred taxes | (118) | (73) | (191) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total change for 2025 | $(205) | $(45) | $(250) |
| Prior service cost | $(19) | $— | $(19) |
| Net actuarial gain | 11638 | 1237 | 12875 |
| Deferred taxes | (227) | (113) | (340) |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at March 31, 2025 | $11392 | $1124 | $12516 |
| Prior service cost | $(10) | $— | $(10) |
| Net actuarial loss | (2641) | (281) | (2922) |
| Deferred taxes | 518 | 122 | 640 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total change for 2026 | $(2133) | $(159) | $(2292) |
| Prior service cost | $(29) | $— | $(29) |
| Net actuarial gain | 8997 | 956 | 9953 |
| Deferred taxes | 291 | 9 | 300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Balance at March 31, 2026 | $9259 | $965 | $10224 |

---

------

The following assumptions were used to determine the expense for the pension plans:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | U.S. Plans | U.S. Plans | U.S. Plans | Non-U.S. Plans | Non-U.S. Plans | Non-U.S. Plans |
| | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2024 | 2026 | 2025 | 2024 |
| Discount rate | 5.37% | 5.33% | 5.08% | 5.75% | 5.37% | 4.94% |
| Rate of increase in future compensation | Not applicable | Not applicable | Not applicable | 7.52% | 10.42% | 5.72% |
| Expected long-term rate of return on plan assets | Not applicable | Not applicable | Not applicable | 5.04% | 4.35% | 4.20% |

---

The following weighted average assumptions were used to determine the benefit obligations for the pension plans:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | U.S. Plans | U.S. Plans | U.S. Plans | Non-U.S. Plans | Non-U.S. Plans | Non-U.S. Plans |
| | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2024 | 2026 | 2025 | 2024 |
| Discount rate | 5.44% | 5.37% | 5.33% | 6.35% | 5.75% | 5.37% |
| Rate of increase in future compensation | Not applicable | Not applicable | Not applicable | 9.07% | 7.52% | 10.42% |

---

***Plan Assets***

The following summarizes asset allocations and the percentage of the fair value of plan assets by asset category:

---

| | | |
|:---|:---|:---|
| | Non-U.S. Plans | Non-U.S. Plans |
| | March 31, | March 31, |
| | 2026 | 2025 |
| Asset category: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 42.3% | 96.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt securities | 53.2% | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate and other investments | 4.5% | 3.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 100.0% | 100.0% |

---

The fair values for the pension plans by asset category are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Non-U.S. Pension Plans | March 31, 2026 | March 31, 2026 | March 31, 2025 | March 31, 2025 |
|  | Total | Level 1 | Total | Level 1 |
| Cash and cash equivalents | $8390 | $8390 | $21538 | $21538 |
| U.S. equities / equity funds |  |  |  |  |
| International equities / equity funds |  |  |  |  |
| U.S. fixed income funds |  |  |  |  |
| International fixed income funds | 10544 | 10544 |  |  |
| Real estate and other<sup>(1)</sup> | 901 |  | 883 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $19835 | $18934 | $22421 | $21538 |
| <sup>(1)</sup> Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. | <sup>(1)</sup> Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. | <sup>(1)</sup> Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. | <sup>(1)</sup> Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. | <sup>(1)</sup> Certain investments that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. |

---

------

***Postretirement Health and Life Insurance Benefits***

The following summarizes benefit obligations, plan assets, and funded status for the postretirement health and life insurance benefits plans:

---

| | | | |
|:---|:---|:---|:---|
| | U.S. Plans | Non-U.S. Plans | Total |
| | March 31, 2026 | March 31, 2026 | March 31, 2026 |
| Benefit obligation, beginning | $3371 | $1386 | $4757 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service cost | 2 |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest cost | 161 | 164 | 325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of currency translation |  | 145 | 145 |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gains) losses | (123) | 318 | 195 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (179) | (145) | (324) |
| Benefit obligation, ending | 3232 | 1868 | 5100 |
| Fair value of plan assets, beginning | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer contributions | 179 | 145 | 324 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (179) | (145) | (324) |
| Fair value of plan assets, ending | $— | $— | $— |
| Funded status of the plan | $(3232) | $(1868) | $(5100) |
|  | U.S. Plans | Non-U.S. Plans | Total |
|  | March 31, 2026 | March 31, 2026 | March 31, 2026 |
| Accrued current benefit liability recorded in accrued expenses and other current liabilities | $(332) | $(173) | $(505) |
| Accrued non-current benefit liability recorded in pension, postretirement, and other long-term liabilities | (2900) | (1695) | (4595) |
| Funded status of the plan | $(3232) | $(1868) | $(5100) |

---

---

| | | | |
|:---|:---|:---|:---|
| | U.S. Plans | Non-U.S. Plans | Total |
| | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| Benefit obligation, beginning | $3525 | $1580 | $5105 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service cost | 2 |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest cost | 177 | 129 | 306 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of currency translation |  | (199) | (199) |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gains) losses | (177) | 19 | (158) |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (156) | (143) | (299) |
| Benefit obligation, ending | 3371 | 1386 | 4757 |
| Fair value of plan assets, beginning | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Employer contributions | 156 | 143 | 299 |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefits paid | (156) | (143) | (299) |
| Fair value of plan assets, ending | $— | $— | $— |
| Funded status of the plan | $(3371) | $(1386) | $(4757) |
|  | U.S. Plans | Non-U.S. Plans | Total |
|  | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| Accrued current benefit liability recorded in accrued expenses and other current liabilities | $(334) | $(133) | $(467) |
| Accrued non-current benefit liability recorded in pension, postretirement, and other long-term liabilities | (3037) | (1253) | (4290) |
| Funded status of the plan | $(3371) | $(1386) | $(4757) |

---

------

The following assumptions were used to determine postretirement benefit obligations:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | U.S. Plans | U.S. Plans | U.S. Plans | Non-U.S. Plans | Non-U.S. Plans | Non-U.S. Plans |
| | March 31, | March 31, | March 31, | March 31, | March 31, | March 31, |
| | 2026 | 2025 | 2024 | 2026 | 2025 | 2024 |
| Discount rate | 5.55% | 5.45% | 5.35% | 11.46% | 11.67% | 9.72% |
| Health care cost trend rate assumed for next year | 7.01% | 6.47% | 6.58% | 8.76% | 8.94% | 8.75% |

---

***Cash Flows***

The Company expects to contribute the following to its benefit plans:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Pension Benefits | Pension Benefits | Postretirement Plans | Postretirement Plans | |
| | U.S. Plans | Non-U.S. Plans | U.S. Plans | Non-U.S. Plans | Total |
| Fiscal Year 2027 | $3306 | $653 | $332 | $173 | $4464 |

---

The Company's contributions to the defined contribution plans are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Contributions | $4856 | $4459 | $4395 |

---

The following summarizes the expected benefit payments to be paid in future fiscal years, as of March 31, 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Pension Benefits | Pension Benefits | Other Benefits | Other Benefits | |
| | U.S. Plans | Non-U.S. Plans | U.S. Plans | Non-U.S. Plans | Total |
| 2027 | $3306 | $1597 | $332 | $173 | $5408 |
| 2028 | 3231 | 1568 | 321 | 178 | 5298 |
| 2029 | 3148 | 1422 | 309 | 183 | 5062 |
| 2030 | 3058 | 1568 | 298 | 189 | 5113 |
| 2031 | 2960 | 1353 | 285 | 194 | 4792 |
| Thereafter | 13083 | 9922 | 1255 | 1056 | 25316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $28786 | $17430 | $2800 | $1973 | $50989 |

---

**22. Contingencies and Other Information**

***Brazilian Tax Credits***

The government in the Brazilian State of Parana ("Parana") issued a tax assessment on October 26, 2007, with respect to local intrastate trade tax credits that result primarily from tobacco transferred between states within Brazil. At March 31, 2026, the assessment for intrastate trade tax credits taken is $2,529 and the total assessment including penalties and interest is $11,306. The Company believes it has properly complied with Brazilian law and will contest any assessment through the judicial process. Should the Company lose in the judicial process, the loss of the intrastate trade tax credits would have a material impact on the consolidated financial statements of the Company.

***Other Matters***

In addition to the above-mentioned matter, the Company or certain of its subsidiaries are involved in other litigation or legal matters incidental to their business activities, including tax matters. While the outcome of these matters cannot be predicted with certainty, they are being vigorously defended and the Company does not currently expect that any of them will have a material adverse effect on its business or financial position. However, should one or more of these matters be resolved in a manner adverse to its current expectation, the effect on the Company's results of operations for a particular fiscal reporting period could be material.

------

**23. Accumulated Other Comprehensive Income**

The following summarizes changes in each component of accumulated other comprehensive income, net of tax, attributable to the Company:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Currency Translation Adjustment | Pensions, Net of Tax | Derivatives, Net of Tax | Accumulated Other Comprehensive Income |
| Balances at March 31, 2023 | $(6392) | $8335 | $3572 | $5515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 700 | (4436) | 1698 | (2038) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified to net income, net of tax |  | 8867 | (4558) | 4309 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax | 700 | 4431 | (2860) | 2271 |
| Balances at March 31, 2024 | $(5692) | $12766 | $712 | $7786 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income before reclassifications | (353) | 62 | (2226) | (2517) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified to net income, net of tax |  | (312) | 2358 | 2046 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive (loss) income, net of tax | (353) | (250) | 132 | (471) |
| Balances at March 31, 2025 | $(6045) | $12516 | $844 | $7315 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 1366 | (1570) | 2819 | 2615 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified to net income, net of tax | (430) | (722) | (2655) | (3807) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax | 936 | (2292) | 164 | (1192) |
| Balances at March 31, 2026 | $(5109) | $10224 | $1008 | $6123 |

---

The following summarizes amounts by component, reclassified from accumulated other comprehensive income to net income:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Affected Line Item in the Consolidated Statements of Operations |
| | 2026 | 2025 | 2024 | Affected Line Item in the Consolidated Statements of Operations |
| Pension and postretirement plans<sup>(1)</sup>: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Settlement (gain) loss | $(283) | $— | $4681 | Gain (loss) on pension settlement |
| &nbsp;&nbsp;&nbsp;&nbsp;Actuarial (gain) loss | (583) | (581) | 6780 | Interest expense, net |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of prior service cost | 2 | 3 | 4 | Interest expense, net |
| Amounts reclassified from equity to the income statement, gross | (864) | (578) | 11465 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax effects of amounts reclassified from accumulated other comprehensive income to net income | 142 | 266 | (2598) |  |
| Amounts reclassified from equity to the income statement, net | $(722) | $(312) | $8867 |  |
| <sup>(1)</sup> Amounts are included in net periodic benefit costs for pension and postretirement plans. | <sup>(1)</sup> Amounts are included in net periodic benefit costs for pension and postretirement plans. | <sup>(1)</sup> Amounts are included in net periodic benefit costs for pension and postretirement plans. | <sup>(1)</sup> Amounts are included in net periodic benefit costs for pension and postretirement plans. | <sup>(1)</sup> Amounts are included in net periodic benefit costs for pension and postretirement plans. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Affected Line Item in the Consolidated Statements of Operations |
| | 2026 | 2025 | 2024 | Affected Line Item in the Consolidated Statements of Operations |
| Derivatives: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on foreign exchange contracts designated as cash flow hedges | $(4022) | $3185 | $(6356) | Cost of goods and services sold;<br>selling, general, and administrative expenses<sup>(1)</sup> |
| Amounts reclassified from equity to the income statement, gross | (4022) | 3185 | (6356) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax effects of amounts reclassified from accumulated other comprehensive income to net income | 1367 | (827) | 1798 |  |
| Amounts reclassified from equity to the income statement, net | $(2655) | $2358 | $(4558) |  |
| <sup>(1)</sup> All amounts recorded in cost of goods and services sold, except during the year ended March 31, 2025, when $2,411 was recorded in cost of goods and services sold and $774 was recorded in selling, general, and administrative expenses. | <sup>(1)</sup> All amounts recorded in cost of goods and services sold, except during the year ended March 31, 2025, when $2,411 was recorded in cost of goods and services sold and $774 was recorded in selling, general, and administrative expenses. | <sup>(1)</sup> All amounts recorded in cost of goods and services sold, except during the year ended March 31, 2025, when $2,411 was recorded in cost of goods and services sold and $774 was recorded in selling, general, and administrative expenses. | <sup>(1)</sup> All amounts recorded in cost of goods and services sold, except during the year ended March 31, 2025, when $2,411 was recorded in cost of goods and services sold and $774 was recorded in selling, general, and administrative expenses. | <sup>(1)</sup> All amounts recorded in cost of goods and services sold, except during the year ended March 31, 2025, when $2,411 was recorded in cost of goods and services sold and $774 was recorded in selling, general, and administrative expenses. |

---

**24. Equity-Based Compensation**

On March 21, 2024 and March 19, 2025, the Board of Directors amended and restated the Incentive Plan to increase the number of shares of the Company's common stock authorized to be issued thereunder to 3,220 shares and to 3,612 shares (which amounts are presented in thousands), respectively. Pursuant to the Incentive Plan, prior to May 10, 2024, the Company granted time-vesting restricted stock units, with the vesting of these restricted stock units being subject to continued employment or service through specified dates and the condition that the Company's common stock be listed for trading on a national securities exchange or an approved foreign securities exchange by March 31, 2028 (the "Listing Condition").

On May 10, 2024 (the "Modification Date"), the restricted stock units granted under the Incentive Plan that were outstanding immediately prior to that date were amended to extend the period by which the Listing Condition must be satisfied for the vesting of such restricted stock units from March 31, 2028 to March 31, 2031 and to provide that the Listing Condition shall be deemed to be satisfied on March 31, 2031, regardless of whether the Company's common stock has been listed by that date on a national securities exchange or foreign securities exchange and would vest earlier upon the occurrence of a "Change in Control" (as defined in the Incentive Plan) as a result of a merger, consolidation, share exchange or sale of all or substantially all of the assets of the Company (a "change-in-control event"). On the Modification Date, the amended Listing Condition was rendered nonsubstantive, and recipients of the outstanding restricted stock units had satisfied the continued service requirement, meaning the then-outstanding restricted stock units were fully earned for vesting.

Performance-based stock units awarded under the Incentive Plan prior to the fiscal year ended March 31, 2025 provided for the issuance of shares based on satisfaction of performance criteria over a three-year measurement period ended March 31, 2024, subject to continued employment, with payouts at 50% of the target level upon satisfaction of threshold performance levels, 100% of the target level upon satisfaction of target performance levels and 150% of the target level upon performance equaling or exceeding the maximum performance levels, with payouts interpolated for performance between these levels. Such performance-based restricted stock units were subject to an additional condition to vesting that the Company's common stock be listed for trading on a national securities exchange or an approved foreign securities exchange by a specified date. The performance criteria for these performance-based stock units were not satisfied at the threshold level for the three-year measurement period ended March 31, 2024 and all such performance-based stock units were forfeited.

------

***Restricted Stock Units***

Restricted stock units granted under the Incentive Plan on or after the Modification Date are earned ratably for certain employees, subject to their continued employment, from the date of the award to March 31, 2027, and for certain non-employee directors, subject to continued board service, from the date of the award to the Company's next annual meeting of shareholders. Restricted stock units vest upon the earlier of March 31, 2031 or the occurrence of certain corporate events as specified in the restricted stock unit award agreement. The following summarizes activity for restricted stock units:

---

| | | |
|:---|:---|:---|
| *(in thousands except grant date fair value)* | Restricted Stock Units | Weighted Average Grant Date Fair Value Per Share |
| Nonvested, March 31, 2024<sup>(1)</sup> | 956 | $3.50 |
| &nbsp;&nbsp;Granted | 862 | 3.41 |
| &nbsp;&nbsp;Canceled or forfeited | (94) | 3.50 |
| Nonvested, March 31, 2025 | 1724 | $3.46 |
| &nbsp;&nbsp;Granted | 85 | 4.23 |
| &nbsp;&nbsp;Canceled or forfeited | (60) | 3.50 |
| Nonvested, March 31, 2026 | 1749 | $3.49 |
| <sup>(1)</sup> The weighted average grant date fair value per share is as of the Modification Date, the date at which these outstanding units were fully earned for vesting. | <sup>(1)</sup> The weighted average grant date fair value per share is as of the Modification Date, the date at which these outstanding units were fully earned for vesting. | <sup>(1)</sup> The weighted average grant date fair value per share is as of the Modification Date, the date at which these outstanding units were fully earned for vesting. |

---

The following summarizes equity-based compensation expense for restricted stock units:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025<sup>(1)</sup> | 2024 |
| Equity-based compensation expense | $1022 | $4110 | $— |
| <sup>(1)</sup> The amount recorded during the year ended March 31, 2025 included the impact of a cumulative catch-up adjustment of $3,263 due to the modification on May 10, 2024 of awards then outstanding under the Incentive Plan. | <sup>(1)</sup> The amount recorded during the year ended March 31, 2025 included the impact of a cumulative catch-up adjustment of $3,263 due to the modification on May 10, 2024 of awards then outstanding under the Incentive Plan. | <sup>(1)</sup> The amount recorded during the year ended March 31, 2025 included the impact of a cumulative catch-up adjustment of $3,263 due to the modification on May 10, 2024 of awards then outstanding under the Incentive Plan. | <sup>(1)</sup> The amount recorded during the year ended March 31, 2025 included the impact of a cumulative catch-up adjustment of $3,263 due to the modification on May 10, 2024 of awards then outstanding under the Incentive Plan. |

---

Unrecognized compensation cost for restricted stock units is $979 as of March 31, 2026, and is expected to be recognized over a weighted average period of 0.93 years, representing the weighted average remaining service period related to the awards, subject to adjustments for actual forfeitures.

***Performance-Based Stock Units***

Performance-based stock units granted under the Incentive Plan on or after the Modification Date will vest if the per share price achieved in a liquidity event equals or exceeds the specified target level. The amount of common stock shares to be issued after a liquidity event will range from 0% to 200% of the number of performance-based stock units granted, contingent upon the per share price achieved in the liquidity event and subject to continued employment through the date of the liquidity event. The contingent liquidity event is not probable as of March 31, 2026, and accordingly, no equity-based compensation expense has been recognized for performance-based stock units. The following summarizes activity for performance-based stock units (at the target performance level):

---

| | | |
|:---|:---|:---|
| *(in thousands except grant date fair value)* | Performance-Based Stock Units | Weighted Average Grant Date Fair Value Per Share |
| Nonvested, March 31, 2024 | 589 | $— |
| &nbsp;&nbsp;Granted | 605 | 4.36 |
| &nbsp;&nbsp;Canceled or forfeited<sup>(1)</sup> | (642) | 4.36 |
| Nonvested, March 31, 2025\* | 553 | $4.36 |
| &nbsp;&nbsp;Granted | 23 | 6.79 |
| &nbsp;&nbsp;Canceled or forfeited | (67) | 4.36 |
| Nonvested, March 31, 2026\* | 508 | $4.47 |
| *\*Amounts may not equal totals due to rounding.* |  |  |
| <sup>(1)</sup> On the Modification Date, the performance-based restricted stock units granted under the Incentive Plan that were outstanding at March 31, 2024 were canceled as the vesting requirements were not met. | <sup>(1)</sup> On the Modification Date, the performance-based restricted stock units granted under the Incentive Plan that were outstanding at March 31, 2024 were canceled as the vesting requirements were not met. | <sup>(1)</sup> On the Modification Date, the performance-based restricted stock units granted under the Incentive Plan that were outstanding at March 31, 2024 were canceled as the vesting requirements were not met. |

---

------

**25. Related Party Transactions** 

The Company engages in transactions with its equity method investees primarily for the procuring and processing of inventory. The following summarizes sales and purchases transactions with related parties:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Sales | $23112 | $16512 | $25059 |
| Purchases | 193856 | 214341 | 204193 |
| Dividends received | 8436 | 12449 | 14486 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

The Company included the following related party balances in its consolidated balance sheets:

---

| | | | |
|:---|:---|:---|:---|
| | March 31, | March 31, | |
| | 2026 | 2025 |<br>Location in Consolidated Balance Sheet |
| Accounts receivable, related parties | $62 | $50 | &nbsp;&nbsp;Other receivables |
| Accounts payable, related parties | 39317 | 19731 | &nbsp;&nbsp;Accounts payable |

---

*Transactions with Significant Shareholders*

Based on a Schedule 13D/A filed with the SEC on June 13, 2024 by Glendon Capital Management, L.P. (the "Glendon Investor"), Holly Kim Olsen, Glendon Opportunities Fund, L.P. and Glendon Opportunities Fund II, L.P., the Glendon Investor reported beneficial ownership of 8,315 shares of the Company's common stock, representing approximately 33.8% of the outstanding shares of the Company's common stock. A representative of the Glendon Investor serves as a director of Pyxus. Based on a Schedule 13D/A filed with the SEC on March 25, 2024, by Monarch Alternative Capital LP (the "Monarch Investor"), MDRA GP LP and Monarch GP LLC, the Monarch Investor reported beneficial ownership of 6,125 shares of the Company's common stock, representing approximately 24.9% of the outstanding shares of the Company's common stock. An individual designated by the Monarch Investor serves as a director of Pyxus. Based on a Schedule 13G/A filed with the SEC on September 3, 2024 by Owl Creek Asset Management, L.P. and Jeffrey A. Altman, Owl Creek Asset Management, L.P. is the investment manager of certain funds and reported beneficial ownership of 3,865 shares of the Company's common stock on August 31, 2024, representing approximately 15.7% of the outstanding shares of the Company's common stock. Funds managed by the Glendon Investor, funds managed by the Monarch Investor, and funds managed by Owl Creek Asset Management, L.P., (such funds are collectively referred to as the "Investor-Affiliated Funds") were holders, in part, of the Intabex Term Loans, the Pyxus Term Loans and the 2027 Notes, which are described in "<u>[Note 16. Debt Arrangements](#i6f44eae8422d46cd9f377051509c10a4_178)</u>," during the fiscal year ended March 31, 2026.

On March 21, 2024, Pyxus Holdings entered into an agreement (the "Debt Repurchase Agreement") with funds affiliated with the Monarch Investor to purchase $77,922 of aggregate principal amount of their holdings in the 2027 Notes for $60,000, a 23.0% discount to par value, plus accrued and unpaid interest and specified customary fees. The Debt Repurchase Agreement also included the right of Pyxus Holdings, at its option, to purchase from such holders an additional $34,191 aggregate principal amount of the 2027 Notes for $26,327, a 23.0% discount to par value, plus accrued and unpaid interest, and $10,345 aggregate principal amount of the Pyxus Term Loans for $9,104, a 12.0% discount to par value, plus accrued and unpaid interest. On April 12, 2024, Pyxus Holdings exercised its rights to complete these repurchases by September 30, 2024.

The Debt Repurchase Agreement and the transactions contemplated thereby, including the exercise by Pyxus Holdings of its right to purchase the Pyxus Term Loans and additional 2027 Notes thereunder, were approved, and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of Pyxus.

Under the terms of the Debt Repurchase Agreement, the Company paid the following amounts to funds affiliated with the Monarch Investor:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On March 28, 2024, the Company paid a total of $62,339, which included $1,849 of accrued and unpaid interest and $490 in other fees, to retire $77,922 of aggregate principal amount of the 2027 Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On May 31, 2024, the Company paid a total of $9,435, which included $332 of accrued and unpaid interest, to retire $10,345 of aggregate principal amount of the Pyxus Term Loans.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On August 2, 2024, the Company paid a total of $26,707, which included $379 of accrued and unpaid interest, to retire $34,191 of aggregate principal amount of the 2027 Notes.

------

Upon completion of the transactions under the Debt Repurchase Agreement, the Monarch Investor is no longer a holder of the 2027 Notes and the Pyxus Term Loans. The Monarch Investor remains a related party as a holder of a portion of the Intabex Term Loans and a beneficial owner of more than five percent of the Company's common stock outstanding.

On August 21, 2024, the Company entered into a privately negotiated transaction with CI Investments, Inc. ("CI Investments"), which at that time was a beneficial owner of greater than five percent of the Company's common stock outstanding, to repurchase 392 (which amount is presented in thousands) shares of its common stock for approximately $1,000, inclusive of broker commission fees, which transaction was completed on August 22, 2024. This transaction was approved and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of Pyxus. Following the completion of this transaction and other contemporaneous dispositions of the Company's common stock by CI Investments, CI Investments ceased to be a beneficial owner of more than five percent of the Company's common stock outstanding.

Accrued expenses and other current liabilities as presented in the consolidated balance sheets as of March 31, 2026 and 2025 included $1,352 and $1,600, respectively, of interest payable to Investor-Affiliated Funds. Interest expense as presented in the consolidated statements of operations included $21,534, $24,416 and $40,909 for the years ended March 31, 2026, 2025, and 2024, respectively, that related to the Investor-Affiliated Funds and CI Investments (applicable only for the periods in which CI Investments was a beneficial owner of more than five percent of the Company's common stock outstanding).

**26. Segment Information**

The Company is primarily engaged in the processing and sale of leaf tobacco to manufacturers of cigarettes and other consumer tobacco products around the world, with a smaller percentage of revenue in each region being derived from performing third-party tobacco processing services. The Company's leaf tobacco operations are organized by six operating segments, represented by five geographic regions and one product category. The geographic regions of Africa, Asia, Europe, North America, and South America, as well as Value-Added Tobacco Products ("VATP"), which is primarily comprised of the Company's cut rag tobacco operations, each have their own management teams responsible for the operating and financial results of their operating segment. Further, revenues for each geographic region and VATP are derived mainly from shipping processed tobacco. The Company evaluated its leaf tobacco operations and concluded they have similar economic characteristics and meet qualitative aggregation criteria to be combined into one reportable segment for financial reporting purposes: Leaf.

The one Leaf reportable segment is consistent with information used by the chief operating decision maker ("CODM") to assess performance, make operating decisions, and allocate resources. The Company's CODM, comprised of both the chief executive officer and the chief financial officer, regularly evaluates performance using operating income as the measure of segment profitability. This measure is utilized during the budgeting and forecasting process to determine future operating plans and enable strategic decision making for the allocation of capital. Corporate general expenses are allocated to the segments based upon segment selling, general, and administrative expenses.

An All Other category exists to reflect business activities that are incidental to our core leaf tobacco operations, and primarily relate to the Company's non-tobacco agricultural products business. The All Other category does not meet the quantitative and qualitative thresholds to be reportable.

------

The following summarizes financial information relating to the Leaf segment (the Company's sole reportable segment) with the All Other category included for purposes of reconciliation of the Leaf segment balances to the consolidated financial statements:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Sales and other operating revenues: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | $2405073 | $2470984 | $2029615 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | 7927 | 10276 | 2944 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated sales and other operating revenues | 2413000 | 2481260 | 2032559 |
| Cost of goods and services sold: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | 2059050 | 2125756 | 1714053 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | 6271 | 12520 | 6171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated cost of goods and services sold | 2065321 | 2138276 | 1720224 |
| Selling, general, and administrative expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | 157381 | 164228 | 154074 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | 5553 | 6770 | 6836 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated selling, general, and administrative expenses | 162934 | 170998 | 160910 |
| Other segment items:<sup>(1)</sup> |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf | 19489 | 16714 | 8281 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other | (296) | (304) | 1158 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated other segment items | 19193 | 16410 | 9439 |
| &nbsp;&nbsp;&nbsp;&nbsp;Leaf segment operating income | 169153 | 164286 | 153207 |
| &nbsp;&nbsp;&nbsp;&nbsp;All Other operating loss | (3601) | (8710) | (11221) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset impairment charges | 2852 | 2259 | 4799 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated operating income | 162700 | 153317 | 137187 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on debt retirement |  | 8178 | 15914 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (loss) on pension settlement | 283 |  | (12008) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 134353 | 128041 | 125620 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes and other items | $28630 | $33454 | $15473 |
| <sup>(1)</sup> Represents the other expense, net caption within the consolidated statements of operations. See "<u>[Note 4. Other Expense, Net](#i6f44eae8422d46cd9f377051509c10a4_145)</u>" for additional information. | <sup>(1)</sup> Represents the other expense, net caption within the consolidated statements of operations. See "<u>[Note 4. Other Expense, Net](#i6f44eae8422d46cd9f377051509c10a4_145)</u>" for additional information. | <sup>(1)</sup> Represents the other expense, net caption within the consolidated statements of operations. See "<u>[Note 4. Other Expense, Net](#i6f44eae8422d46cd9f377051509c10a4_145)</u>" for additional information. | <sup>(1)</sup> Represents the other expense, net caption within the consolidated statements of operations. See "<u>[Note 4. Other Expense, Net](#i6f44eae8422d46cd9f377051509c10a4_145)</u>" for additional information. |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2026 | 2026 | 2025 | 2025 | 2025 | 2024 | 2024 | 2024 |
| | Leaf | All Other | Total | Leaf | All Other | Total | Leaf | All Other | Total |
| Depreciation and amortization | $19375 | $1518 | $20893 | $18772 | $1562 | $20334 | $17767 | $1483 | $19250 |
| Capital expenditures | 19878 | 2195 | 22073 | 21137 | 2977 | 24114 | 18062 | 2973 | 21035 |

---

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | March 31, 2026 | March 31, 2026 | March 31, 2026 | March 31, 2025 | March 31, 2025 | March 31, 2025 |
| | Leaf | All Other | Total | Leaf | All Other | Total |
| Assets | $1660016 | $34676 | $1694692 | $1466400 | $37443 | $1503843 |
| Trade and other receivables, net | 264410 | 497 | 264907 | 204054 | 175 | 204229 |
| Investments in unconsolidated affiliates | 99239 | 6624 | 105863 | 90238 | 6690 | 96928 |

---

The following summarizes geographic information for sales and other operating revenues by destination of the product shipped:

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| Sales and Other Operating Revenues: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;China | $354250 | $497437 | $362778 |
| &nbsp;&nbsp;&nbsp;&nbsp;Indonesia | 268913 | 227369 | 215491 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 267567 | 244556 | 192745 |
| &nbsp;&nbsp;&nbsp;&nbsp;Belgium<sup>(1)</sup> | 205644 | 160337 | 156085 |
| &nbsp;&nbsp;&nbsp;&nbsp;United Arab Emirates | 204674 | 213321 | 182687 |
| &nbsp;&nbsp;&nbsp;&nbsp;Turkey | 116376 | 84957 | 62089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Poland | 100497 | 79390 | 63826 |
| &nbsp;&nbsp;&nbsp;&nbsp;Russia | 75496 | 53564 | 70794 |
| &nbsp;&nbsp;&nbsp;&nbsp;Egypt | 35411 | 133023 | 43495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 784172 | 787306 | 682569 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $2413000 | $2481260 | $2032559 |
| <sup>(1)</sup> The Belgium destination represents a customer-owned storage and distribution center from which the tobacco will be shipped on to manufacturing facilities.  | <sup>(1)</sup> The Belgium destination represents a customer-owned storage and distribution center from which the tobacco will be shipped on to manufacturing facilities.  | <sup>(1)</sup> The Belgium destination represents a customer-owned storage and distribution center from which the tobacco will be shipped on to manufacturing facilities.  | <sup>(1)</sup> The Belgium destination represents a customer-owned storage and distribution center from which the tobacco will be shipped on to manufacturing facilities.  |

---

The following summarizes the customers, including their respective affiliates, that account for 10% or more of total sales and other operating revenues for the respective periods, as indicated by an "x":

---

| | | | |
|:---|:---|:---|:---|
| | Years Ended March 31, | Years Ended March 31, | Years Ended March 31, |
| | 2026 | 2025 | 2024 |
| China National Tobacco Corporation | x | x | x |
| Japan Tobacco International | x | x | x |
| Philip Morris International Inc. | x | x | x |

---

The following summarizes geographic information for property, plant, and equipment by location:

---

| | | |
|:---|:---|:---|
| | March 31, | March 31, |
| | 2026 | 2025 |
| Property, Plant, and Equipment, Net: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Brazil | $37648 | $33720 |
| &nbsp;&nbsp;&nbsp;&nbsp;Malawi | 25856 | 26091 |
| &nbsp;&nbsp;&nbsp;&nbsp;Zimbabwe | 23565 | 24049 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 25241 | 22293 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tanzania | 10483 | 11131 |
| &nbsp;&nbsp;&nbsp;&nbsp;Jordan | 8626 | 9588 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 11735 | 11304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $143154 | $138176 |

---

------

**27. Subsequent Events** 

***Securitized Receivables***

On May 29, 2026, the Finacity Facility arrangement was extended to May 31, 2027. Additionally, on June 1, 2026, the investment limit of the Finacity Facility was decreased from $160,000 to $120,000 of trade receivables.

------

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the shareholders and the Board of Directors of Pyxus International, Inc.

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Pyxus International, Inc. and subsidiaries (the "Company") as of March 31, 2026 and March 31, 2025, the related consolidated statements of operations, comprehensive income, stockholders' equity, and cash flows, for each of the three years in the period ended March 31, 2026, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and March 31, 2025, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2026, in conformity with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

***Income Taxes — Accounting for Uncertainty in Income Taxes — Refer to Note 1 and Note 5 to the financial statements***

*Critical Audit Matter Description*

The Company's annual tax rate is based on its pre-tax income by jurisdiction, statutory tax rates, and tax planning opportunities available in the various jurisdictions in which it operates. Tax laws are complex and subject to different interpretations by the taxpayer and respective governmental taxing authorities. Significant judgment is required in determining tax expense and in evaluating tax positions, including evaluating uncertainties. The Company records unrecognized tax benefits in multiple jurisdictions and evaluates the future potential outcomes of tax positions, based upon interpretation of the country-specific tax law and the likelihood of future settlement. Conclusions on recognizing and measuring uncertain tax positions involved significant management estimates and judgment and included complex considerations of local tax laws and related regulations in the various jurisdictions in which the Company operates.

We identified certain uncertain tax positions as a critical accounting matter because of the significant estimates and assumptions involved in recording uncertain tax positions. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our tax specialists, when performing audit procedures to evaluate the reasonableness of management's estimates.

------

*How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to management's estimates and assumptions utilized in the Company's determination of these uncertain tax positions included the following, among others:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• With the assistance of our income tax specialists, we read and evaluated management's documentation, including relevant accounting policies, relevant authoritative tax literature, and information obtained by management from outside tax specialists and attorneys, that detailed the basis of these uncertain tax positions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• With the assistance of our income tax specialists, we evaluated management's judgment of the appropriate unit of account for unrecognized tax benefits and audited the measurement calculations, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We challenged the reasonableness of management's judgments regarding the future resolution of these uncertain tax positions, through evaluating the technical merits of the uncertain tax positions by considering how tax law, including statutes, regulations, and case law, impacted management's judgments and through consideration of the Company's history of settlements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For these uncertain tax positions that had not been settled, we evaluated whether management had appropriately considered new information that could significantly change the recognition or measurement of uncertain tax positions through evaluation of correspondence with taxing authorities and evaluation of changes to issued guidance.

/s/ Deloitte & Touche LLP

Raleigh, North Carolina

June 4, 2026

We have served as the Company's auditor since its fiscal 2006.

------

**<u>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</u>**

None.

**<u>Item 9A. Controls and Procedures</u>**

**Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) designed to provide reasonable assurance that the information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that this information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Due to inherent limitations, our disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance (not absolute) that the objectives of the disclosure controls and procedures are met.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as required by Rule 13a-15(b) of the Exchange Act), as of March 31, 2026. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective to provide reasonable assurance as of March 31, 2026.

**Management's Report on Internal Control Over Financial Reporting**

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). The Company's internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes, and includes those policies and procedures that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Our management assessed the effectiveness of the Company's internal control over financial reporting based on the criteria established in *Internal Control - Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management concluded that our internal control over financial reporting is effective as of March 31, 2026.

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002 due to the Company's filing status as a smaller reporting company and a non-accelerated filer.

**Changes in Internal Control over Financial Reporting**

There have been no changes to our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended March 31, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

In the course of our ongoing preparations for making management's report on internal control over financial reporting as required by Section 404 of the Sarbanes-Oxley Act of 2002, from time to time we have identified areas in need of improvement and have taken remedial actions to strengthen the affected controls as appropriate. We make these and other changes to enhance the effectiveness of our internal controls over financial reporting, which do not have a material effect on our overall internal control.

We will continue to evaluate the effectiveness of our disclosure controls and procedures and internal control over financial reporting on an ongoing basis and will take action as appropriate.

------

**<u>Item 9B. Other Information</u>**

During the three months ended March 31, 2026, none of the Company's directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (as such terms are defined in Item 408 of Regulation S-K).

**<u>Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</u>**

Not applicable.

**PART III**

**<u>Item 10. Directors, Executive Officers and Corporate Governance</u>**

The information concerning directors and persons nominated to become directors of Pyxus International, Inc. included in the Proxy Statement under the headings "Board of Directors - Proposal One - Election of Directors" and "Board of Directors - Director Biographies" is incorporated herein by reference.

**Executive Officers of Pyxus International, Inc.**

The following information is furnished with respect to the Company's executive officers and the capacities in which they serve.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Title** |
| J. Pieter Sikkel | 62 | President and Chief Executive Officer |
| Dustin L. Styons | 44 | Executive Vice President - Chief Financial Officer |
| Scott A. Burmeister | 49 | Executive Vice President - Chief Operating Officer |
| Tracy G. Purvis | 63 | Executive Vice President - Global Business & Information Services |
| T. David Singer | 46 | Senior Vice President - Chief Legal Officer and Secretary |

---

The business experience summaries provided below for the Company's executive officers describe positions held by the named individuals during the last five years.

**J. Pieter Sikkel** has served as President and Chief Executive Officer of Pyxus International, Inc., since August 2020, having previously served as President and Chief Executive Officer of Old Pyxus (as defined below) since March 2013, as President of Old Pyxus from December 14, 2010 through February 2013, Executive Vice President - Business Strategy and Relationship Management of Old Pyxus from May 2007 through December 13, 2010, and Regional Director of Asia of Old Pyxus from May 2005 through April 2007.

**Dustin L. Styons** has served as Executive Vice President - Chief Financial Officer of Pyxus International, Inc. since July 2025, after serving as the interim Chief Financial Officer from February 2025, and Executive Vice President - Business Strategy & Sales from September 2023. Previously, Dustin served as Senior Vice President - Chief Financial Officer of Alliance One International ("AOI"), the Company's leaf tobacco subsidiary, and also served as Vice President of Corporate Finance and Business Development, after having served as Regional Financial Director for North and Central America of the Company's predecessor since February 2017.

**Scott A. Burmeister** has served as Executive Vice President - Chief Operating Officer since September 2023. He has previously served as Regional Director for Europe, Middle East & Africa from September 2020 to September 2023 and before that served as Managing Director for Turkey and Regional Director for Europe from October 2015.

**Tracy G. Purvis** has served as Executive Vice President - Global Business & Information Services since August 2020, having previously served as Executive Vice President - Business Services of Old Pyxus since February 2019, Senior Vice President - Business Services of Old Pyxus from September 2018 through January 2019, Vice President - Global Information Services of Old Pyxus from January 2011 through August 2018, Vice President - Chief Application Architect of Old Pyxus from April 2009 through December 2010, and Vice President - Chief Technology Officer of Old Pyxus from May 2005 through March 2009.

**T. David Singer** rejoined the Company in August 2024 and has served as Senior Vice President - Chief Legal Officer and Secretary since then. Prior to rejoining Pyxus, Mr. Singer served as Chief Administrative Officer and General Counsel for Kymera International, a global specialty materials company. Prior to this role, Mr. Singer served on the Company's legal team

------

from August 2018 to May 2022, and before that, served in various legal capacities during his career, including holding senior in-house counsel positions and in private practice as a litigation, corporate and regulatory attorney.

On June 15, 2020, Old Holdco, Inc. (then named Pyxus International, Inc.) ("Old Pyxus") and its then subsidiaries Alliance One International, LLC, Alliance One North America, LLC, Alliance One Specialty Products, LLC and GSP Properties, LLC (collectively, the "Debtors") filed voluntary petitions (the "Chapter 11 Cases") under Chapter 11 of the United States Bankruptcy Code with the Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") to implement a prepackaged Chapter 11 plan of reorganization to effectuate a financial restructuring of Old Pyxus' secured debt. On August 21, 2020, the Bankruptcy Court issued an order (the "Confirmation Order") confirming the Amended Joint Prepackaged Chapter 11 Plan of Reorganization (the "Plan") filed by the Debtors in the Chapter 11 Cases. On August 24, 2020, the Plan became effective in accordance with its terms, and the Debtors emerged from the Chapter 11 Cases. In connection with the satisfaction of the conditions to effectiveness as set forth in the Confirmation Order and the Plan, Old Pyxus completed a series of transactions pursuant to which the business assets and operations of Old Pyxus were vested in Pyxus Holdings, Inc., which is an indirect subsidiary of the Company. Pursuant to the Confirmation Order and the Plan, at the effectiveness of the Plan, all outstanding shares of common stock, and rights to acquire the common stock, of Old Pyxus were cancelled and the shares of common stock of the Company were delivered to certain creditors of Old Pyxus. Each of Mr. Sikkel and Ms. Purvis served as executive officers of Old Pyxus, in the capacities described above, at the commencement of the Chapter 11 Cases.

**Audit Committee**

The information included in the Proxy Statement under the headings "Board of Directors - Board Committees and Membership" and "Audit Matters" is incorporated herein by reference.

**Section 16(a) Compliance**

The information included in the Proxy Statement under the heading "Ownership of Equity Securities - Delinquent Section 16(a) Reports" is incorporated herein by reference.

**Code of Business Conduct**

The information included in the Proxy Statement under the heading "Governance of the Company - Code of Business Conduct" is incorporated herein by reference.

**Corporate Governance**

The Board of Directors has adopted corporate governance guidelines and charters for its Audit Committee, Compensation Committee, and Environmental, Social, Governance and Nominating Committee. These governance documents are available on our website, www.pyxus.com, or by written request, without charge, addressed to: Corporate Secretary, Pyxus International, Inc., 6001 Hospitality Court, Suite 100, Morrisville, NC 27560-2009.

**Insider Trading Policy**

The Company has an insider trading policy governing the purchase, sale and other dispositions of the Company's securities that applies to all Company personnel, including directors, officers, employees, and other covered persons. The Company also follows procedures for the repurchase of its securities. The Company believes that its insider trading policy and repurchase procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of the Company's insider trading policy is filed as Exhibit 19 to this Form 10-K.

**<u>Item 11. Executive Compensation</u>**

The information contained in the Proxy Statement under the captions "Board of Directors - Compensation of Directors" and "Executive Compensation" is incorporated herein by reference.

------

**<u>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Equity Compensation Plan Information** | **Equity Compensation Plan Information** | **Equity Compensation Plan Information** | **Equity Compensation Plan Information** |
| **as of March 31, 2026** | **as of March 31, 2026** | **as of March 31, 2026** | **as of March 31, 2026** |
|  | (a) | (b) | (c) |
| Plan Category | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights <sup>(3)</sup> | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a)) |
| Equity Compensation Plans Approved by Security Holders<sup>(1)</sup> | 2765362 |  | 846794 |
| Equity Compensation Plans Not Approved by Security Holders | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;— |
| &nbsp;&nbsp;&nbsp;&nbsp;Total<sup>(2)</sup> | &nbsp;&nbsp;&nbsp;2765362 | &nbsp;&nbsp;&nbsp;— | &nbsp;&nbsp;&nbsp;846794 |
| <sup>(1)</sup> The awards outstanding on March 31, 2026 under the Incentive Plan are restricted stock units and performance-based stock units awarded to employees and restricted stock units awarded to non-employee directors. The amounts presented in the table assume the number of shares to be issued upon vesting of the performance-based stock units is based on the maximum level of performance.  | <sup>(1)</sup> The awards outstanding on March 31, 2026 under the Incentive Plan are restricted stock units and performance-based stock units awarded to employees and restricted stock units awarded to non-employee directors. The amounts presented in the table assume the number of shares to be issued upon vesting of the performance-based stock units is based on the maximum level of performance.  | <sup>(1)</sup> The awards outstanding on March 31, 2026 under the Incentive Plan are restricted stock units and performance-based stock units awarded to employees and restricted stock units awarded to non-employee directors. The amounts presented in the table assume the number of shares to be issued upon vesting of the performance-based stock units is based on the maximum level of performance.  | <sup>(1)</sup> The awards outstanding on March 31, 2026 under the Incentive Plan are restricted stock units and performance-based stock units awarded to employees and restricted stock units awarded to non-employee directors. The amounts presented in the table assume the number of shares to be issued upon vesting of the performance-based stock units is based on the maximum level of performance.  |
| <sup>(2)</sup> On November 18, 2020, the Board of Directors of the Company adopted the Pyxus International, Inc. 2020 Incentive Plan (as amended, the "Incentive Plan") which initially authorized the issuance of 2,200,000 shares of the Company's common stock pursuant to awards thereunder and which was approved at the 2021 annual meeting of shareholders on August 19, 2021. On March 21, 2024, the Board of Directors amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,220,000, which was approved at the 2024 annual meeting of shareholders on August 15, 2024. On March 19, 2025, the Board of Directors further amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,612,156. The Incentive Plan permits the grant of options, stock appreciation rights (or SARs), stock awards, stock unit awards, performance share awards, and incentive awards. | <sup>(2)</sup> On November 18, 2020, the Board of Directors of the Company adopted the Pyxus International, Inc. 2020 Incentive Plan (as amended, the "Incentive Plan") which initially authorized the issuance of 2,200,000 shares of the Company's common stock pursuant to awards thereunder and which was approved at the 2021 annual meeting of shareholders on August 19, 2021. On March 21, 2024, the Board of Directors amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,220,000, which was approved at the 2024 annual meeting of shareholders on August 15, 2024. On March 19, 2025, the Board of Directors further amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,612,156. The Incentive Plan permits the grant of options, stock appreciation rights (or SARs), stock awards, stock unit awards, performance share awards, and incentive awards. | <sup>(2)</sup> On November 18, 2020, the Board of Directors of the Company adopted the Pyxus International, Inc. 2020 Incentive Plan (as amended, the "Incentive Plan") which initially authorized the issuance of 2,200,000 shares of the Company's common stock pursuant to awards thereunder and which was approved at the 2021 annual meeting of shareholders on August 19, 2021. On March 21, 2024, the Board of Directors amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,220,000, which was approved at the 2024 annual meeting of shareholders on August 15, 2024. On March 19, 2025, the Board of Directors further amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,612,156. The Incentive Plan permits the grant of options, stock appreciation rights (or SARs), stock awards, stock unit awards, performance share awards, and incentive awards. | <sup>(2)</sup> On November 18, 2020, the Board of Directors of the Company adopted the Pyxus International, Inc. 2020 Incentive Plan (as amended, the "Incentive Plan") which initially authorized the issuance of 2,200,000 shares of the Company's common stock pursuant to awards thereunder and which was approved at the 2021 annual meeting of shareholders on August 19, 2021. On March 21, 2024, the Board of Directors amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,220,000, which was approved at the 2024 annual meeting of shareholders on August 15, 2024. On March 19, 2025, the Board of Directors further amended and restated the Incentive Plan to increase the number of shares of the Company's common stock that may be issued thereunder to 3,612,156. The Incentive Plan permits the grant of options, stock appreciation rights (or SARs), stock awards, stock unit awards, performance share awards, and incentive awards. |
| <sup>(3)</sup> The awards outstanding as of March 31, 2026 under the Incentive Plan do not have an exercise price. | <sup>(3)</sup> The awards outstanding as of March 31, 2026 under the Incentive Plan do not have an exercise price. | <sup>(3)</sup> The awards outstanding as of March 31, 2026 under the Incentive Plan do not have an exercise price. | <sup>(3)</sup> The awards outstanding as of March 31, 2026 under the Incentive Plan do not have an exercise price. |

---

The information contained in the Proxy Statement under the caption "Ownership of Equity Securities" is incorporated herein by reference.

**<u>Item 13. Certain Relationships and Related Transactions, and Director Independence</u>**

The information contained in the Proxy Statement under the captions "Governance of the Company - Determination of Independence of Directors," "Board of Directors - Independence," "Board of Directors - Compensation of Directors," and "Related Party Transactions" is incorporated herein by reference.

**<u>Item 14. Principal Accountant Fees and Services</u>**

The information contained in the Proxy Statement under the captions "Audit Matters - Policy for Pre-Approval of Audit and Non-Audit Services" and "Audit Matters - Audit and Non-Audit Fees" is incorporated herein by reference.

**PART IV**

**<u>Item 15. Exhibits and Financial Statement Schedules</u>**

(a) The following documents are filed as part of this Annual Report on Form 10-K:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The following consolidated financial statements of Pyxus International, Inc. and Subsidiaries are filed as part of this report under Item 8. Financial Statements and Supplementary Data: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Statements of Operations - Years ended March 31, 2026, 2025, and 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Consolidated Statements of Comprehensive Income - Years ended March 31, 2026, 2025, and 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Balance Sheets - March 31, 2026 and 2025

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Statements of Stockholders' Equity - Years ended March 31, 2026, 2025, and 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Statements of Cash Flows - Years ended March 31, 2026, 2025, and 2024

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Notes to Consolidated Financial Statements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Report of Independent Registered Public Accounting Firm

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.All other financial statement schedules are not applicable, or the required information is shown in the consolidated financial statements or notes thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The following documents are filed as exhibits to this report pursuant to Item 601 of Regulation S-K:

---

| | |
|:---|:---|
| <u>[2.01](https://www.sec.gov/Archives/edgar/data/939930/000119312520227440/d938292dex21.htm)</u> | Order dated August 24, 2020 issued by the United States Bankruptcy Court for the District of Delaware in the case captioned In re Pyxus International, Inc., et al. (Case No. 20-11570 (LLS)), incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K of Old Holdco, Inc. filed on August 24, 2020 (File No. 001-13684). |
| <u>[2.02](https://www.sec.gov/Archives/edgar/data/939930/000119312520227440/d938292dex22.htm)</u> | Amended Joint Prepackaged Chapter 11 Plan of Reorganization filed by the Debtors in the case before the United States Bankruptcy Court for the District of Delaware captioned In re Pyxus International, Inc., et al. (Case No. 20-11570 (LLS)), incorporated by reference to Exhibit 2.2 of the Current Report on Form 8-K of Old Holdco, Inc. filed on August 24, 2020 (File No. 001-13684). |
| <u>[3.01](https://www.sec.gov/Archives/edgar/data/939930/000119312520228583/d943320dex31.htm)</u> | Amended and Restated Articles of Incorporation of Pyxus International, Inc., incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K12G3 filed on August 24, 2020 (File No. 000-25734). |
| <u>[3.02](https://www.sec.gov/Archives/edgar/data/939930/000119312520228583/d943320dex32.htm)</u> | Amended and Restated Bylaws of Pyxus International, Inc., incorporated by reference to Exhibit 3.2 to the registrant's Current Report on Form 8-K12G3 filed on August 24, 2020 (File No. 000-25734). |
| <u>[4.01](https://www.sec.gov/Archives/edgar/data/939930/000119312520228583/d943320dex42.htm)</u> | Shareholders Agreement dated as of August 24, 2020 among Pyxus International, Inc. and the Investors (as defined therein), incorporated by reference to Exhibit 4.2 to the registrant's Current Report on Form 8-K12G3 filed on August 24, 2020 (File No. 000-25734). |
| <u>[4.02](https://www.sec.gov/Archives/edgar/data/939930/000119312520245186/d16242dex41.htm)</u> | First Amendment to Shareholders Agreement dated as of September 14, 2020 among Pyxus International, Inc., Glendon Capital Management LP on behalf of its Affiliates that hold common shares of Pyxus International, Inc., and Monarch Alternative Capital LP, on behalf of its Affiliates that hold common shares of Pyxus International, Inc., incorporated by reference to Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on September 14, 2020 (File No. 000-25734). |
| <u>[4.03](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex41.htm)</u> | Indenture, dated as of February 6, 2023, among Pyxus Holdings, Inc., the guarantors party thereto, Wilmington Trust, National Association, as trustee, and Alter Domus (US) LLC, as collateral agent, incorporated by reference to Exhibit 4.1 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[4.04](https://www.sec.gov/Archives/edgar/data/939930/000093993021000034/pyx-20210331xex404.htm)</u> | Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934, incorporated by reference to Exhibit 4.04 to the registrant's Annual report on Form 10-K for the fiscal year ended March 31, 2021 (File No. 000-25734). |
| <u>[10.01](https://www.sec.gov/Archives/edgar/data/939930/000093993022000006/a8-kfeb8ex.htm)</u> | ABL Credit Agreement, dated as of February 8, 2022, by and among Pyxus Holdings, Inc., as Borrower Agent, the Borrowers and Parent Guarantors Party thereto, the Lenders Party thereto, and PNC Bank, National Association, as Administrative Agent and Collateral Agent, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on February 9, 2022 (File No. 000-25734). |
| <u>[10.02](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex104.htm)</u> | Limited Consent and Amendment to ABL Credit Agreement, dated as of January 5, 2023, by and among Pyxus Holdings, Inc., the other borrowers and guarantors party thereto, the several lenders party thereto and PNC Bank, National Association, as administrative agent and collateral agent, incorporated by reference to Exhibit 10.4 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[10.03](https://www.sec.gov/Archives/edgar/data/939930/000093993023000039/exhibit101may232023.htm)</u> | Second Amendment to ABL Credit Agreement dated as of May 23, 2023 by and among Pyxus Holdings, Inc., the other borrowers and guarantors party thereto, the lenders party thereto and PNC Bank, National Association, as administrative agent and collateral agent, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on May 30, 2023 (File No. 000-25734). |
| <u>[10.04](https://www.sec.gov/Archives/edgar/data/939930/000093993024000007/pyx-2023x12x31xex10x01.htm)</u> | Third Amendment to the ABL Credit Agreement dated as of October 24, 2023 by and among Pyxus Holdings, Inc., the other borrowers and guarantors party thereto, the lenders party thereto and PNC Bank, National Association, as administrative agent and collateral agent, incorporated by reference to Exhibit 10.01 to the registrant's Quarterly Report on Form 10-Q for the period ended December 31, 2023 (File No. 000-25734). |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| <u>[10.05](https://www.sec.gov/Archives/edgar/data/939930/000093993025000025/exhibit101fourthamendmentt.htm)</u> | Fourth Amendment to the ABL Credit Agreement dated as of May 12, 2025 by and among Pyxus Holdings, Inc., the other borrowers and guarantors party thereto, the lenders party thereto and PNC Bank, National Association, as administrative agent and collateral agent, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on May 13, 2025 (File No. 000-25734). |
| <u>[10.06](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex105.htm)</u> | Amended and Restated ABL Intercreditor Agreement, dated as of February 6, 2023, among Pyxus Holdings, Inc., the guarantors party thereto, PNC Bank, National Association, as ABL Agent, Alter Domus (US) LLC, as Pyxus Term Loan Administrative Agent, Intabex Term Loan Administrative Agent and Senior Collateral Agent, and Wilmington Trust, National Association, as Senior Notes Trustee, incorporated by reference to Exhibit 10.5 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[10.07](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex101.htm)</u> | Pyxus Term Loan Credit Agreement, dated as of February 6, 2023, among Pyxus Holdings, Inc., the guarantors party thereto, the several lenders party thereto and Alter Domus (US) LLC, as administrative agent and senior collateral agent, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[10.08](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex102.htm)</u> | Intabex Term Loan Credit Agreement, dated as of February 6, 2023, among Pyxus Holdings, Inc., Intabex Netherlands B.V., the other guarantors party thereto, the several lenders party thereto and Alter Domus (US) LLC, as administrative agent and senior collateral agent, incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[10.09](https://www.sec.gov/Archives/edgar/data/939930/000119312523032684/d428678dex103.htm)</u> | Intercreditor and Collateral Agency Agreement, dated as of February 6, 2023, among Pyxus Holdings, Inc., the guarantors party thereto, Alter Domus (US) LLC, as New Intabex Term Loan Administrative Agent, New Pyxus Term Loan Administrative Agent and Senior Collateral Agent, and Wilmington Trust, National Association, as Senior Notes Trustee, incorporated by reference to Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on February 10, 2023 (File No. 000-25734). |
| <u>[10.10](https://www.sec.gov/Archives/edgar/data/939930/000093993012000021/aoi-2012x0331xex1031.htm)</u> | Amended and Restated Receivables Purchase Agreement dated as of March 30, 2012 among Alliance One International, Inc., Finacity Receivables 2006-2, LLC and Finacity Corporation, incorporated by reference to Exhibit 10.31 to the Annual Report on Form 10-K of Old Holdco, Inc. for the year ended March 31, 2012, filed on June 13, 2012 (File No. 001-13684). |
| <u>[10.11](https://www.sec.gov/Archives/edgar/data/939930/000093993012000021/aoi-2012x0331xex1032.htm)</u> | Second Amended and Restated Receivables Purchase Agreement dated as of March 30, 2012 among Alliance One International AG, Finacity Receivables 2006-2, LLC and Finacity Corporation, incorporated by reference to Exhibit 10.32 to the Annual Report on Form 10-K of Old Holdco, Inc. for the year ended March 31, 2012, filed on June 13, 2012 (File No. 001-13684). |
| <u>[10.12](https://www.sec.gov/Archives/edgar/data/939930/000093993012000021/aoi-2012x0331xex1033.htm)</u> | Second Amended and Restated Receivables Sale Agreement dated as of March 30, 2012 among Finacity Receivables 2006-2, LLC, Finacity Corporation, Alliance One International AG, Norddeutsche Landesbank Girozentrale, Standard Chartered Bank, the other Purchaser Agents from time to time party thereto, the Bank Purchasers from time to time party thereto, Hannover Funding Company LLC, and the other Conduit Purchasers from time to time party thereto, incorporated by reference to Exhibit 10.33 to the Annual Report on Form 10-K of Old Holdco, Inc. for the year ended March 31, 2012, filed on June 13, 2012 (File No. 001-13684). |
| <u>[10.13](https://www.sec.gov/Archives/edgar/data/939930/000093993025000016/exhibit101amendedandrestat.htm)</u> | Pyxus International, Inc. Amended and Restated 2020 Incentive Plan, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on March 20, 2025 (File No. 000-25734). † |
| <u>[10.14](https://www.sec.gov/Archives/edgar/data/939930/000093993021000034/pyx-20210331xex1009.htm)</u> | Form of Restricted Stock Unit Award Agreement, incorporated by reference to Exhibit 10.09 to the<br>registrant's Annual report on Form 10-K for the fiscal year ended March 31, 2021 (File No. 000-25734). † |
| <u>[10.15](https://www.sec.gov/Archives/edgar/data/939930/000093993024000054/exhibit101formofrestricted.htm)</u> | Form of Restricted Stock Unit Award Agreement (2024), incorporated by reference to Exhibit 10.1 to the<br>registrant's Current Report on Form 8-K filed on May 14, 2024 (File No. 000-25734). † |
| <u>[10.16](https://www.sec.gov/Archives/edgar/data/939930/000093993021000034/pyx-20210331xex1010.htm)</u> | Form of Performance-based Stock Unit Award Agreement, incorporated by reference to Exhibit 10.10 to the registrant's Annual report on Form 10-K for the fiscal year ended March 31, 2021 (File No. 000-25734). † |
| <u>[10.17](https://www.sec.gov/Archives/edgar/data/939930/000093993024000054/exhibit102formofperformanc.htm)</u> | Form of Performance-based Stock Unit Award Agreement (2024), incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on May 14, 2024 (File No. 000-25734). † |
| <u>[10.18](https://www.sec.gov/Archives/edgar/data/939930/000093993025000007/pyx-2024x12x31xex10x01.htm)</u> | Form of Restricted Stock Unit Award Agreement for Non-Employee Directors, incorporated by reference to Exhibit 10.01 to the registrant's Quarterly report on Form 10-Q for the period ended December 31, 2024 (File No. 000-25734). † |
| <u>[10.19](https://www.sec.gov/Archives/edgar/data/939930/000093993024000086/exhibit101pyxusinternation.htm)</u> | Pyxus International, Inc. Executive Severance Plan, incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on June 14, 2024 (File No. 000-25734). † |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| <u>[10.20](https://www.sec.gov/Archives/edgar/data/939930/000093993009000010/exhibit106.htm)</u> | Alliance One International, Inc. Supplemental Retirement Account Plan (amended and restated as of January 1, 2009), incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q of Old Holdco, Inc. for the period ended December 31, 2008, filed on February 17, 2009 (File No. 001-13684). † |
| <u>[10.21](https://www.sec.gov/Archives/edgar/data/939930/000119312513041652/d482316dex101.htm)</u> | Executive Employment Agreement dated as of March 1, 2013 between Alliance One International, Inc. and J. Pieter Sikkel, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of Old Holdco, Inc. filed on February 7, 2013 (File No. 001-13684). † |
| <u>[10.22](https://www.sec.gov/Archives/edgar/data/939930/000119312520228583/d943320dex103.htm)</u> | Form of Indemnification Agreement entered into by Pyxus International, Inc. with each of Patrick Fallon, Holly Kim, and Jamie Ashton, incorporated by reference to Exhibit 10.3 to the registrant's Current Report on Form 8-K12G3 filed on August 24, 2020 (File No. 000-25734). † |
| <u>[10.23](https://www.sec.gov/Archives/edgar/data/939930/000093993021000019/pyx-2020x12x31xex10x01.htm)</u> | Form of Indemnification Agreement entered into by Pyxus International, Inc. with each of Robert George, Cynthia Moehring, J. Pieter Sikkel, Richard Topping, John Alphin, and Patrick Bartels, incorporated by reference to Exhibit 10.01 to the registrant's Quarterly Report on Form 10-Q for the period ended December 31, 2020, filed on February 9, 2021 (File No. 000-25734). † |
| <u>[10.24](https://www.sec.gov/Archives/edgar/data/939930/000093993024000081/pyx-20240331xex1020.htm)</u> | Employment Contract dated as of December 30, 2019 between Alliance One International Services Limited and Scott Anthony Burmeister, with modifications dated as of August 31, 2020 and September 12, 2023, incorporated by reference to Exhibit 10.20 to the registrant's Annual report on Form 10-K for the fiscal year ended March 31, 2024 filed on June 6, 2024 (File No. 000-25734). † |
| <u>[19](https://www.sec.gov/Archives/edgar/data/939930/000093993025000035/pyx-20250331xex19.htm)</u> | Insider Trading Policy incorporated by reference to Exhibit 19 to the registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2025 (File No. 000-25734). |
| <u>[21](pyx-20260331xex21.htm)</u> | List of subsidiaries (filed herewith). |
| <u>[23](pyx-20260331xex23.htm)</u> | Consent of Deloitte & Touche LLP (filed herewith). |
| <u>[31.1](pyx-20260331xex311.htm)</u> | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). |
| <u>[31.2](pyx-20260331xex312.htm)</u> | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith). |
| <u>[32](pyx-20260331xex32.htm)</u> | Certification by Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). †† |
| 101.INS | XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). |
| 101.SCH | Inline XBRL Taxonomy Extension Schema (filed herewith). |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith). |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase (filed herewith). |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase (filed herewith). |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith). |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in the Interactive Data Files submitted as Exhibits 101.\*). |
|  | † Indicates management compensatory plan, contract, or arrangement. |
|  | †† This exhibit is furnished herewith, but not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to liability under that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate it by reference. |

---

Instruments with respect to long-term debt, the amount of securities authorized thereunder being less than ten percent of the Company's consolidated assets, have been omitted and the Company agrees to furnish such instruments to the Securities and Exchange Commission upon request.

**<u>Item 16. Form 10-K Summary</u>**

The Company has chosen not to include an optional summary of the information required by this Form 10-K. For a reference to information in the Form 10-K, investors should refer to the **Table of Contents** to this Form 10-K.

------

---

| | | |
|:---|:---|:---|
| **SIGNATURES** | **SIGNATURES** | **SIGNATURES** |
| Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on June 4, 2026. | Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on June 4, 2026. | Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on June 4, 2026. |
|  |  | PYXUS INTERNATIONAL, INC. |
|  | By: | /s/ J. Pieter Sikkel |
|  |  | J. Pieter Sikkel<br>President and Chief Executive Officer |
| Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on June 4, 2026. | Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on June 4, 2026. | Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on June 4, 2026. |
| /s/ J. Pieter Sikkel |  | /s/ Patrick J. Bartels, Jr. |
| J. Pieter Sikkel&nbsp;&nbsp;&nbsp;&nbsp;<br>President and Chief Executive Officer and Director<br>(Principal Executive Officer) |  | Patrick J. Bartels, Jr.<br>Director |
| /s/ Dustin L. Styons |  | /s/ Robert D. George |
| Dustin L. Styons<br>Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer) |  | Robert D. George<br>Director |
| /s/ Christopher G. Meredith |  | /s/ Cynthia P. Moehring |
| Christopher G. Meredith<br>Corporate Controller<br>(Principal Accounting Officer) |  | Cynthia P. Moehring<br>Director |
| /s/ John S. Alphin |  | /s/ Richard J.C. Topping |
| John S. Alphin<br>Director |  | Richard J.C. Topping<br>Director |
| /s/ Jamie J. Ashton |  |  |
| Jamie J. Ashton<br>Director |  |  |

---

## Ex-21

**<u>Exhibit 21</u>**

**Subsidiaries of the Company (consolidated as of March 31, 2026)**

---

| | |
|:---|:---|
| **Name of Subsidiary** | **Organized Under Law Of:** |
| Alliance One (Beijing) Enterprise Management and Consulting Co. LTD. | China |
| Alliance One Brasil Exportadora de Tabacos Ltda. | Brazil |
| Alliance One International GmbH | Switzerland |
| Alliance One International Holdings, Ltd. | United Kingdom |
| Alliance One International Services Limited | United Kingdom |
| Alliance One International Singapore Pte. Ltd. | Singapore |
| Alliance One International Tobacco, Inc. | United States |
| Alliance One International, LLC | United States |
| Alliance One Macedonia AD | North Macedonia |
| Alliance One Services (Thailand) | Thailand |
| Alliance One Specialty Products, LLC | United States |
| Alliance One Tobacco (Malawi) Limited | Malawi |
| Alliance One Tobacco Argentina S.A. | Argentina |
| Alliance One Tobacco Canada, Inc. | Canada |
| Alliance One Tobacco Guatemala, S.A. | Guatemala |
| Alliance One Tobacco Tanzania Ltd. | Tanzania |
| Alliance One Tutun A.S. | Turkey |
| Alliance One Zambia Ltd. | Zambia |
| Gadora Tobacco P.S.C. | Jordan |
| Intabex Netherlands B.V. | The Netherlands |
| Leaf Trading Company Ltd. | Russia |
| Mashonaland Tobacco Company (Pvt.) Ltd. | Zimbabwe |
| Mauritius Tobacco Investments Ltd. | Mauritius |
| P.T. Alliance One Indonesia | Indonesia |
| P.T. Indonesia Tri Sembilan | Indonesia |
| Pyxus Agricultural Holdings Ltd. | United Kingdom |
| Pyxus Agriculture Ltd. (Malawi) | Malawi |
| Pyxus Holdings, Inc. | United States |
| Pyxus Parent, Inc. | United States |
| Standard Commercial Tobacco Company (U.K.) Ltd. | United Kingdom |
| Trans-Continental Leaf Tobacco Corporation Ltd. | Liechtenstein |

---

Pursuant to Item 601(b)(21) of Regulation S–K, the Company has omitted some subsidiaries that, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary as of March 31, 2026 under Rule 1–02(w) of Regulation S–X.

## Ex-23

**<u>Exhibit 23</u>**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-253909, 333-278276, and 333-286096 on Form S-8 of our report dated June 4, 2026, relating to the financial statements of Pyxus International, Inc. appearing in this Annual Report on Form 10-K for the year ended March 31, 2026.

/s/ Deloitte & Touche LLP

Raleigh, North Carolina

June 4, 2026

## Exhibit 31.1

**<u>Exhibit 31.1</u>**

**CERTIFICATION**

I, J. Pieter Sikkel, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Annual Report on Form 10-K of Pyxus International, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ J. Pieter Sikkel |
| J. Pieter Sikkel&nbsp;&nbsp;&nbsp;&nbsp;<br>President and Chief Executive Officer |
| June 4, 2026 |

---

## Exhibit 31.2

**<u>Exhibit 31.2</u>**

**CERTIFICATION**

I, Dustin L. Styons, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Annual Report on Form 10-K of Pyxus International, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| /s/ Dustin L. Styons |
| Dustin L. Styons<br>Executive Vice President and Chief Financial Officer |
| June 4, 2026 |

---

## Ex-32

**<u>Exhibit 32</u>**

**CERTIFICATION PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

**(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)**

In connection with the Annual Report on Form 10-K of Pyxus International, Inc. (the "Company") for the fiscal year ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned officers hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), to their knowledge, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 4, 2026

---

| |
|:---|
| /s/ J. Pieter Sikkel |
| J. Pieter Sikkel&nbsp;&nbsp;&nbsp;&nbsp;<br>President and Chief Executive Officer |
| /s/ Dustin L. Styons |
| Dustin L. Styons<br>Executive Vice President and Chief Financial Officer |

---

<br>